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abbreviations
adoHcy S-adenosylhomocysteine
adomet S-adenosylmethionine
aHCY S-adenosylhomocysteine hydrolase
alDH1l1 aldehyde dehydrogenase 1 family, member l1
amD1 adenosylmethionine decarboxylase 1
amt aminomethyltransferase
aPeX arrayed primer extension 
atiC 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/imP 
cyclohydrolase
B12 vitamin B12 (cobalamin)
B2 vitamin B2 (riboflavin)
B6 vitamin B6 (pyridoxine)
BHmt betaine-homocysteine S-methyltransferase
BHmt2 betaine-homocysteine methyltransferase 2
bp basepair
CBS cystathionine-beta-synthase
CH2tHf 5,10-methylenetetrahydrofolate
CH3tHf 5-methyltetrahydrofolate
CnV  copy-number variation
COmt catechol-O-methyltransferase
COQ3 coenzyme Q3 homolog, methyltransferase
CtH cystathionase
CuBn cubilin (intrinsic factor-cobalamin receptor)
CVD  cardiovascular disease
Cys cysteine
Cysta cystathionine
DHfr dihydrofolate reductase
Dna deoxyribonucleic acid
Dnmt1 Dna (cytosine-5-)-methyltransferase 1
Dnmt3a Dna (cytosine-5-)-methyltransferase 3 alpha
Dnmt3B Dna (cytosine-5-)-methyltransferase 3 beta
fCH familial combined hyperlipidemia
fOlH1 folate hydrolase (prostate-specific membrane antigen)1
fOlr1 folate receptor 1 (adult)
fOlr2 folate receptor 2 (fetal)
fOlr3 folate receptor 3
a B B r e V i a t i O n S  7
8 
fPGS folylpolyglutamate synthase
ftCD formiminotransferase cyclodeaminase
fut2  fucosyltransferase 2 
Gamt guanidinoacetate n-methyltransferase
Gart phosphoribosylglycinamide formyltransferase
GGH gamma-glutamyl hydrolase
Gnmt glycine n-methyltransferase
GWa  genome-wide association
Hcy homocysteine
Hhcy hyperhomocysteinemia
HPlC  high-pressure liquid chromatography
HWe  Hardy-Weinberg equilibrium 
iCmt isoprenylcysteine carboxyl methyltransferase
imP  inosine monophosphate
lD  linkage disequilibrium
lOD logarithm of odds
maf  minor allele frequency
mat methionine adenosyltransferase
mat1a methionine adenosyltransferase i, alpha
mat2a methionine adenosyltransferase ii, alpha
mDr multifactor dimensionality reduction
met methionine
mettl1 methyltransferase-like gene 1 
mGmt O-6-methylguanine-Dna methyltransferase
mtHfD methylenetetrahydrofolate dehydrogenase
mtHfD1 methylenetetrahydrofolate dehydrogenase (naDP+ dependent) 1
mtHfD2 methylenetetrahydrofolate dehydrogenase (naDP+ dependent) 2
mtHfr methylenetetrahydrofolate reductase
mtHfS 5,10-methenyltetrahydrofolate synthetase
mtr methionine synthase
mtrr methionine synthase reductase
mts adomet-dependent methyltransferases
nat2 n-acetyltransferase 2 (arylamine n-acetyltransferase)
nnmt nicotinamide n-methyltransferase
nOS1 nitric oxide synthase 1 
nOS2a nitric oxide synthase 2a (inducible, hepatocytes)
nOS3 nitric oxide synthase 3 (endothelial cell)
ntD neural tube defect
Or odds ratio
a B B r e V i a t i O n S  9
PCmt1 protein-l-isoaspartate (D-aspartate) O-methyltransferase
PCr  polymerase chain reaction 
Pe   pulmonary embolism
POn1 paraoxonase 1
PParG   peroxisome proliferator-activated receptor gamma gene 
Prmt1 protein arginine methyltransferase 1
Prmt2 protein arginine methyltransferase 2
Qtl quantitative trait locus
rBC  red blood cell
rfC reduced folate carrier
rflP  restriction fragment length polymorphism 
rna ribonucleic acid
rnmt rna (guanine-7-) methyltransferase
rOS reactive oxygen species 
rVt recurrent venous thrombosis
SaHH S-adenosylhomocysteine hydrolase
SarDH sarcosine dehydrogenase
SHmt serine hydroxymethyltransferase
SHmt1 serine hydroxymethyltransferase 1
SHmt2 serine hydroxymethyltransferase 2
SlC19a1 solute carrier family 19 (folate transporter), member 1
SnP single nucleotide polymorphism
Str short (simple) tandem repeat
tCn2 transcobalamin ii
tHcy total homocysteine
tHf tetrahydrofolate
trDmt1 trna aspartic acid methyltransferase 1
tS thymidylate synthetase
tYmS thymidylate synthetase
uCP2  uncoupling protein-2 
Vntr variable number tandem repeat
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1.1 Homocysteine is a key intermediate in one-carbon metabolism
Homocysteine is an intermediate sulphur-containing amino acid in one-carbon me-
tabolism. One-carbon metabolism, which comprises the folate cycle and methionine 
pathway, regulates the transfer of carbon groups and is related to essential physi-
ologic processes. these include formation of purines and thymidine for Dna and rna 
synthesis, methylation of Dna, rna, lipids and proteins, and regulation of oxidative 
stress. Homocysteine is formed in cells from the essential amino acid methionine via 
methyl transfer reactions (figure 1.1). Homocysteine can be removed from the cell via 
(1) remethylation to methionine, (2) irreversible transsulfuration to cysteine (which is 
limited to cells of the liver, kidney, pancreas and gastro-intestinal tract), or (3) release 
of excess intracellular homocysteine into plasma. the intracellular concentration of 
homocysteine is regulated via these processes that require the action of several en-
zymes and cofactors. approximately 70% of plasma homocysteine is disulphide bound 
to proteins. the remaining 30% is bound to cysteine or homocysteine to form homo-
cysteine-cysteine or homocysteine-homocysteine (or homocystine) mixed disulfides. 
Only a very small portion is present as unbound, free homocysteine. the term plasma 
total homocysteine (tHcy) refers to the sum of all homocysteine species in plasma. 
Values for plasma tHcy in fasting state between 5 and 15 µmol/l are considered 
normal.  arbitrarily, moderate, intermediate and severe hyperhomocysteinemia (Hhcy) 
are classified as concentrations of >15-30 µmol/l, >30-100 µmol/l, and >100 µmol/l, 
respectively(1). an example of the distribution of plasma tHcy concentrations in the 
general population, with its typical long tail toward higher plasma tHcy concentrations, 
is given in figure 1.2. 
1.2  Observational studies indicate associations between increased plasma 
tHcy and several chronic diseases but mechanism is unclear
Homocystinuria is a rare, autosomal recessive disorder, first described in the 1960s(2,3). 
in general, it presents at young age and is characterized by severe Hhcy and exten-
sive urinary excretion of homocystine. the clinical features of homocystinuria due 
to cystathione ß-synthase deficiency, the most common cause, include dislocated 
ocular lenses, mental retardation, osteoporosis and skeletal deformities, and vascular 
disease(4). the presence of early-onset vascular disease in homocystinuria patients led 
to the hypothesis of a relation between mildly elevated concentrations of plasma tHcy 
and vascular damage(5,6). 
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figure 1.1  Schematic overview of homocysteine metabolism
Homocysteine (Hcy) is formed out of S-adenosylhomocysteine (adoHcy), product from S-adenosylmethi-
onine (adomet) dependent methyltransferase reactions. in all mammalian cells, Hcy can be remethylated 
to methionine (met) by action of methionine synthase (mtr), an enzyme that uses vitamin B12 as cofactor 
and 5-methyltetrahydrofolate (CH3tHf) as methyldonor. alternatively, in the liver and kidney, Hcy can be 
remethylated to met in a reaction catalyzed by betaine-homocysteine S-methyltransferase (BHmt) and 
betaine as methyldonor. Hcy can be transsulfurated to cysteine (Cys) in an irreversible reaction of which 
the first step is catalyzed by cystathionine-beta-synthase (CBS) and in which vitamin B6 serves as cofactor. 
if the intracellular Hcy concentration cannot be regulated effectively, excess Hcy will be transported into 
plasma.
 
adoHcy: S-adenosylhomocysteine; adomet: S-adenosylmethionine; B2: vitamin B2 (riboflavin); B6: vitamin 
B6 (pyridoxine); B12: vitamin B12 (cobalamin); BHmt: betaine-homocysteine S-methyltransferase; CBS: cys-
tathionine-beta-synthase; CH2tHf: 5,10-methylenetetrahydrofolate; CH3tHf: 5-methyltetrahydrofolate; Cys: 
cysteine; Cysta: cystathionine; CtH: cystathionase; DHfr: dihydrofolate reductase; Hcy: homocysteine; mat: 
methionine adenosyltransferase; met: methionine; mts: adomet-dependent methyltransferases; mtHfr: 
methylenetetrahydrofolate reductase; mtr: methionine synthase; mtrr: methionine synthase reductase; 
SaHH: S-adenosylhomocysteine hydrolase; SHmt: serine hydroxymethyltransferase; tHf: tetrahydrofolate; 
tS: thymidylate synthetase; X: methylacceptor.
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indeed, in 1976 Wilcken and Wilcken(7) showed abnormal homocysteine metabolism 
after methionine loading in patients with coronary artery disease. this first report was 
followed by many retrospective and prospective observational studies. these stud-
ies have been described in review articles and showed an overall positive association 
between plasma tHcy concentration and vascular disease (coronary heart disease, 
cerebrovascular disease, peripheral vascular diseases, and venous thrombosis)(8-13). 
a meta-analysis in 2002 estimated that a reduction of 3 µmol/l plasma tHcy is asso-
ciated with 16%, 25%, and 24% reduction for ischemic heart disease, deep vein 
thrombosis, and stroke, respectively(10). Somewhat weaker effects were found in 
prospective and mendelian randomization studies (see section 1.4)(9,14-16). random-
ized clinical trials to study the effect of homocysteine-lowering B-vitamin therapy on 
(secondary prevention of) mortality and morbidity from vascular disease were initiated 
a few years ago(17,18). at the start of the current PhD study, the results of these ran-
domized clinical trials were not yet published. the first publications and meta-analyses 
have shown inconclusive results with regard to effects on vascular disease risk and 
mortality(19-22) and have led to doubt about a causal and modifiable role for plasma 
tHcy in vascular disease pathology. 
figure 1.2  Distribution of fasting plasma total homocysteine concentration in a population-
based series of 461 Caucasian individuals (population is described in Chapters 3-6). 
 in addition to vascular disease, several observational studies have proposed a role 
for increased plasma tHcy in the aetiology of neurological dysfunction in the elderly(23), 
 alzheimer’s disease(24), schizophrenia(25), mood disorders(26), osteoporosis(27), and can-
cer(28,29).
 elevated concentrations of plasma tHcy have also been linked to increased risk 
for pregnancy complications and congenital abnormalities(30-32), including neural tube 
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defects (ntDs)(33-36). the observation of decreased concentrations of folate in blood 
and diets of mothers of ntD-affected offspring triggered the initiation of randomized 
clinical trials for maternal periconceptional folic acid supplementation in the nineteen-
eighties and early nineties. these trials showed that the occurrence and recurrence of 
ntD is reduced by 50-85%(37,38) and led to the general advice of periconceptional folic 
acid supplementation and to folic acid fortification in the united States. 
 the exact mechanism by which plasma tHcy concentration is related to disease is 
unknown and is likely to vary for different diseases. numerous causal mechanisms, 
which call for downstream pathological effects of increased plasma tHcy, have been 
proposed. for vascular disease, these include promotion of endothelial dysfunc-
tion(39-41), oxidative stress(41), protein modification(41,42), and impairment of methylation 
ability(43). the protective effect of folic acid supplementation on ntD risk clearly indi-
cates a role for folate-related metabolism in ntD aetiology. However, the underlying 
mechanism of this protective effect and the inability to prevent ntDs in a substantial 
number of families is not yet fully understood. the increased maternal concentrations 
of plasma tHcy in ntD-affected pregnancies, which are inherently related to decreased 
folate concentrations, and the tHcy-lowering effect of folic acid supplementation sug-
gested a role for homocysteine accumulation. Other proposed ntD mechanisms include 
maternal immunological responses that influence folate transport, impaired methyla-
tion rate (of Dna, rna, lipids, proteins), and impaired nucleotide biosynthesis(36,44). 
1.3  Elucidation of genetic aetiology of plasma tHcy-associated multi-
factorial diseases is important but difficult
the plasma tHcy-related diseases mentioned above (e.g. cardiovascular disease, 
venous thrombosis, ntDs) are, with exception of some rare monogenic forms, complex 
multifactorial diseases. features of multifactorial diseases include the involvement 
of environmental as well as genetic risk factors, ‘threshold’ inheritance (presence of 
multiple genetic susceptibility variants is required), aetiological heterogeneity (pheno-
typically similar patients may have different underlying risk profiles), and presence of 
gene-gene (epistatic) and gene-environment interactions. in addition, the frequencies 
and penetrances of the involved genetic variants are likely to range from very small to 
moderate(45-47). elucidation of the genetic background of these complex diseases may 
aid in the understanding of the disease aetiology, the development of diagnostic and 
prognostic tools, and allow the identification of modifiable risk factors for the develop-
ment of preventive and therapeutic measures. However, the abovementioned com-
plexities make the identification and characterization of these genetic determinants for 
multifactorial diseases a challenging task(45-47).
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1.4  Focus on plasma tHcy as genetically determined intermediate pheno-
type is easier and promotes elucidation of aetiology of multifactorial 
diseases
On the path between genetic variation and environmental exposures on one hand 
and discrete disease outcomes on the other, intermediate phenotypes can be de-
fined(45,48). intermediate phenotypes can be viewed as measurable variables that may 
be related to underlying pathogenic mechanisms which are positioned more closely 
to elementary genetic and/or environmental disease susceptibility factors (figure 
1.3). intermediate phenotypes that are influenced by genetic variations are also called 
endophenotypes(49). Due to their intermediate location in disease aetiology the number 
of involved genes and genetic complexity is expected to be less which will make the 
genetic analysis of intermediates easier compared to that of the ultimate disease 
phenotype itself. in addition, if quantitative, the increased power of analysis of continu-
ous compared to dichotomous disease traits can be exploited. also, larger effect sizes 
can be expected(45,48). an intermediate phenotype will be most useful in the search 
for genetic determinants of the associated complex diseases when it is a strong causal 
factor for disease and a sensitive indicator of the underlying pathogenic process, has 
a high heritability and shows a strong genetic correlation with the disease of inter-
est, has a relatively simple genetic aetiology with no or limited aetiological (genetic) 
heterogeneity, and can be measured easily, precisely and reliably. ideally, it is modifi-
able by environmental exposures (e.g. nutrition or drug) and hence offers direct target 
points for disease therapy. 
figure 1.3  Plasma tHcy concentration as intermediate phenotype for a multifactorial disease. 
Genetic and environmental factors, that may be interacting, underlie plasma tHcy concentra-
tions and may also lead to disease. In addition, genetic and environmental factors that are 
unrelated to plasma tHcy are involved in disease aetiology. Elucidation of the genetic aetiol-
ogy of plasma tHcy is less complex than that of the disease itself.
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Genetic determinants of intermediate phenotypes can be assessed for association to 
the disease outcome and provide direct indications for involved disease mechanisms. 
the associations between genetic variants and phenotype are generally insensitive 
for confounding by environmental factors due to the randomization that occurs during 
meiosis. Hence, the existence of randomly allocated genetic variants that predispose 
for an intermediate phenotype can be used to evaluate the effect of this intermediate 
phenotype on disease risk in an observational setting that is analogous to a random-
ized experimental design and allows causal inference. this concept was first introduced 
by Katan(50) and is known as ‘mendelian randomization’. the additional uses and limi-
tations of mendelian randomization have been described extensively by Davey Smith 
and ebrahim(51). uses include the ability to study lifetime effects and the absence of 
“reversed causation” for fixed genetic variants. limitations include the need for a reli-
able association between a genetic variant and the environmental risk factor under 
study, and the potential of confounding due to either population stratification or pleio-
tropic effects (a single genetic variant influences multiple phenotypes). in addition, 
very large sample sizes are required if the minor allele frequency (maf) of the studied 
genetic variant and/or the effect on the intermediate phenotype is small.
 the reported associations between plasma tHcy and multifactorial disease risk 
render this trait as a potentially useful intermediate one-carbon metabolism-related 
phenotype that can be modified by nutrition. the fact that several diseases are ac-
companied by elevated plasma tHcy concentrations, a heritable trait (see section 
1.5), may imply the presence of shared underlying genetic factors. indeed, Souto and 
colleagues(52) have estimated an age and sex adjusted genetic correlation between 
susceptibility to thrombosis and plasma tHcy of 0.652 which indicates that to a large 
extent the same genetic effects impact on both thrombosis and plasma tHcy. this may 
also hold for the other associated disorders. Hence, in the last decade or so, several 
groups have searched for genetic determinants of plasma tHcy concentrations. 
1.5 Genetic underpinnings of plasma tHcy are not clear yet
Plasma tHcy concentrations may be elevated by physiologic and lifestyle factors, 
including dietary deficiencies of folate, vitamin B12 (cobalamin), vitamin B6 (pyridoxal 
phosphate), and vitamin B2 (riboflavin), old age, male sex, smoking, impaired renal 
function, and the use of certain drugs(53). in addition, genetic causes affect the variation 
in plasma tHcy observed in the population. Several twin and family studies in healthy 
and diseased populations have evaluated the heritability (the part of the observed 
phenotypic variation of a trait or disease in a population that can be attributed to 
genetic variation within the population(54)) of plasma tHcy. the plasma tHcy concentra-
tions in these studies were often analyzed with and without adjustment for a (sub)set 
i n t r O D u C t i O n  19
of plasma tHcy associated factors including age, sex, B-vitamin intake, folate, vita-
min B2 , vitamin B12 and creatinin concentrations, smoking, alcohol consumption, and 
677C>t genotype in the methylenetetrahydrofolate reductase gene (MTHFR). all but 
one(55) showed a significant contribution of variation in genes to the observed variation 
in plasma tHcy with reported heritability estimates varying from 28% to 63%(56-59 . 
 the severely elevated plasma tHcy concentrations seen in homocystinuria patients 
are due to genetically determined deficiencies of enzymes in the homocysteine 
metabolism, including deficiency of methionine synthase and methylenetetrahydro-
folate reductase but mostly cystathionine ß-synthase deficiency(4). the mutations that 
cause these enzyme deficiencies, however, are very rare and hardly contribute to the 
heritability of plasma tHcy in the general population. Other, more common, Dna vari-
ants are presumed to be responsible for the heritable variation in plasma tHcy in the 
population. the knowledge about genetic causes of homocystinuria and homocysteine 
metabolism has been used in an attempt to efficiently select genes that have a high 
prior probability of influencing plasma tHcy concentrations, so called candidate genes.
 in 2005, Gellekink et al.(60) reviewed epidemiological studies that assessed the as-
sociation between candidate Dna variants and plasma tHcy concentrations. table 1.1 is 
adapted from this review and reflects the status of research into genetic determinants 
for plasma tHcy at the start of this PhD project. Genetic research has focused on a lim-
ited number of key genes in folate and homocysteine metabolism and on single locus 
effects of non-synonymous Dna variants that were discovered by direct sequencing of 
coding regions. for some of the evaluated Dna variants, an effect on gene expression 
or functional activity has been demonstrated. 
 in 1995 the negative influence of the MTHFR677C>t variant on mtHfr enzyme ac-
tivity and the resulting increase of plasma tHcy was described(61). after that, numerous 
studies have replicated the association between the Dna variant and increased plasma 
tHcy. approximately 12% of Caucasian individuals have the MTHFR677tt genotype and 
show ~50% of normal mtHfr activity and 2.5 µmol/l higher plasma tHcy than those 
with the MTHFR677CC genotype. Some have shown that the effect of this variant on 
plasma tHcy concentrations is dependent on folate and vitamin B2 status(53). Depen-
dency of the effect of MTHFR677C>t on the 31 base-pair variable number of tandem 
repeats (Vntr) in cystathionine ß-synthase gene (CBS) has also been indicated(62). in 
addition, interactions among MTHFR677C>t and 2576a>G in 5-methyltetrahydrofolate-
homocysteine methyltransferase (MTR) and 66a>G in 5-methyltetrahydrofolate-
homocysteine methyltransferase reductase (MTRR) have been reported(63). most other 
genetic determinants that have been evaluated for association to plasma tHcy have 
shown contradicting results among different studies. also, the number of studies into 
these potential candidate variants is small and the estimated effects on plasma tHcy 
concentrations were often relatively small(60). 
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Several other studies have shown that the contribution of MTHFR677C>t and other 
Dna variants to variation in plasma tHcy is small to moderate and that other, yet 
unidentified, genetic factors remain to be identified(56,59,63) (especially for post-load 
plasma tHcy(57)); only one study suggested that the MTHFR locus is responsible for al-
most all the genetic variation in plasma tHcy(58). this argues for a search for additional 
(single locus and multi-locus) genetic factors that contribute to plasma tHcy variance. 
Preferably, this search includes exploration of non-coding regions in candidate genes, 
evaluation of candidate genes that have so far not been studied, study of gene-gene 
interactions, and application of genome-wide mapping techniques(60). 
1.6  Plasma tHcy-related genetic aetiology of NTD and venous thrombosis 
also unresolved
the presence of a genetic component in ntD aetiology has been emphasized by 
several studies(36,64-66). Genes can contribute to congenital disease risk directly via the 
offspring genotype, with or without differential effects for maternal or paternal origin 
of the risk allele (parent-of-origin or imprinting effects). in addition, the maternal 
genotype can contribute to disease risk in offspring by influencing the intrauterine 
environment to which the developing offspring is exposed. a role for maternal genetic 
effects in ntD aetiology has been suggested(66). the elucidation of genetic causes of 
ntD has been the focus of our research group for several years. triggered by the ntD 
risk reduction due to periconceptional folic acid supplementation, genetic research has 
concentrated on a number of candidate genes in folate and homocysteine metabo-
lism(36,65). an extensive review on genetic variation related to homocysteine and folate 
metabolism and ntD risk has been written by van der linden et al. in 2006(65). in short, 
in 1995 MTHFR677C>t was identified by our group as first genetic ntD risk factor for 
mothers as well as offspring(67). after that, a number of Dna variants in coding regions 
of genes related to folate and homocysteine metabolism have been explored for 
their association to ntDs in offspring or mothers. Generally, strong associations were 
not found but several variants may be associated to ntDs (e.g. maternal MTRRa66G). 
research including variants other than the obvious candidate variants in folate and 
homocysteine metabolism, multi-locus effects, and more elaborate examination of 
maternal and offspring effects, may lead to identification of new genetic determinants 
of ntD(36,44,65).
 in 1995, our group was one of the first to describe the association between plasma 
tHcy concentrations and thrombosis risk(68). a causal role for plasma tHcy in thrombosis 
has been supported by some, but not all studies(22,69-71). recently, a role for low methi-
onine concentrations in thrombosis aetiology was suggested(72). the contribution of ge-
netic variation to thrombosis liability has been estimated to ~55% in two studies(52,73). 
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the genetic correlation of 0.652 between plasma tHcy and liability to thrombosis 
estimated by Souto et al. (52) underlines the presence of shared genetic determinants. 
a recent meta-analysis by den Heijer et al.(13) demonstrated a positive association be-
tween MTHFR677C>t, an established determinant of plasma tHcy, and venous throm-
bosis although not all studies showed a significant result(13,74). also other homocysteine 
metabolism-related genetic variants have been evaluated for association to thrombosis 
risk in small scale studies. the 68 base pair insertion in CBS (CBS844ins68) did not 
show significant association in most studies(75-77) but one study did report a protective 
effect(78). inconsistent results regarding influence of combined presence of CBS844ins68 
and MTHFR677C>t polymorphisms and thrombosis risk have been described(77-79). 
negative association results for MTR2576a>G(80-82), MTRR66a>G(75,82), 776C>G in the 
transcobalamin gene (TCN2)(83), and polymorphisms in S-adenosylhomocysteine hydro-
lase (AHCY), thymidylate synthetase (TYMS), reduced folate carrier (RFC1 or SLC19A1) 
and aiCar transformylase/inosine monophosphate (IMP) cyclohydrolase (ATIC)(84,85) 
have been reported. additional epidemiological studies into genetic variations that 
influence plasma tHcy as well as thrombosis risk are warranted to decipher the disease 
mechanisms underlying the association between plasma tHcy and thrombosis.
1.7  Alternative genetic epidemiological study designs and analyses  
may promote elucidation of genetic background of plasma tHcy  
and related phenotypes 
in this thesis, the search for and characterization of genetic determinants of plasma 
tHcy concentration and venous thrombosis and ntD risk will involve a genetic epidemi-
ological approach. Genetic epidemiology is the study of the role of genetic factors and 
their interaction with environmental factors in the occurrence of disease in human pop-
ulations(86). many similarities between concepts and methods used in classical epide-
miology and the subspecialty of genetic epidemiology exist. However, the latter makes 
use of specific concepts and methodological tools to accommodate for the more or less 
predictable transmission from one generation to the next of the genetic determinants 
under study. roughly, the process of genetic epidemiology involves establishment of 
a genetic component to the disease trait of interest, clarification of the underlying ge-
netic inheritance model, localisation of the susceptibility genes, and identification and 
characterization of the causal genetic variants that underlie the disease trait(87). 
 as outlined in the sections above, epidemiological analysis of genetic determinants 
of plasma tHcy and associated disease phenotypes focused on direct association stud-
ies for potentially functional Dna variants in coding regions of a limited number of 
key genes in the folate cycle and homocysteine metabolism. this approach entails a 
high prior probability of actually genotyping the biologically relevant functional variant. 
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However, these hypothesis-driven candidate gene association studies rely on exist-
ing knowledge in the selection of genes and Dna variants of interest. important Dna 
variants may be overlooked using this approach. increase of the number of measured 
candidate genes and Dna variants can maximize the probability of genotyping the 
relevant variants. in addition, alternative approaches can be applied: linkage analysis 
and indirect association studies.
 linkage analysis allows for unbiased evaluation of the complete genome or ge-
nomic regions for Dna variants that influence disease traits. linkage analysis involves 
the evaluation of cosegregation of polymorphic, non-functional Dna variants with 
known location (markers) with disease in families. Cosegregation indicates a lack of 
recombination and, hence, proximity of the marker and the disease locus. the ability 
to genotype sets of hundreds of markers spread throughout the human genome has 
contributed to the successful identification of many genes underlying monogenic and 
simple mendelian diseases in the last two decades of the 20th century. the identified 
linkage region usually contains many genes and has to be scanned and evaluated in 
more detail to ultimately identify the specific genetic variant that causes the linkage 
signal(88). unfortunately, this linkage approach is not powerful for complex multifactorial 
disease traits; the influence of multiple genetic determinants with small marginal ef-
fects requires large number of families in which the disease trait segregates to obtain 
adequate power to map disease loci. therefore, the focus of genetic epidemiology has 
shifted from linkage to association studies(89,90).
 association studies were facilitated by the development of rapid and cheaper ge-
notyping techniques and the completion of the draft of the human genome sequence 
in 2003 and the subsequent increase in knowledge on Dna variants across the human 
genome(91). One can distinguish between direct and indirect association studies. in 
the first, putative causal variants are genotyped, relying on existing knowledge about 
candidate Dna variants. indirect association studies aim at measurement of causal 
variants via genotyping of Dna variants that are in linkage disequilibrium (lD) with 
these unmeasured, causal variants. the power to identify a causal variant is dependent 
on the strength of the lD measure r2 that exists between the measured variants and 
the unmeasured causal locus. Optimal utilization of this indirect approach depends on 
knowledge of lD in the human genome. at the end of 2002 the international Haplo-
type mapping (Hapmap) project was initiated with the goal of constructing genome-
wide maps of lD patterns by measuring a vast number of SnPs in four populations to 
facilitate the efficient execution of lD mapping(92). the first and second phases of this 
project have been finished in 2005 and 2007, respectively(93,94) and the generated 
data are freely available via the World Wide Web (http://www.hapmap.org/). Hence, 
nowadays indirect association studies offer an alternative to the direct association 
approaches that have been used in the past and can be applied to candidate genes 
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or genomic regions to efficiently search for additional genetic variants for plasma tHcy 
and related disease phenotypes.
 the statistical analysis of genetic association studies for plasma tHcy and related 
disease phenotypes generally involved a single Dna variant (single locus analysis). 
analysis of multiple Dna variants simultaneously (i.e. multi-locus analysis) based on 
haplotypes (combinations of linked alleles at different loci on the same chromosomal 
background) can however be advantageous in indirect association studies where 
the r2 between a haplotype and the unmeasured causal variant is stronger than that 
between the single Dna variants and the unmeasured causal variant or when allelic 
interactions are present. the analysis of combinations of genotypes that may be lo-
cated in the same or different genes allows the study of multi-locus genotypic effects 
and interactions and increases the chance to detect causal Dna variants with small 
marginal effects but larger interactive effects(92). interaction analyses using traditional 
parametric regression analysis are hampered by problems including sparse data and 
multiple testing. However, a variety of advanced non-parametric techniques for analyz-
ing multi-locus effects have been developed and described(95). these have however 
not been widely applied yet and information on their performance is limited. more 
knowledge on the strengths and weaknesses may promote their correct application to 
real data, also for the analysis of genetic determinants of plasma tHcy.
 the importance of distinguishing maternal from offspring genotypic effects in con-
genital disorders like ntD has been touched upon in the previous section. the popula-
tion-based case-mother/control-mother design and the family-based case-parent triad 
design allow for this distinction. in the popular population-based case-control design 
association is based on evaluation of differences in (genotype or allele) frequencies of 
the Dna variant between case and control series. associations may arise due to true 
direct or indirect association, chance, or confounding (due to other factors than lD). 
as stated earlier in section 1.3, associations between Dna variants and a disease trait 
are generally insensitive to confounding. Genetic case-control studies may be con-
founded, however, if the case and control samples are selected from a population that 
exists of several subpopulations with different allele frequencies of the genetic variant 
under study and differences in baseline disease risk. the extent to which population 
stratification may bias associations in populations of european origins, is still unclear. 
Several techniques to deal with confounding due to population stratification have been 
described and include selection of cases and controls from homogeneous outbred 
populations, division of the association test statistics of interest by the median test 
statistic of simultaneously measured genetic markers that are unrelated to the disease 
trait (genomic control), and the use of family-based association studies. 
 in the analysis of family-based designs (e.g. case-parent triads, nuclear families) the 
transmission rates of genotypes or alleles from parents to affected individuals are com-
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pared with the untransmitted genotypes or alleles of those transmitted to unaffected 
family members. Hence, the control sample is inherently matched to the case sample 
with regard to genetic background and no bias from population stratification can arise. 
a disadvantage of these family-based studies is that ascertainment of study samples 
may be more difficult and that power is limited compared to equally-sized population-
based case-control studies(92). Hybrid designs, that entail genotyping of case-parent-
triads and unrelated controls or unrelated control-parent pairs have recently been 
proposed and evaluated(96-98). they were shown to exploit the advantages of both the 
population-based and family-based design. However, alternative hybrid designs can be 
constructed as well. evaluation of these additional designs may enhance the toolbox 
for genetic epidemiological studies into genetic determinants of congenital disorders 
like ntDs.
1.8 Objectives and outline of this thesis
the main objective (part 1) of this thesis was to identify Dna variants that influence 
plasma total homocysteine concentrations and related diseases by use of genetic 
epidemiological studies. in this thesis we focused on neural tube defects and venous 
thrombosis. a second objective (part 2) was to develop and evaluate genetic epidemi-
ological tools that support the main objective of this thesis and enhance the identifica-
tion and characterization of genetic risk factors in multifactorial traits in general.
Part 1: Genetic determinants of homocysteine and related diseases
Chapter 2 describes a genome-wide linkage study that allows localisation of quanti-
tative trait loci (Qtls) that influence plasma tHcy concentrations without the need to 
predefine candidate gene variants of interest. Chapters 3 and 4 describe extensive 
candidate-gene association studies for plasma tHcy in which we measured Dna varia-
tion in genes that are involved in homocysteine and folate metabolism. in chapter 
3 we analysed the association between 79 variants in 40 genes and homocysteine, 
folate and methionine concentrations using a SnP-microarray approach. these 79 vari-
ants included mutations and polymorphisms that were known to change the function 
or regulation of a gene product and had already shown association with a disease but 
also contained synonymous and intronic SnPs that may indirectly measure untyped 
causal Dna variants via lD. in chapter 4 we re-examined the association between 
36 Dna variants in 19 genes and plasma tHcy. the single locus associations for these 
candidate variants were already reported previously. in the current study we applied 
haplotype and multi-locus genotype analyses to allow for the detection of haplotype 
effects and genotype interactions. in chapters 5 and 6 we performed candidate-gene 
association studies for plasma tHcy and neural tube defects and venous thrombosis. 
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this enabled the simultaneous evaluation of the influence of the Dna variants on plas-
ma tHcy concentration as well as the disease phenotype and hence the assessment of 
involved disease mechanisms. Chapter 5 presents a case-control study on 45 folate-
related genes and 87 Dna variants for spina bifida, the most common type of ntD, 
based on the same SnP-microarray as used in chapter 3. the Dna variants that were 
most strongly associated with spina bifida were assessed for association to homocys-
teine, folate and cobalamine concentrations in the control population. unpublished 
preliminary results indicated a role for a 45 base pair deletion/insertion polymorphism 
in the uncoupling protein-2 gene (UCP2), a potential regulator of mitochondrial reactive 
oxygen species production and hence involved in oxidative stress, and plasma tHcy. 
in chapter 6 the relation between this variant and plasma tHcy as well as recurrent 
venous thrombosis is evaluated in a case-control setting. 
Part 2: Genetic epidemiological designs and analyses
Chapter 7 presents a new hybrid design that augments collection of case-parent triad 
and control-mother dyad genotype data to estimate offspring as well as maternal 
genetic effects in disease causation, an analysis that is especially relevant in congenital 
and early-onset disorders like ntDs. its performance compared to existing alternative 
designs is evaluated. Chapter 8 describes the evaluation of four existing techniques of 
analysis that can be applied to study multi-locus interactions in case-control studies: 
traditional parametric logistic regression, sum statistics, logic regression, and the multi-
factor dimensionality reduction method. 
a general discussion of the studies that are presented in this thesis is given in  
chapter 9. 
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a genome-wide linkage scan for 
homocysteine levels suggests 
three regions of interest 
abstract
Background
An elevated plasma total homocysteine (tHcy) level is a risk factor for 
many clinical conditions, including vascular disease and venous throm-
bosis. The tHcy levels are partly determined by genetic factors. Extensive 
candidate gene studies have identiﬁed several genetic variants, including 
the MTHFR 677C>T, that inﬂuence tHcy levels, but so far only part of the 
genetic variation in tHcy can be explained. 
Objective
In order to identify chromosomal regions that inﬂuence tHcy levels, a 
genome-wide linkage analysis was conducted. 
Patients/methods
Our study population consisted of 13 pedigrees and 469 subjects with 
data on fasting plasma tHcy levels. A set of 377 markers covering the 
genome was genotyped in 275 subjects. The variance component linkage 
method (SOLAR version 2.1.3) was used for the two-point and multipoint 
linkage analyses. 
Results
The heritability of the age- and sex-adjusted homocysteine levels was 
44%. The multipoint linkage analysis identiﬁed one region with sugges-
tive linkage on chromosome 16q (LOD score 1.76; nominal P=0.0024). 
Weaker evidence of linkage was found for regions on chromosome 12q 
(LOD score 1.57; nominal P=0.0036) and chromosome 13q (LOD score 
1.52; nominal P=0.0041). 
Conclusions
In our families the plasma tHcy level was highly heritable. The multipoint 
linkage analysis identiﬁed three regions that showed weak to suggestive 
linkage to tHcy levels. 
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Introduction 
Homocysteine is a sulfur-containing intermediate in the methionine metabolism. an 
elevated level of plasma total homocysteine (tHcy), or hyperhomocysteinemia, is as-
sociated with many clinical conditions, including vascular disease(1–3), stroke(1,4), venous 
thrombosis(3,5), congenital abnormalities (6) and alzheimer’s disease(7). 
 a substantial part of the variation in plasma tHcy levels can be contributed to 
genetic factors; heritability estimates vary from 8 to 47%(8–10). to date, the search 
for genetic determinants of plasma tHcy levels has been focusing on the candidate 
gene approach, in which genes are selected on basis of our current knowledge of the 
homocysteine metabolism. Genetic variants within these candidate genes have been 
evaluated for their association with plasma tHcy levels, mostly in population-based 
association studies. the most important genetic determinant identified so far is the 
mtHfr 677C>t polymorphism. this single nucleotide polymorphism has been reported 
to explain 4–9% of the variation in plasma tHcy levels(9–12). Other genetic variants have 
been studied, but they showed weak and inconsistent effects(13). So, despite extensive 
candidate gene studies, it seems that only little of the genetic variation of plasma tHcy 
levels can be explained. 
 Here, we report one of the first conducted genome-wide linkage scans for plasma 
tHcy levels. an advantage of this method is that it does not rely on the selection of 
candidate genes beforehand. Our objective was to find quantitative trait loci (Qtls) that 
contribute to variation in plasma tHcy levels, which may lead to the identification of 
genes that have not been found through the candidate gene approach.
Subjects and methods 
Study population 
the study population is part of a large family study on familial combined hyperlipid-
emia (fCH) in which families were recruited in 1994 and followed up in 1999. this 
population has been described previously(14,15). Briefly, ascertainment of the families 
took place through probands who were diagnosed as having fCH based on the pres-
ence of high cholesterol and/or high triglyceride levels. a family was only included if 
a multiple type of hyperlipidemia was found in first-degree relatives and the proband 
or a first-degree relative presented premature cardiovascular disease before the age of 
60 years. Subjects had to be 12 years or older to be included, and all individuals were 
Caucasian. in total, 50 families comprising 1036 individuals entered the study. the ethi-
cal committee of the radboud university nijmegen medical Centre approved the study 
protocol. 
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thirteen informative families consisting of 482 subjects were selected for the genome 
scan. these families varied in size from 12 to 114 individuals and spanned at least 
three generations. Genotyping has been performed in 275 persons who were selected 
based on their positions in the pedigree and expected informativity. Selection of the 
pedigrees and 275 persons was performed using the SlinK simulation software(16,17). 
Plasma homocysteine measurement
Blood samples of individuals in a subpopulation of the fCH study, including the 13 
genome scan pedigrees, were collected by venipuncture after a 4-week withdrawal 
period of lipid-lowering medication and an overnight fast, and were put on ice imme-
diately. total fasting homocysteine concentration in plasma was measured by an auto-
mated high-performance liquid chromatography method with reverse phase separation 
and fluorescence detection(18). the plasma tHcy level was successfully determined in 
469 of the 482 subjects. 
Genotyping 
Dna was obtained from peripheral blood lymphocytes by a standard method(19). 
Genotyping of 377 markers in the autosomal genes at an average 10 cm density and 
with an average marker heterozygosity of 0.75 was performed by the marshfield 
mammalian Genotyping Service (marshfield, Wi, uSa). the markers primarily origi-
nated from screening set 9 and in part from screening set 10. Sex-averaged marker 
maps were obtained from the marshfield Center of medical Genetics (http://research.
marshfieldclinic.org/genetics/). the mtHfr 677C>t polymorphism was tested by poly-
merase-chain reaction in 333 subjects, essentially according to the method of frosst et 
al.(20). Discrepancies in genotyping were checked using the PedCheck program(21) and 
inconsistent marker genotypes were set to missing (0.5%). 
Statistical analysis 
Quantitative genetic analysis and two-point and multipoint linkage analysis were per-
formed using the variance components method as implemented in the SOlar package 
(version 2.1.3)(22). the variance components method assumes multivariate normality 
of the trait and is vulnerable to a high kurtosis(23). in order to obtain more normally 
distributed values, homocysteine levels were logarithmically transformed and z-scores 
were calculated. the homocysteine values of two outliers were reduced to the next 
less extreme value. Prior to heritability calculations and linkage analysis, adjustments 
for age and sex were made using the regression modeling option. allele frequencies of 
the markers were estimated through maximum likelihood techniques and were used 
to impute missing genotype data and to create identical by descent (iBD) files. the 
program HOmO that is implemented in the SOlar package was used to assess genetic 
heterogeneity. Simulation techniques were applied to calculate empirical point wise  
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P-values of observed lOD scores. as pedigrees were selected through fCH probands 
and no association between tHcy levels and fCH exists in these pedigrees(18), no ascer-
tainment correction was made. using simulation techniques in SOlar, we calculated 
our power to detect a Qtl with an effect size of 25%, that is, a locus that explains 25% 
of variation in plasma tHcy levels, based on the number of observations with both in-
formation on plasma tHcy level and genome scan data. the power to find the Qtl with 
a lOD score of 2, 1.5 and 1 or higher was 41%, 57% and 75%, respectively. therefore, 
lOD scores of 1 or higher were reported here. 
Results
the mean age of the 469 subjects with homocysteine measurements who were avail-
able for the quantitative genetic analysis was 43.3 years (range: 13–88 years). the 
percentages of males (45%) and females (55%) were comparable. after correction of 
the two outliers with tHcy values of 1.9 and 46.6 µmol l-1, the geometric mean fasting 
tHcy level was 11.0 µmol l-1 with a range of 4.1–34.2 µmol l-1. the heritability of the 
unadjusted log transformed plasma tHcy levels was 40.7%. after adjustment for age 
and sex the heritability increased to 44.4% (P < 0.0001). 
 two hundred and sixty-four subjects had both homocysteine measurements and ge-
nome scan data and were available for the linkage analysis. their mean age was 48.5 
years (range 14– 88 years), 47% was male and 53% was female, and the geometric 
mean tHcy level in this subgroup was 11.1 µmol l-1 (range 4.3–34.2 µmol l-1). 
MTHFR 677C>T polymorphism 
the mtHfr 677C>t polymorphism was genotyped in 333 subjects with tHcy measure-
ments. Geometric means of plasma homocysteine levels (95% confidence intervals; 
Ci) for the mtHfr677 genotype groups were 9.9 (9.4–10.4), 10.7 (10.2–11.2) and 
12.1 (10.2–14.3) µmol l-1 for the CC, Ct and tt group, respectively. the mtHfr 677C>t 
polymorphism was associated with plasma tHcy levels and accounted for 3.0% of the 
variation in tHcy levels in this study population.
Multipoint linkage analysis 
the results of the multipoint genome scan for the adjusted plasma tHcy levels are 
shown in fig. 2.1. three areas with a lOD score exceeding 1 were observed. the region 
with the highest score of 1.76 (nominal P=0.0024) was located on chromosome 16q12 
between markers D16S3253 and Gata138C05 and a peak location of 75 cm. the link-
age peak was very broad with a 1-lOD support interval (interval in which the lOD score 
is within 1.0 of its maximum) of 33 cm till 90 cm. furthermore, tentative indications 
of linkage to regions on chromosome 12q14 (lOD score 1.57; nominal P=0.0036) and 
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chromosome 13q31 (lOD score 1.52; nominal P=0.0041) were identified. the linkage 
regions on chromosome 12 and 13 were also very broad with 1-lOD support intervals 
of 40–92 cm and 68–100 cm and peak locations of 83 cm and 87 cm, respectively. the 
reported lOD score on chromosome 16 could be found by chance approximately one 
time every genome scan, and can be interpreted as suggestive linkage evidence(24). 
the other lOD scores did not meet the criterion for suggestive linkage. no genetic 
heterogeneity was observed for the three regions. 
 
fig. 2.1  Results from the genome-wide multipoint linkage scan for the autosomal chromo-
somes. The hatch marks on the left side of the chromosome indicate the locations of the 
genotyped markers. The bold line indicates the LOD score for the chromosomal locus. 
the multipoint linkage analysis is sensitive to errors in marker maps. therefore, two-
point linkage analysis was conducted. the three multipoint peaks were also found in 
the two-point analysis with lOD scores of 2.0 (D12S1052, 83.2 cm), 1.4 (D13S796, 
93.5 cm) and 1.3 (D16S3253, 71.8 cm) for chromosomes 12, 13 and 16, respec-
tively. Other linkage peaks in the two-point analysis were located on chromosome 1 
(D1S1609, 274.5 cm, lOD score 1.5), chromosome 3 (D3S1768, 61.5 cm, lOD score 
1.6), and chromosome 20 (Gata129B03, 35.5 cm, lOD score 1.1) but these were not 
observed in the multipoint analysis.
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Discussion 
We conducted a genome-wide linkage analysis for plasma tHcy levels in an fCH popu-
lation consisting of 13 extended pedigrees comprising 469 subjects with homocysteine 
measurements and 275 subjects with genome scan data. the heritability of age- and 
sex-adjusted plasma tHcy levels was 44%, indicating that in our population additive 
genetic effects determined a substantial part of the variation in homocysteine levels. 
three regions on chromosome 12, 13 and 16 with weak to suggestive linkage to Qtls 
for tHcy were identified. 
 Souto and colleagues recently reported results of the first genome scan for plasma 
tHcy levels in Spanish families in the Gait Study (25). in this study, 12 families were 
ascertained through a proband with thrombophilia, and nine were recruited without 
regard to phenotype. Significant linkage evidence (lOD score 3.1) was found for chro-
mosome 11q23 and suggestive linkage (lOD score 1.7) for chromosome 10q22. the 
nicotinamide n-methyltransferase (nnmt) gene, a positional candidate gene located 
in the 11q23 linkage region, showed significant association with plasma tHcy levels. in 
our study, we could not confirm these linkage results. However, a small linkage peak 
was observed proximal of the nnmt location with a peak lOD score of 0.61 at 105 cm. 
Differences or non-replication of the results of the linkage scan in the Spanish families 
and ours may have arisen because of (genetic) heterogeneity between the popula-
tions or to relatively low power of both studies to identify Qtls with small effects. 
 Homocysteine level can be regarded as a multifactorial trait; environmental factors 
and several genes with different effect sizes are involved and gene–environment and 
gene–gene interactions can play a role. it is common knowledge that moderate size 
linkage studies can lack power to identify small effect Qtls in complex traits with high 
lOD scores and that, as in every study with (multiple) testing, there is a chance of 
false positive signals that has to be reckoned with. this calls for a careful interpreta-
tion of the linkage results that, possibly together with information from other studies 
and sources, could lead to new hypotheses regarding chromosomal regions or genes 
involved in the trait of interest. Simulations showed that in our study we had 41% 
power to detect a Qtl that explained 25% in tHcy variation or more with a lOD score 
of 2. Our linkage study was not powerful enough to provide conclusive linkage evi-
dence for Qtls with relatively small effect sizes. 
 Jee et al.(10) suggest the presence of a major gene for homocysteine in addition 
to mtHfr that may explain as much as 37% of the variation in adjusted homocyste-
ine levels, based on results of a family study with probands who underwent elective 
coronary arteriography. the presence of an additional major gene independent of the 
mtHfr 677C>t could not be confirmed by a segregation analysis we performed in 51 
families ascertained through hyperhomocysteinemic probands(9). the mtHfr 677C>t 
polymorphism was measured in 333 subjects in this study; it was associated with 
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plasma tHcy levels and accounted for ~3% of plasma tHcy variation in our families. 
With the heritability estimate of 44% in mind, these findings indicate that other genes 
besides the mtHfr can in theory play a major role in determining plasma tHcy levels. 
However, our results do not support the presence of a major Qtl with a very large ef-
fect, as indicated in the article by Jee et al.(10). 
 although the linkage regions we found were very broad, we scanned the three 
regions on chromosome 16, 12 and 13 for biologically plausible candidate genes that 
could explain the observed linkage peaks with help of the uCSC Genome Browser 
(http://genome.ucsc.edu/cgi-bin/hgGateway). the 1-lOD support interval around the 
peak on chromosome 16q was mapped to a region of ~60 cm and contains numerous 
genes. We could not select an obvious candidate gene. also, we did not find positional 
candidate genes in the linkage region on chromosome 13. 
 the region on chromosome 12 contains the serine hydroxy-methyltransferase 2 
(SHmt2) gene that is located on chromosome 12q13.2 and encodes the mitochondrial 
isoform of this methyltransferase. this enzyme catalyzes the reversible reaction of ser-
ine and tetrahydrofolate into glycine and 5,10-methylene tetrahydrofolate. theoretical-
ly, deleterious genetic variants within this gene could lead to elevation of tHcy levels. 
a few years ago, we already investigated this gene in 70 patients with spina bifida but 
no significant association with tHcy levels was found(26). as far as we know, no other 
association studies for variants in this gene and plasma tHcy have been performed. it 
is therefore questionable if genetic variants in this gene could be responsible for the 
observed linkage signal. 
 furthermore, the methyltransferase-like gene 1 (mettl1) that is assigned to 
chromosome location 12q13 lies within the 1-lOD-support interval. this small gene 
contains a highly conserved S-adenosylmethionine-binding domain and therefore prob-
ably encodes a methyltransferase(27). mettl1 could be viewed as a possible positional 
candidate gene. it has not been studied for its relation with tHcy levels yet, but further 
studies to explore its association could be warranted. 
 Other known candidate genes involved in the homocysteine metabolism were not 
found in the linkage analysis. the mtHfr gene is the most important known genetic 
determinant of plasma tHcy level and maps to chromosome 1p36.3. We did not find 
evidence of linkage for this region; a lOD score of ~0.2 was observed. With help of 
simulation studies we calculated an expected lOD score (elOD) of ~0.2 for a Qtl 
with the effect size of 3% as we observed for the mtHfr 677C>t polymorphism in 
this study. not finding a high linkage peak for the mtHfr gene in this study could be 
expected because of its low impact on tHcy levels in this population. 
 Overall, one region with suggestive linkage evidence and two other potentially 
interesting regions were identified. two candidate genes that may be responsible for 
the linkage peak on chromosome 12 are SHmt2 and mettl1 but their relation to the 
linkage peak is very speculative. investment in fine mapping of the linkage regions 
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could narrow the 1-lOD support intervals and refine the location of the putative genetic 
determinants. Confirmation of the linkage regions or confirmation of possible involve-
ment of the genomic regions in homocysteine levels in other studies is warranted 
before further steps are taken.
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Candidate-gene association study 
for one-carbon metabolism- 
related genes and folate, 
 homocysteine, and methionine 
concentrations
abstract
Concentrations of folate, homocysteine, and methionine have been asso-
ciated with common disorders like neural tube defects, vascular disease, 
and cancer. Identiﬁcation of genetic determinants of these one-carbon 
metabolism intermediates can be used as a tool to elucidate pathogenic 
mechanisms and identify modiﬁable risk factors. Previous studies have 
focussed on a limited number of key genes and have not led to complete 
understanding of the genetic underpinnings of these three metabolites. 
Therefore, we analyzed 79 DNA variants in 40 genes related to the folate 
cycle, remethylation, transmethylation, and transsulfuration for association 
with fasting serum folate, fasting and post-load plasma total homocyste-
ine (tHcy), and fasting plasma methionine concentration in 190 popula-
tion-based Caucasian subjects. SNP rs1801133 (MTHFR677C>T) was main 
determinant of serum folate (nominal p=0.002); other strong determi-
nants included rs8101626 in DNMT1 (nominal p=0.003) and rs1801394 
(MTRR66A>G) (nominal p=0.011). MTHFR677C>T was also nominally 
associated to fasting and post-load plasma tHcy (nominal p=0.026 and 
0.006, respectively). SNP rs2276598 (DNMT3A1523G>A) showed nomi-
nal association to fasting tHcy (nominal p=0.035). CBS844_845ins(68bp) 
was signiﬁcant determinant of post-load tHcy (nominal p=0.0005; family-
wise p=0.044) and explained 6.3% of its variance. A non-synonymous 
variant (rs672346) in BHMT (nominal p=0.014) and 3’ UTR rs1078004 in 
ICMT (nominal p=0.030) were related to methionine. Substantial overlap 
in strong DNA variants for fasting and post-load plasma tHcy was present. 
Only MTHFR677C>T showed strong association to more than one of the 
three metabolites. In conclusion, our study resulted in establishment of 
known and identiﬁcation of new candidate DNA variants for folate, homo-
cysteine, and methionine concentrations.
Introduction
One-carbon metabolism involves the transfer of carbon groups and is related to es-
sential physiologic processes. these include formation of purines and thymidine for 
Dna and rna synthesis, methylation of Dna, rna, lipids and proteins, and regula-
tion of oxidative stress (figure 3.1). Concentrations of the one-carbon intermediates 
folate, homocysteine, and, to a lesser extent, methionine, have been associated to 
the development of numerous disorders including neural tube defects (ntDs), vascular 
disease, cancer and neurological disorders (12). the mechanisms underlying the associa-
tion between clinical conditions and these correlated metabolites are still unclear and 
have been proposed to be causal. this has been supported by the fact that pericon-
ceptional folic acid supplementation reduces the occurrence and recurrence of ntDs by 
50-85%(3,4). also, a causal role has been indicated by numerous observational studies, 
including genetic association studies on the 677C>t single nucleotide polymorphism 
(SnP; rs1801133) in the methylenetetrahydrofolate reductase gene (MTHFR) that 
exploit the principle of mendelian randomization(5), (e.g. 6-8). However, contradicting 
observational findings have also been published (e.g. 9,10), and recent secondary inter-
vention trials with plasma tHcy-lowering therapy, including folic acid, were inconclusive 
with regard to effects on vascular disease risk and mortality(11-13).
 Proper function of one-carbon metabolism and maintenance of adequate concen-
trations of its intermediate metabolites are dependent on genetic factors in addition 
to habitual dietary intake of folate and B-vitamins and biological factors like age and 
sex(14). the contribution of genetic variability to the population interindividual variation 
of serum folate, reflecting short-term fluctuation in dietary intake and mainly present in 
the form of 5-methyl-tHf, has been examined in one study; heritability was estimated 
to be 32% (after adjustment for age, sex and smoking)(15). no heritability estimates for 
methionine concentrations have been published, to our knowledge. in contrast, several 
reports on the heritability of plasma tHcy have been published with estimates varying 
from 8% to 63%(16-20). notably, variation in post-methionine load (hereafter referred to 
as post-load) plasma tHcy is presumably under stronger influence of genetic variation 
than fasting state plasma tHcy(18).
 the identification of Dna variants that influence the concentrations of disease-relat-
ed one-carbon intermediates can increase our understanding of the underlying pathol-
ogy of one-carbon metabolism-related diseases, and may lead to the identification of 
nutrition-gene interactions that contribute to disease risk. although numerous genetic 
association studies for plasma tHcy and, to a lesser extent, folate, have been reported, 
the MTHFR677C>t is the only Dna variant for which the relation with decreased folate 
and increased plasma tHcy is established. Since its discovery in 1995(21) the associa-
tion of this SnP, which affects mtHfr activity, and plasma tHcy and folate has been 
confirmed in multiple populations(22-26). the study of other Dna variants in key genes
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figure 3.1  Simplified representation of one-carbon metabolism with depiction of four 
metabolic processes (see Table 3.1; outlined and numbered), major metabolites (bold), and 
metabolic substrates and products (italics). 
One-carbon metabolism regulates the availability of methyl groups for essential physiologic processes. 
activation of methionine by adenosine triphosphate (atP) results in formation of S-adenosylmethionine 
(adomet), a universal methyl donor for methylation of deoxyribonucleic acid (Dna), ribonucleic acid (rna), 
lipids and proteins. S-adenosylhomocysteine (adoHcy), the demethylated product of these reactions, is the 
precursor of homocysteine. Homocysteine can be irreversibly transsulfurrated to cysteine and, eventually, 
glutathionine. the latter is involved in oxidative stress mechanisms. Homocysteine can also be remeth-
ylated to methionine. the methyl donor for this reaction is 5-methyltetrahydrofolate (5-CH3tHf). the 
remethylation reaction thus involves donation of a methyl group from the folate cycle to the methionine 
cycle. tetrahydrofolate (tHf), formed in this remethylation reaction, but also via other reactions, is substrate 
for purine and pyrimidine synthesis, the building blocks of Dna and rna.
in one-carbon metabolism has not led to conclusive results and identification of ad-
ditional major determinants(25,26). However, the 31 base pairs (bp) variable number of 
tandem repeats (Vntr) polymorphism in cystathionine beta-synthase (CBS), 766G>C 
(rs1801198) in transcobalamin II (TCN2), 324G>a (rs4680) in catechol-o-methyl-
transferase (COMT), and 1364G>t (rs1021737) in cystathionine γ-lyase (CTH), may be 
regarded as weaker determinants of (post-load or fasting) plasma tHcy that warrant 
further investigation(25). recently, a population-based study including 10,601 subjects 
investigated the associations of 12 one-carbon-related metabolites, including folate, 
homocysteine and methionine concentrations, with 13 candidate-gene Dna vari-
ants(24). they did not find significant associations between methionine concentrations 
homo- 
cysteine
methionine
2. remethylation
3. methyltransfer
4. transsulfuration
1. folate cycle
AdoMet
5-CH3-THF
THF
purine and pyrimidine synthesis
DNA, RNA,
lipids, proteins
cysteine
methylated DNA,
RNA, lipids, proteins
AdoHcy
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and any of the investigated polymorphisms but did find associations with plasma tHcy 
and MTHFR677C>t, MTHFR1286a>C, 2756a>G in 5-methyltetrahydrofolate-homocyste-
ine methyltransferase (MTR), and the CBS844_845ins68 variant. in addition, associa-
tions for serum folate with MTHFR677C>t, MTHFR1286a>C, 1958G>a in methylenetet-
rahydrofolate dehydrogenase (NADP+ dependent) 1 (MTHFD1), and 80G>a in solute 
carrier family 19 (folate transporter), member 1 (SLC19A1, RFC1) were reported.
 the aim of this study was to identify genetic determinants of folate, homocysteine 
and methionine concentrations. So far, the search for genetic determinants of folate and 
homocysteine has mainly focused on a restricted number of Dna variants in several rel-
evant genes. in the present study, we have applied a custom SnP-microarray approach 
to allow simultaneous genotyping of a large number of Dna variants in genes related 
to one-carbon metabolism and that span the processes of folate metabolism, remeth-
ylation, methyl transfer, and transsulfuration. Seventy-nine Dna variants in 40 genes 
were analyzed for their association with fasting and post-methionine load plasma tHcy, 
fasting serum folate, and fasting plasma methionine in 190 Caucasian subjects.
Methods and materials
Study sample
One hundred and ninety unrelated subjects of self-reported Caucasian ethnicity out of 
a population-based sample comprising 500 individuals were included in the current 
study. these 500 individuals were ascertained via a general practice in the Hague in 
1993 and have been described previously. the study protocol was approved by the 
ethics committee of the leyenburg Hospital(27).
Metabolite measurements
Venous blood samples were collected after an overnight fast and 6 hours after an oral 
methionine loading (100 mg l-methionine per kg bodyweight dissolved in 200 ml or-
ange juice). eDta plasma was stored at –20°C, serum at –70°C. Serum folate was mea-
sured using the Dualcount SPnB (solid phase no boil) radioassay (Diagnostic product 
Corporation, los angeles, uSa). Plasma tHcy was measured according to the method 
described by fiskerstrand et al.(28) which was slightly modified(29). Concentration of 
methionine in plasma was measured using a modification of the method described 
by Holm et al.(30). to account for oxidation of methionine during storage we calculated 
total methionine as the sum of methionine and methionine sulfoxide.
Selection of candidate genes and DNA variants and genotyping 
the selection and genotyping of candidate genes and Dna variants has been described 
previously(31). Briefly, we selected the variants based on literature and databases 
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(dbSnP, url: http://www.ncbi.nlm.nih.gov/SnP/; SnPper at Chip Bioinformatics tools, 
url: http://snpper.chip.org/bio/) during 2002. for Dna variants selected from litera-
ture, we focused on those that were known to change the function or regulation of a 
gene product and those that had already shown association with (any) disease or con-
dition. if such Dna variant could not be found in a gene, we searched the databases 
for SnPs. We preferably selected those that had been confirmed (e.g. by at least two 
submissions), had a known frequency in the Caucasian population and were potentially 
functional (due to location in splice sites, promoters or other regulatory regions, or by 
changing an amino acid). if these SnPs were not found in a gene, we selected SnPs 
within or near exons and in the promoter region to identify associations due to linkage 
disequilibrium. in genes in which functional polymorphisms were available, we did 
not select additional SnPs for analysis. in total, 50 genes and 154 Dna variants were 
selected for genotyping. Genotyping of most SnPs was carried out at aSPer Biotech 
(tartu, estonia) using arrayed primer extension (aPeX) technology(32). in case the 
design of an aPeX assay for a SnP was not possible as well as for non-SnP variants, 
genotyping was carried out at the Departments of Human Genetics and Pediatrics in 
nijmegen, the netherlands. assay conditions for these Dna variants are available from 
the corresponding author. 
 We included only those Dna variants in the statistical analysis that (1) had a minor 
allele frequency (maf) higher than 0.05, (2) had less than 25% missing genotype 
data, and (3) were in Hardy-Weinberg equilibrium (HWe) (P-value>0.01). Seventy-nine 
Dna variants in 40 genes, classified according to five one-carbon metabolic processes, 
fulfilled these criteria (table 3.1). 
Statistical analysis
tests for deviation from HWe were performed by means of Chi-square tests. fisher’s 
exact test was chosen when expected genotype counts dropped below five. for multi-
allelic variants a monte Carlo exact test was applied. the pair-wise linkage disequilib-
rium (lD) measure r2 was estimated for di-allelic variants using Haploview 
(http://www.broad.mit.edu/haploview/haploview?q=mpg/haploview)(47).
Distributions of metabolite concentrations were skewed to the right and therefore 
logarithmically transformed. residual metabolite values, adjusted for age and sex, and 
pair-wise Pearson correlation coefficients (r) were calculated using Stata version 9.1.
tests for association of the Dna variants with metabolite concentrations were per-
formed using Plink version 1.02 (http://pngu.mgh.harvard.edu/purcell/plink/)(48). 
in the main analysis we evaluated the association between the Dna variants and 
metabolites assuming an additive effect of allele dosage. multi-allelic variants were 
 recoded for all association analyses into di-allelic variants (table 3.1). nominal empiri-
cal p-values and family-wise empirical p-values (corrected for all performed tests for 
the metabolite) were generated using 2000 permutations. 
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in addition, we performed a multi-locus set-based analysis as implemented in Plink. 
the five sets of Dna variants were defined using the categorization of the genes in five 
metabolic processes as outlined in figure 3.1 and table 3.1. this set-test is based on 
calculating the average test statistic for the best Dna variant per set, for the best two 
variants per set, et cetera. empirical p-values unadjusted for multiple testing, adjusted 
for all tests within each set, and adjusted for all tests in all sets were generated using 
2000 permutations. We excluded Dna variants rs2372536 and rs1997059 in amino-
imidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase (ATIC) 
and rs682985 in betaine-homocysteine methyltransferase 2 (BHMT2) since they were 
strongly correlated with other Dna variants within these genes (see results). We al-
lowed a maximum of five Dna variants in each sum for each set. this set-based analy-
sis allowed us to explore which variant or variants within each metabolic process are 
most strongly associated to the metabolites and permits comparison of the importance 
of the genetic variants within and between metabolites. in all analyses, two-sided p-
values were calculated and values < 0.05 were considered statistically significant.
Results
DNA variants measured and analysed previously
fifteen out of the 79 Dna variants have been measured and analysed for association 
to folate and/or plasma tHcy in (subsets of) the population-based sample, previously. 
also, for four additional Dna variants we have recently evaluated the association to 
fasting rBC and serum folate and plasma tHcy in the 190 subjects used in the cur-
rent study(31). table 3.1 indicates these 19 Dna variants and includes the references in 
which the associations were described. for completeness and additional analyses we 
have included these Dna variants also in the current study.
Metabolite concentrations
Of the 190 subjects included in this study, 40% was male and median (5th - 95th per-
centile) age was 43.1 (27.0 - 55.2) years. median (5th - 95th percentile) fasting serum 
folate, plasma fasting and post-load tHcy, and methionine were 12.1 (5.7 – 30.1) 
nmol/l, 10.4 (5.2 – 18.4) µmol/l, 36.3 (23.1 – 77.0) µmol/l, and 23.7 (17.4 – 32.5) 
µmol/l, respectively. a strong correlation between fasting and post-load plasma tHcy 
(Pearson’s r=0.652; p<0.0001) was observed. moderate inverse correlations were 
found between fasting plasma tHcy and serum folate, and post-load plasma tHcy and 
serum folate (Pearson’s r=-0.364, and -0.308, respectively (all p≤0.0001)). no signifi-
cant correlations with plasma methionine were observed. 
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LD patterns
examination of pair-wise lD patterns revealed that high lD (r2>0.75) was present 
between rs682985 and rs526264 in BHMT2, and between rs2372536 and rs1997059, 
rs2372536 and rs4673991, and rs1997059 and rs4673991 in ATIC.
Serum folate
Here, we will focus on the ten Dna variants that showed the strongest association 
with each of the four metabolites as depicted in table 3.2 (all other results available 
from corresponding author). the rs1801133 (MTHFR677C>t) was associated most 
strongly with serum folate (nominal p=0.002) and explained 5.2% of its variance. 
Other serum folate predictors included an intronic variant in DNA (cytosine-5-)-meth-
yltransferase 1 (DNMT1), for which also a second intronic variant was found among 
the strongest predictors (pair-wise r2 between the SnPs = 0.706), and the non-synon-
ymous rs1801394 (66a>G) in 5-methyltetrahydrofolate-homocysteine methyltrans-
ferase reductase (MTRR). Dna variants located in genes encoding enzymes involved 
in uptake of folate and cobalamin were found among the strongest determinants of 
serum folate: rs1893007 in FOLR1 and rs1801231 in CUBN and rs1801198 (776C>G) in 
TCN2. also, Dna variants in genes encoding enzymes involved in the folate cycle were 
among the strongest predictors: the intronic rs2586183 in 5,10-methenyltetrahydrofo-
late synthetase (MTHFS) and the non-synonymous rs1979277 (1420C>t) in SHMT1.
 the complete results for the multi-locus set-based analysis are available as 
Supplementary table 3.1. We found that for serum folate a combination containing 
rs1801133 in MTHFR, rs1801394 in MTRR, rs1801231 in CUBN, and rs1801198 in TCN2, 
all involved in the remethylation pathway, was most strongly associated; the sum-
statistic almost reached statistical significance after correction for all performed tests 
(p=0.06597). there were no indications for association between (sums of) Dna vari-
ants involved in transsulfuration with serum folate.
Fasting and post-load plasma total homocysteine
the variance in fasting plasma tHcy explained by rs1801133 (MTHFR677C>t) was 2.8% 
(nominal p=0.026). We also found two variants of the transsulfuration pathway, the 
CBS844_845ins(68bp) and rs490574 in CTH, among the strongest determinants. three 
Dna variants in ATIC in high lD (pair-wise r2 >0.75) were among the strongest deter-
minants of fasting plasma tHcy; the intronic rs4673991 explained 3.4% of the variance 
of plasma tHcy (nominal p=0.011). 
 for post-load plasma tHcy, both CBS variants measured in this study (pair-wise r2 
0.246) were represented among the strongest determinants; CBS844_845ins(68bp) 
explained 6.3% of the variation in residual post-load plasma tHcy and the associa-
tion reached statistical significance after correction for multiple testing (p=0.044); 
CBS g.14037(31bp)16-21 explained 2.9% of variance. the rs1801133 (MTHFR677C>t) 
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showed stronger association with post-load than with fasting plasma tHcy, as did the 
synonymous rs2276598 in DNA (cytosine-5-)methyltransferase 3 alpha (DNMT3A). 
the intronic rs1205366 in S-adenosylhomocysteine hydrolase (AHCY) was nomi-
nally associated to post-load tHcy only. for both fasting and post-load plasma tHcy, 
rs4819205 in formiminotransferase cyclodeaminase (FTCD) was found among the 
strongest associated Dna variants. as can be seen in table 3.2, the overlap in impor-
tant genetic determinants for fasting/post-load plasma tHcy and serum folate was 
limited; only rs1801133 showed strong association with folate as well as tHcy.   
for fasting and post-load plasma tHcy the multi-locus set-based analyses showed 
strongest associations for sums comprising Dna variants related to the transsulfuration 
pathway. for post-load tHcy, the sum containing only CBS844_845ins(68bp) showed 
statistical significant association after correction for all tests in all sets (p=0.032); for 
fasting plasma tHcy the sum including all Dna variants in CBS and CTH with exception 
of rs1021737 (also known as CTH1364G>t) was most strongly associated (p adjusted for tests 
within set = 0.111).
Plasma methionine
two uncorrelated non-synonymous Dna variants in BHMT were found among the 
strongest determinants for methionine concentrations, explaining 3.2 (nominal 
p=0.014) and 2.0% (nominal p=0.058) of variance. also, two uncorrelated CUBN vari-
ants were identified; rs703075 (nominal p=0.040; also associated to fasting plasma 
tHcy) and rs1801239 (nominal p=0.064). two Dna variants related to adomet-
dependent methylation were also observed: rs1802353 in isoprenylcysteine carboxyl 
methyltransferase (ICMT) and rs1078004 in methionine adenosyltransferase II, alpha 
(MAT2A). 
 the strongest association in the set-based analysis was observed for the sum of 
the ‘remethylation’ set containing rs672346 in BHMT, rs703075 in CUBN, rs3733890 in 
BHMT, rs1801239 and rs1907362 in CUBN, but with high p-values (p adjusted for tests within set 
= 0.093 and p adjusted for all tests = 0.380). 
Discussion
in the current study we aimed at identifying genetic determinants of three main inter-
mediate metabolites of one-carbon metabolism that have been associated to disease: 
folate, homocysteine, and methionine. Our extensive one-carbon metabolism candi-
date-gene approach learned that multiple Dna variants from various pathways within 
the one-carbon metabolism each explained a small percentage of observed variance 
of metabolite concentrations in our population. new candidate Dna variants were 
identified among the strongest predictors of metabolite concentrations (e.g. variants in 
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CUBN, DNMTs, FOLR1, FTCD) in addition to candidates which have been studied by us 
and others previously (i.e. variants in AHCY, BHMT, CBS, MTHFR, MTRR, SHMT1, TCN2). 
We found that rs1801133 (MTHFR6777C>t) was a main determinant for serum folate 
as well as, although to a lesser extent, fasting and post-load plasma tHcy. the latter 
was under strong influence of measured CBS variants. Overlap between Dna variants 
for fasting and post-load plasma tHcy were present, as expected given their correla-
tion. the MTHFR677C>t was the only variant that showed very strong association to 
folate as well as tHcy. 
 Previous reports based on study samples including (a subset) of the 190 sub-
jects that were used in the current study already revealed the association between 
 MTHFR677tt and increased plasma fasting and post-load tHcy and decreased serum 
folate concentrations(40,41). this is in accordance with published reports, the known re-
duced mtHfr activity associated with this variant, and the fact that MTHFR677C>t has 
been shown to result in accumulation of non-methyltetrahydrofolates at the expense 
of 5-methyltetrahydrofolate(21-26,49). 
 this study suggests that rs1801231 in CUBN, TCN2776C>G, and -8633C>t in FOLR1, 
all involved in remethylation of homocysteine and uptake and transport of dietary 
folate and cobalamin, are important contributors to variation in serum folate levels. 
Cubilin is, among others, involved in the uptake of cobalamin from the intestine. Co-
balamin acts as cofactor for 5-methyltetrahydrofolate-homocysteine methyltransferase 
(mtr) and is needed for the 5-methyltetrahydrofolate-dependent remethylation of ho-
mocysteine to methionine that takes place in all cells with exception of erythrocytes. in 
addition, cobalamin serves as cofactor for methylmalonyl-Coa in the mitochondria(26,50). 
CUBN variants also showed association to plasma tHcy and methionine concentrations; 
however, the specific Dna variants did not overlap with those strongly associated with 
folate concentrations. We recently reported on the association between a CUBN variant 
(rs1907362) and risk of spina bifida that showed nominal association to red blood cell 
folate and vitamin B12 concentrations but not to serum folate or plasma tHcy concen-
trations(31). Others have not investigated Dna variants in CUBN in relation to concen-
trations of one-carbon metabolism intermediates to our knowledge. transcobalamin 
(tC), encoded by tCn2, is required for cellular uptake of cobalamin from blood(26). the 
common, non-synonymous rs1801198 (776C>G) in TCN2 has been shown to decrease 
tC availability and has been associated to increased plasma tHcy, although inconsis-
tently(25,26). the increase in serum folate that we observed here has not been reported 
earlier; we did not find an association with plasma tHcy (nominal p=0.124 and 0.450 
for fasting and post-load, respectively)(46). the rare rs1893007, located in the promoter 
region of FOLR1, was associated with increased serum folate levels. this gene encodes 
the folate receptor α that is involved in cellular uptake of 5-methyl-tHf; only few mu-
tations in this gene have been reported(26,51), and this is the first study on the associa-
tion between rs1893007 and folate concentrations. 
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the importance of the transsulfuration pathway in maintaining adequate homocysteine 
concentrations is evident; rare mutations in CBS are the main cause of the severely 
elevated plasma tHcy levels seen in homocystinuria(52). We found an association 
between CBS844_845ins68 and decreased plasma tHcy concentrations, especially post-
load, and a strong association between the g.14037(31bp)16-21 and post-load plasma 
tHcy concentrations in our current and previous(36,37) studies. Conflicting results for 
CBS844_845ins68 and plasma tHcy concentrations have been reported(25); the associa-
tion between g.14037(31bp)16-21 and post-load plasma tHcy concentrations has been 
confirmed in the framingham Offspring Study(53) and our lab has shown variable CBS 
activity for different alleles of this polymorphism(36). no associations with folate and 
methionine concentrations were found for these two CBS variants in the present study 
in agreement with a recent large sample size study(24)
 three correlated SnPs in ATIC, a gene involved in de novo purine synthesis, showed 
strong correlation with fasting plasma tHcy concentrations in the current study. Based 
on preliminary results of this study we have increased genotyping of the non-synony-
mous rs2372536 in ATIC in 241 additional Caucasian individuals in our original popu-
lation-based sample. We have recently reported the findings of the association of this 
extended genotyping effort: we could not confirm the association to plasma tHcy(34) 
thereby raising doubt on the replicability of the SnP associations for this gene reported 
here.
 among the strongest determinants of methionine were rs672346 and rs3733890, 
two non-synonymous variants in BHMT. BHmt catalyzes an alternative remethylation 
route confined to the liver and kidneys in which betaine serves as a methyl donor(35). 
the amino acid encoded by the codon in which the first SnP is located, is highly con-
served. the second SnP has been previously investigated in a population including the 
current study subjects; no association with plasma tHcy was found(35), in accordance 
with other studies(25). fredriksen et al.(24) evaluated the association between rs3733890 
and methionine concentrations but did not find a relation. 
 the results of our current study also suggested a role for genetic variation in methyl 
transfer-related genes and folate, homocysteine and methionine concentrations with 
little overlap in the implicated genes for the different metabolites: DNMT1 variants 
contributed to variance in serum folate levels, variants in DNMT3A and AHCY explained 
over 3% variance each in post-load plasma tHcy, and a role for ICMT and MAT2A vari-
ants was indicated for methionine concentrations. a relation between one-carbon 
intermediate metabolites and impaired methylation potential has been described 
earlier(54). for plasma tHcy, variation in nicotinamide n-methyltransferase (NNMT) has 
been suggested to influence plasma tHcy concentratons(55) and an association for the 
324G>a variant in the catechol-O-methyltransferase gene (COMT) and plasma tHcy 
has been described by our group(56). also, a recent study by our group implicated 
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rs2295809 in TRDMT1 in spina bifida etiology and showed indiciations for associations 
to increased folate concentrations, although not significantly(31). 
 Our data indicated that only few of our measured Dna variants may influence mul-
tiple measured metabolites (e.g. MTHFR677C>t and folate and homocysteine) while 
most show strong association to one metabolite only (e.g. variants in CBS and homo-
cysteine). this is in line with findings from fredriksen et al.(24) and has been supported 
by study of mouse models(57). indeed, the phenotypic correlations between the mea-
sured metabolites in the current study were consistent with influences of both shared 
genetic and/or environmental factors as well as metabolite-specific factors for folate 
and homocysteine. Pleiotropic effects of Dna variants may hamper the interpretation 
of mendelian randomization studies. However, the existence of Dna variants that influ-
ence only one intermediate one-carbon metabolite of interest offers opportunities for 
studies based on mendelian randomization to indicate which specific metabolite may 
have a role in disease causation(5). 
 We performed a candidate-gene association study for three metabolites with 
the largest number of measured candidate Dna variants until now. We preferably 
selected Dna variants that changed the function or regulation of the gene product, 
were potentially functional, and those that had already shown association with (any) 
disease or condition, thereby increasing the probability of actually genotyping causal 
variants. Genotyping of additional Dna variants in the selected genes increased our 
chance of indirectly finding genetic determinants via lD. However, we cannot assure 
that our study covered all relevant Dna variation in the selected genes. ideally, future 
studies will optimize gene coverage, and, in addition, pathway coverage. alternatively, 
genome-wide coverage may be aimed for to allow for identification of genetic deter-
minants without reliance on current knowledge of potential candidate genes.
 the complexity of the studied metabolic pathways urges the need for large sample 
sizes in genetic association studies of complex traits. Power calculations showed that 
under an additive genetic model we had 80% power to find a genetic variant that ex-
plains 4% and 3.2% of the variance in the trait at a nominal significance level of 0.05 
and 0.10, respectively, which rendered our study underpowered for low-penetrance 
variants. Correction for multiple testing further diminishes power and increases the 
required number of subjects. the standardized measurements of fasting (and post-
load) levels of metabolites and adjustments for age and sex will have increased our 
power as the variation in metabolite concentration due to differences in age, sex, and, 
short-term dietary intake was reduced. However, future studies that include a larger 
study sample and replication of our findings are necessary. larger samples also allow 
the analysis of (higher-order) interactions between Dna variants that will likely influ-
ence metabolite concentrations. in addition, gene-nutrient interactions and haplotype 
associations may be evaluated.
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Here, we reported on the currently most extensive candidate-gene study for folate, 
homocysteine and methionine concentrations. Our study has established earlier find-
ings and provided new leads for future research into genetic determinants of these 
one-carbon metabolites. We found little overlap in genetic determinants for folate, 
homocysteine, and methionine and mainly observed that Dna variants were strongly 
related to one metabolite, only.
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Supplementary table 3.1  Results of multi-locus set-based analysis for fasting serum folate, 
fasting plasma total homocysteine (tHcy), post-load plasma total homocysteine, and fasting 
methionine concentrations. 
Fasting serum folate
Metabolic 
 process 
Nr. of DNA 
variants 
in sum
Gene DNA variant p_0 A p_1 B p_2 C
folate cycle 1 MTHFS rs2586183 0.4393 0.5312 0.9845
folate cycle 2 FOLR1 rs1893007 0.3613 0.4583 0.96
folate cycle 3 SHMT1 rs1979277 0.3763 0.4773 0.9655
folate cycle 4 MTHFD2 rs1667627 0.3733 0.4748 0.9655
folate cycle 5 GGH rs1031552 0.3523 0.4488 0.953
remethylation 1 MTHFR rs1801133 0.02649 0.04498 0.2044
remethylation 2 MTRR rs1801394 0.01299 0.02499 0.1104
remethylation 3 CUBN rs1801231 0.01099 0.01949 0.09345
remethylation 4 TCN2 rs1801198 0.006997 0.01349 0.06597
remethylation 5 CUBN rs2271461 0.007996 0.01599 0.07296
methyl transfer 1 DNMT1 rs8101626 0.05897 0.09245 0.3838
methyl transfer 2 DNMT1 rs2290684 0.1139 0.1644 0.5817
methyl transfer 3 COQ3 rs7755791 0.1464 0.2019 0.6697
methyl transfer 4 ICMT rs1802353 0.1699 0.2359 0.7206
methyl transfer 5 MGMT rs2020893 0.1804 0.2509 0.7471
transsulfuration 1 CTH rs501939 0.9825 0.9885 1
transsulfuration 2 CBS 844_845ins(68bp) 0.973 0.9805 1
transsulfuration 3 CTH rs3767205 0.9705 0.9785 1
transsulfuration 4 CTH rs490574 0.968 0.9755 1
transsulfuration 5 CTH rs1021737 0.9705 0.9785 1
other 1 NOS1 4775(CA)14-22 0.4473 0.5252 0.985
other 2 NOS2A rs2297518 0.3608 0.4403 0.96
other 3 NOS2A IVS1-2660(CCTTT)8-18 0.3163 0.3958 0.929
other 4 NOS1 IVS14+267(AAT)8-16 0.2554 0.3328 0.8706
other 5 NOS3 rs1799983 0.1954 0.2644 0.7801
a p_0: empirical p-value for average test-statistic. 
B p_1: empirical p-value for average test-statistic corrected for all tests within this set. 
C p_2: empirical p-value for average test-statistic corrected for all tests in all sets.
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Fasting plasma tHcy
Metabolic 
 process 
Nr. of DNA 
variants 
in sum
Gene DNA variant p_0 A p_1 B p_2 C
folate cycle 1 ATIC rs4673991 0.2814 0.3713 0.8921
folate cycle 2 FTCD rs4819205 0.3203 0.4143 0.924
folate cycle 3 MTHFD1 rs1950902 0.3398 0.4323 0.937
folate cycle 4 GGH rs1031552 0.3928 0.4923 0.964
folate cycle 5 GGH rs719235 0.4288 0.5247 0.9755
remethylation 1 MTHFR rs1801133 0.2654 0.3488 0.8756
remethylation 2 CUBN rs703075 0.2349 0.3148 0.8366
remethylation 3 TCN2 rs1801198 0.2459 0.3268 0.8491
remethylation 4 CUBN rs1907362 0.2244 0.3018 0.8231
remethylation 5 CUBN rs2271461 0.2034 0.2814 0.7926
methyl transfer 1 DNMT3A rs2276598 0.3868 0.4928 0.961
methyl transfer 2 AHCY rs1205366 0.5097 0.6122 0.99
methyl transfer 3 MGMT rs2020893 0.5147 0.6157 0.9905
methyl transfer 4 ICMT rs1802353 0.5042 0.6062 0.99
methyl transfer 5 DNMT3A rs2289195 0.4823 0.5862 0.986
transsulfuration 1 CBS 844_845ins(68bp) 0.3423 0.4188 0.939
transsulfuration 2 CTH rs490574 0.2174 0.2844 0.8116
transsulfuration 3 CTH rs3767205 0.1294 0.1729 0.6342
transsulfuration 4 CTH rs501939 0.09695 0.1379 0.5317
transsulfuration 5 CBS g.14037(31bp)16-21 0.07546 0.1114 0.4558
other 1 NOS1 IVS14+267(AAT)8-16 0.5552 0.6282 0.992
other 2 NOS2A rs2297518 0.4728 0.5487 0.9845
other 3 NOS2A IVS1-2660(CCTTT)8-18 0.5257 0.5997 0.992
other 4 NOS3 rs1799983 0.5657 0.6397 0.993
other 5 NOS3 IVS4+245(GAAGTCTAGACC
TGCTGCAGGGGTGAG)4-6
0.5822 0.6532 0.9945
a p_0: empirical p-value for average test-statistic. 
B p_1: empirical p-value for average test-statistic corrected for all tests within this set. 
C p_2: empirical p-value for average test-statistic corrected for all tests in all sets.
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Post-load plasma tHcy
Metabolic 
 process 
Nr. of DNA 
variants 
in sum
Gene DNA variant p_0 A p_1 B p_2 C
folate cycle 1 FTCD rs4819205 0.3243 0.4238 0.9215
folate cycle 2 ATIC rs4673991 0.3823 0.4818 0.9555
folate cycle 3 FOLR1 rs1893007 0.4173 0.5182 0.97
folate cycle 4 ALDH1L1 rs1127717 0.4573 0.5542 0.9795
folate cycle 5 GGH rs1031552 0.4738 0.5737 0.9805
remethylation 1 MTHFR rs1801133 0.08896 0.1339 0.5087
remethylation 2 CUBN rs703075 0.1689 0.2404 0.7291
remethylation 3 BHMT rs651852 0.1804 0.2539 0.7506
remethylation 4 CUBN rs2271461 0.1719 0.2429 0.7351
remethylation 5 BHMT2 rs526264 0.1969 0.2744 0.7776
methyl transfer 1 DNMT3A rs2276598 0.1179 0.1714 0.6032
methyl transfer 2 AHCY rs1205366 0.05347 0.08546 0.3538
methyl transfer 3 NNMT rs1941404 0.06247 0.09845 0.4003
methyl transfer 4 AHCY rs819158 0.06147 0.09695 0.3958
methyl transfer 5 ICMT rs1802353 0.06747 0.1064 0.4173
transsulfuration 1 CBS 844_845ins(68bp) 0.003498 0.006997 0.03198
transsulfuration 2 CBS g.14037(31bp)16-21 0.003998 0.007996 0.03598
transsulfuration 3 CTH rs3767205 0.004998 0.008996 0.04298
transsulfuration 4 CTH rs490574 0.005997 0.01049 0.05147
transsulfuration 5 CTH rs501939 0.007496 0.01249 0.06247
other 1 NOS2A rs2297518 0.4543 0.5382 0.9785
other 2 NOS3 rs1799983 0.4463 0.5312 0.977
other 3 NOS2A IVS1-2660(CCTTT)8-18 0.4498 0.5347 0.9775
other 4 NOS1 4775(CA)14-22 0.4118 0.4993 0.968
other 5 NOS1 IVS14+267(AAT)8-16 0.3973 0.4818 0.9625
a p_0: empirical p-value for average test-statistic. 
B p_1: empirical p-value for average test-statistic corrected for all tests within this set. 
C p_2: empirical p-value for average test-statistic corrected for all tests in all sets.
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Fasting plasma methionine
Metabolic 
 process 
Nr. of DNA 
variants 
in sum
Gene DNA variant p_0 A p_1 B p_2 C
folate cycle 1 GART rs8971 0.7341 0.8036 1
folate cycle 2 SARDH rs2073815 0.6887 0.7706 1
folate cycle 3 ALDH1L1 rs1127717 0.6097 0.6987 0.9975
folate cycle 4 TYMS CCGCGCCACTTGGCCTGCCTCCGTC
CCG>CCGCGCCACTTCGCCTGCCTC
CGTCCCG
0.5402 0.6457 0.9925
folate cycle 5 SARDH rs2073817 0.4883 0.5937 0.986
remethylation 1 BHMT rs672346 0.1919 0.2619 0.7756
remethylation 2 CUBN rs703075 0.1644 0.2329 0.7191
remethylation 3 BHMT rs3733890 0.1244 0.1839 0.6267
remethylation 4 CUBN rs2271461 0.07896 0.1249 0.4623
remethylation 5 CUBN rs1907362 0.05947 0.09345 0.3798
methyl transfer 1 ICMT rs1802353 0.3073 0.3978 0.9065
methyl transfer 2 MAT2A rs1078004 0.2334 0.3123 0.8376
methyl transfer 3 DNMT3A rs2276598 0.2249 0.3028 0.8241
methyl transfer 4 AHCY rs1205366 0.2214 0.2989 0.8216
methyl transfer 5 TRDMT1 rs2295809 0.2129 0.2884 0.8091
transsulfuration 1 CTH rs3767205 0.6977 0.7596 1
transsulfuration 2 CTH rs1021737 0.6807 0.7426 1
transsulfuration 3 CTH rs490574 0.6902 0.7506 1
transsulfuration 4 CTH rs501939 0.7051 0.7651 1
transsulfuration 5 CBS 844_845ins(68bp) 0.7226 0.7801 1
other 1 NOS1 4775(CA)14-22 0.5262 0.6082 0.9915
other 2 NOS2A rs2297518 0.5352 0.6177 0.9925
other 3 NOS3 IVS4+245(GAAGTCTAGACCTGCTG
CAGGGGTGAG)4-6
0.5472 0.6292 0.9935
other 4 NOS1 IVS14+267(AAT)8-16 0.5802 0.6617 0.9965
other 5 NOS3 rs1799983 0.5787 0.6592 0.9965
a p_0: empirical p-value for average test-statistic. 
B p_1: empirical p-value for average test-statistic corrected for all tests within this set. 
C p_2: empirical p-value for average test-statistic corrected for all tests in all sets.
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abstract
The application of multi-locus analysis techniques may aid in the eluci-
dation of the genetic aetiology of multi-factorial traits. Elevated plasma 
total homocysteine (tHcy) concentration is a multi-factorial risk factor for 
cardiovascular diseases, venous thrombosis, congenital defects, and neu-
rodegenerative diseases. Its genetic background is unresolved. Our study 
objective was to evaluate candidate DNA variants for plasma tHcy concen-
tration using multi-locus analysis. Thirty-six DNA variants in 19 genes re-
lated to homocysteine metabolism were measured in a study population 
comprising 461 Caucasian individuals. Single locus, haplotype, and multi-
locus genotype analysis using logic regression were performed for fasting 
and post-methionine load plasma tHcy concentration. Single locus results 
were previously reported and suggested main roles for MTHFR677C>T, 
CBS844ins68, CBS 31bp VNTR, and COMT324G>A. No haplotype effects 
independent of single locus effects were found. Logic regression identi-
ﬁed a multi-locus genotype {CBS 31bp VNTR 18-18 and FOLH11561CC 
and (MTHFD2011GG or BHMT595GA) and MTHFR677CT/TT} that is pres-
ent in 10% of the study population and associated with 5 µmol/L higher 
fasting plasma tHcy. It explained ~17% of trait variance in our population; 
the 5 DNA variants separately explained ~5% of plasma tHcy variance. 
MTHFR677C>T and CBS 31bp VNTR are main genetic determinants of 
plasma tHcy concentration with modest marginal effects. A deleterious 
combination of genotypes at ﬁve measured DNA variants predisposed to 
highly elevated plasma tHcy concentration. Results of this study demon-
strate the additional value of multi-locus analysis in the elucidation of the 
genetic aetiology of plasma tHcy concentration.
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Introduction
an increased awareness of potential advantages of a joint evaluation of multiple loci 
for multi-factorial traits has arisen in the last years and sophisticated techniques for 
analyzing multi-locus effects have been developed(1). indeed, the analysis of single 
Dna variants only allows identification and characterization of those variants that show 
an independent, marginal contribution to the phenotype of interest, either directly 
or indirectly via linkage disequilibrium (lD) to another, causal Dna variant. However, 
interactions between Dna variants, that show small or no marginal individual effects, 
are expected to contribute to the phenotypic variance in multi-factorial traits. these 
may concern interactions between multiple Dna variants located in the same genes 
or separate genes, or specific interactions between alleles of variants that are located 
on the same chromosomal background (i.e. in cis). the latter type of interaction can 
be explicitly identified using haplotype analysis, in which the combination of alleles 
on multiple (linked) variants on a chromosome is evaluated for association to the trait. 
also, analysis of haplotypes can be advantageous compared to single locus analysis 
when unmeasured, causal genetic variants show stronger lD to the haplotype than to 
the single genetic variants themselves(2).
 elevated plasma total homocysteine (tHcy) concentrations are associated with 
increased risk for several multi-factorial disorders including cardiovascular diseases, 
venous thrombosis, congenital defects, and neurodegenerative diseases(3-8). However, 
recent secondary intervention trials with plasma tHcy-lowering therapy did not show 
conclusive results for mortality and vascular disease risk and raised doubt on the 
causality of these associations(9-11). Clarification of the genetic aetiology of plasma tHcy 
can help to elucidate the pathophysiological pathways underlying the disease associa-
tions and lead to an increased understanding of disease aetiology. Plasma tHcy is a 
multi-factorial trait itself; the inter-individual variation in plasma tHcy in the general 
population is caused by environmental and genetic determinants that interact with one 
another(12,13).
 in the past years we and others have been involved in deciphering the genetic 
aetiology of plasma tHcy through a candidate gene approach in which variants of 
genes encoding key enzymes in homocysteine metabolism were evaluated for their 
association with plasma tHcy(14). the best established genetic determinant of plasma 
tHcy concentration in the general population is the 677C>t single nucleotide polymor-
phism (SnP) in the methylenetetrahydrofolate reductase (MTHFR) gene that plays a 
regulatory role in the remethylation of homocysteine to methionine(15). Other, common 
and uncommon, candidate gene variants have been studied. However, contradic-
tive association findings exist and the genetic background of plasma tHcy remains 
unresolved(14). Generally, genetic association studies for plasma tHcy concentrations 
examined one or few deoxyribonucleic acid (Dna) variants in one or few genes and 
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entailed statistical analyses in which each measured variant was analysed separately. 
the aim of the present study was to examine the Dna variants that we have mea-
sured over the last years in our study population for association with plasma tHcy using 
a multi-locus analysis approach and perform haplotype and logic regression analysis. 
for completeness of the results, we also present single locus associations.
 Our candidate gene approach entailed the study of 36 Dna variants in 19 candi-
date genes in homocysteine metabolism (figure 4.1) in a population comprising 500 
subjects in which fasting as well as post-methionine load (hereafter named post-
load) plasma tHcy have been measured. these two homocysteine phenotypes have 
a different genetic aetiology(13). the associations between the single measured Dna 
variants and plasma tHcy have been described earlier by our group(16-36). in few cases, 
associations with composite genotypes within a gene(21,30-32), between genes(16,19), 
or haplotype associations(20) were evaluated. main findings of our studies include 
the confirmation of the association between MTHFR677C>t and plasma tHcy(31), and 
the identification of the 1444_1467+7(16_21) (known as 31 base-pair (bp) Vntr) in 
the gene encoding cystathionine ß-synthase (CBS) (30) and the 324G>a SnP in the 
catechol-O-methyltransferase gene (COMT)(20) as genetic determinants of plasma tHcy. 
in addition, we found associations between fasting and/or post-load plasma tHcy and 
80G>a in solute carrier family 19 (folate transporter), member 1 (SLC19A1=RFC1)(19), 
the 146_164 deletion in dihydrofolate reductase (DHFR)(18), and the 45 bp insertion/
deletion variant (1032-1077dup) in uncoupling protein 2 (UCP2)(25). also, interactions 
between 346C>G in 5-aminoimidazole-4-carboxamide ribonucleotide formyltransfer-
ase/imP cyclohydrolase (ATIC) and SLC19A180G>a(19), and between the 31bp Vntr in 
CBS and MTHFR677C>t were described(16). 
 the current study will focus on multi-locus analyses with the aim to increase insight 
in the genetic aetiology of plasma tHcy and the role of interplay between gene vari-
ants, within and among genes. moreover, it will give a quantitative overview of the 
results of our candidate gene approach.
Materials and methods
Study population
the study population has been described extensively before (37). in short, 500 healthy 
individuals were recruited in 1993 via a general practice in the Hague. thirty-nine 
non-Caucasian subjects were excluded for this study. Of the remaining 461 subjects 
42% was male and median age was 50 years (range 21 – 84 years). median (5th – 95th 
percentile) fasting (n=461) and post-load plasma tHcy levels (n=457) were 10.7 (5.8 - 
18.4) µmol/l and 37.7 (23.6 – 66.2) µmol/l, respectively.
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figure 4.1  Simplified representation of homocysteine metabolism. Enzymes and receptors for 
which DNA variants in the encoding genes are measured in the current study are depicted 
(with exception of ATIC, GCLM, NOS3, and UCP2). 
adoHcy: S-adenosylhomocysteine; adomet: S-adenosylmethionine; aHCY: S-adenosylhomocysteine hydro-
lase; atiC: 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/imP cyclohydrolase; B2: vita-
min B2 (riboflavin); B6: vitamin B6 (pyridoxine); B12: vitamin B12 (cobalamin); BHmt: betaine-homocysteine 
S-methyltransferase; CBS: cystathionine-beta-synthase; CH2tHf: 5,10-methylenetetrahydrofolate; CH3tHf: 
5-methyltetrahydrofolate; COmt: catechol-O-methyltransferase; Cys: cysteine; Cysta: cystathionine; DHfr: 
dihydrofolate reductase; fGCP: folylpoly-glutamyl carboxypeptidase; GClm: glutamate-cysteine ligase, 
modifier subunit; Hcy: homocysteine; met: methionine; mtHfD: methylenetetrahydrofolate dehydrogenase; 
mtHfr: methylenetetrahydrofolate reductase; mtr: methionine synthase; mtrr: methionine synthase 
reductase; nOS3: nitric oxide synthase 3; SCl19a1: solute carrier family 19 (folate transporter), member 1; 
SHmt: serine hydroxymethyltransferase; tCn2; transcobalamin ii; tHf: tetrahydrofolate; tYmS: thymidylate 
synthetase; uCP2: uncoupling protein 2; X: methylacceptor. 
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Genotyping and phenotypic measurements 
Blood samples were drawn from the antecubital vein and Dna was extracted using 
standard procedures(38). We studied 36 Dna variants in 19 candidate genes that were 
selected for their essential roles in homocysteine and folate metabolism. Selection 
of the Dna variants within candidate genes was mainly based on gene sequencing 
in patient populations or on other published findings with priority for variants with 
(potential) functionality. Genotyping was mostly done by means of Polymerase Chain 
reaction (PCr) and restriction fragment length Polymorphism (rflP) analysis tech-
niques over the last 13 years at different time points and resulted in different numbers 
of successfully genotyped individuals for the Dna variants. Details regarding the Dna 
variants, their selection, and genotyping procedures can be found in the papers by our 
group in which they were first described (table 4.1).
 Venous blood samples were collected after an overnight fast. total fasting plasma 
tHcy was measured by automated high-pressure liquid chromatography (HPlC) with 
reverse phase separation and fluorescent detection(40). a second plasma tHcy assess-
ment took place 6 hours after an oral methionine loading (100 mg l-methionine per 
kg bodyweight dissolved in 200 ml orange juice). During these 6 hours, the subjects 
obtained a protein-restricted diet. Serum creatinine was measured with a Kodak 
ektachem Processor.
Statistical genetic analyses
Single locus analysis Deviations from Hardy-Weinberg equilibrium (HWe) for di-allelic 
and multi-allelic variants were evaluated using Chi-square tests and the monte Carlo 
method(41), respectively. the distribution of plasma tHcy was skewed to the right and 
tHcy values were natural logarithmically transformed prior to all analyses. Genotypic 
differences in fasting and post-load plasma tHcy were tested using multivariable linear 
regression techniques under assumption of a genotypic and additive gene model. re-
gression analysis was performed for unadjusted plasma tHcy and for plasma tHcy ad-
justed for age, sex and creatinine levels; these latter variables are known determinants 
of plasma tHcy. empirical nominal P-values were based on a permutation procedure 
using 1000 replications. We used Stata (version 9.0) and the GenHW add-on pack-
age(42) to perform these analyses. all reported P-values are two-sided; we considered 
nominal P-values <0.05 to indicate statistically significant results. 
Haplotype analysis lD coefficients between gene variants located within one gene 
were estimated and haplotype block structure, based on the algorithm described by 
Gabriel et al(43), was mapped using Haploview(44) (http://www.broad.mit.edu/per-
sonal/jcbarret/haploview/index.php). Haplotype analysis for unadjusted and adjusted 
plasma tHcy was performed using the Whap program (http://pngu.mgh.harvard.
edu/~purcell/whap/)(45). We first applied an omnibus test, jointly testing all haplo-
types, and then evaluated haplotype-specific effects relative to a reference haplotype. 
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Haplotypes with a frequency of less than 2% were excluded. the multi-allelic variants 
were recoded into multiple di-allelic variants prior to lD and haplotype analysis. We 
used permutation testing procedures to generate empirical nominal P-values using 
1000 replications. again, all reported P-values are two-sided and P-values <0.05 were 
considered statistically significant.
Logic regression logic regression is an explorative regression method designed to 
identify a Boolean (logical) combination (or combinations) of original binary variables 
associated with the outcome of interest. the method has been extensively described 
before(46,47). Our goal was to find combinations of Dna variants that may interact with 
one another and that are associated with plasma tHcy. We used the linear logic regres-
sion technique as implemented as an r package (http://bear.fhcrc.org/~ingor/logic/) 
(r version 2.3.1). Dna variants were recoded into binary variables using a recessive 
and dominant coding. indicator variables were generated for the 31 bp Vntr and 
the Gt simple tandem repeat (Str) (-5697(Gt)10-20) in CBS, and for the 9 bp repeat 
(-388(9bp)3-9) in DHFR with omission of low frequency genotypes. model selection 
was guided by ten-fold cross-validation (as integrated in the logic regression package) 
for model sizes ranging from one to three trees with a maximum of eight leaves in 
total. logic regression was limited to subjects with complete data for all included Dna 
variants. to increase the number of analysed subjects, we selected only those Dna 
variants that showed association with fasting or post-load plasma tHcy with P-value 
< 0.10 and >1% variety for the recoded binary variable. We repeated single locus 
analysis in the logic regression sub-sample to allow for fair comparison between the 
single locus and multi-locus genotype analysis. We explored marginal and interactive 
contributions to variation in plasma tHcy of the Dna variants identified in the logic 
regression using analysis of variance (anOVa) models.
Results
table 4.1 shows characteristics of the analysed candidate genes and Dna variants. 
We measured four repeat variants, five insertion/deletion variants, and 27 single 
nucleotide di-allelic variants, of which 4 had a minor allele frequency (maf) <1%. Only 
the 31 bp Vntr in CBS showed slight deviation from HWe (P = 0.022). twenty Dna 
variants resulted in an amino acid change and most of the variants are known or sus-
pected to affect function of the encoded protein (see our earlier papers). the number 
of successfully genotyped individuals varied from 301 to 445. 
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table 4.2  Genotypic single locus association results for unadjusted plasma tHcy concentration 
for DNA variants with P <0.05.
Gene symbol DNA variant Genotype N (%) Fasting tHcy Post-load tHcy
% difference (95% CI) % difference (95% CI)
BHMT 595G>A  GG 402 (98.8) - 1 - 1
GA 5 (1.2) 47.7 (5.7 to 106.3) 2 11.3 (-16.0 to 47.7) 
AA - (-) - - 
CBS 699C>T CC 155 (41.0) -
CT 170 (45.0) -9.4 (-16.2 to -1.9) 2 -6.9 (-12.8 to -0.6) 2
TT 53 (14.0) -5.6 (-15.7 to 5.7) -6.8 (-15.1 to 2.3)
CBS 833T>C TT 380 (99.0) - -
TC 4 (1.0) 42.9 (-2.1 to 108.6) 3 106.6 (51. 9 to 181.0)
CC 0 (0) - -
CBS 844_845ins68 del del 319 (83.1) - -
del ins 60 (15.6) -10.8 (-19.7 to -0.9) -10.9 (-18.5 to -2.7)
ins ins 5 (1.3) -32.8 (-52.0 to -5.8) -18.1 (-38.2 to 8.5)
CBS 31 bp VNTR4 18 18 233 (60.2) - -
17 18 52 (13.4) -11.5 (-21.0 to -1.0) -11.7 (-19.6 to -3.0)
18 19 62 (16.2) -8.4 (-17.5 to 1.7) -9.5 (-17.0 to -1.3)
COMT 324G>A AA 111 (28.2) - -
AG 193 (49.1) -5.1 (-13.2 to 3.7) -1.5 (-8.5 to 6.1)
  GG 89 (22.6) -11.7 (-20.6 to -1.8) -9.3 (-17.0 to -0.9)
DHFR 146_164del ins ins 103 (34.2) - -
ins del 139 (46.2) -1.0 (-9.6 to 8.4) 4.7 (-3.3 to 13.4)
del del 59 (19.6) -14.4 (-23.6 to -4.1) -3.3 (-12.6 to 7.0)
FOLH1 1561C>T CC 368 (89.3) - -
CT 41 (10.0) -4.3 (-15.2 to 8.1) 3.5 (-6.7 to 14.8)
TT 3 (0.7) -42.8 (-62.7 to -12.3) -24.4 (-47.5 to 8.7)
GCLM -588C>T CC 236 (60.5) - -
CT 131 (33.6) -9.0 (-16.2 to -1.3) -1.0 (-7.6 to 6.1)
TT 23 (5.9) -13.8 (-26.8 to 1.6) -8.5 (-20.5 to 5.3)
MTHFR 677C>T CC 225 (50.6) - -
CT 177 (39.8) 3.8 (-3.6 to 11.6) 7.4 (1.0 to 14.2)
TT 43 (9.7) 20.1 (6.4 to 35.6) 16.0 (4.45 to 28.7)
SLC19A1 80G>A GG 150 (37.7) - -
GA 194 (48.7) -6.0 (-13.3 to 1.9) -9.0 (-14.9 to -2.6)
AA 54 (13.6) -9.9 (-19.9 to 1.4) 1.1 (-8.5 to 11.7)
1 reference category; 2 P-value >0.05 after adjustment for age, sex and creatinine; 3 P-value <0.05 after 
adjustment for age, sex and creatinine; 4 Only the three most frequent genotype groups are presented
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Single locus association
Here, we only discuss the Dna variants that were associated to fasting or post-load 
plasma tHcy with nominal P-value < 0.05 (table 4.2) (the results of all single locus 
analyses can be requested from the corresponding author). table 4.2 shows that four 
CBS variants were found among the strongest association results. relative difference in 
plasma tHcy for the MTHFR677tt genotype compared to MTHFR677CC genotype was 
20% (crude geometric mean tHcy levels were 12.3 µmol/l and 10.2 µmol/l, respec-
tively); other common Dna variants showed smaller effects. the low-frequency vari-
ants BHMT595G>a, CBS833t>C, CBS844_845ins68 and FOLH11561C>t did show large 
effect on plasma tHcy in our population. the minor alleles of the Dna variants in table 
4.2 were all associated with decreased plasma tHcy, except for the MTHFR677 t allele, 
the CBS833 C allele and increasing length of the 31 bp Vntr in CBS. results for fasting 
and post-load plasma tHcy differed slightly. for instance, the decreases in plasma tHcy 
of GCLM-588C>t, DHFR146_164del, and FOLH11561C>t, were less strong for post-load 
plasma tHcy. the 833t>C variant and the 31 bp Vntr in CBS, however, were associated 
with stronger increases in post-load compared to fasting levels.
Haplotype association 
MTHFR677C>t and MTHFR1298a>C were located in one haplotype block, as were the 
844_845ins68, the 1080C>t, and the 31 bp Vntr in CBS, and the 36t>C and 324a>G 
variant in COMT which indicated that alleles of these variants are inherited together on 
the same chromosomal background. Strong lD in terms of r2 was only found for the 
latter two variants in COMT (r2=0.892) and the ‘17’ allele of the 31 bp Vntr and the 
844_845ins68 variant in CBS (r2=0.833) which indicated that these variants ‘tag’ each 
other well and one can serve as a good proxy for the other (data not shown).
 Statistically significant haplotype block effects for MTHFR, CBS and COMT for fasting 
plasma tHcy were identified (table 4.3). Conditional analysis showed that haplotype 
effects were no longer significant after conditioning on MTHFR677C>t, 844_845ins68 
or 31 bp Vntr in CBS, and COMT324G>a, respectively. this indicated that haplotype 
associations did not contribute to plasma tHcy in addition to the marginal single variant 
effects. the same was observed for post-load plasma tHcy; after adjustment for the 
MTHFR677C>t and the CBS 31 bp Vntr the P-values of the haplotype tests increased to 
non-significant values. Haplotype analyses including all measured loci within a gene, 
irrespective of block structure, showed the same patterns (data not shown). 
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figure 4.2  Box plot for unadjusted fasting and post-load plasma tHcy concentration for the 
group that did and did not suffice the Boolean multi-locus genotype criterion as identified by 
logic regression. Number of subjects fulfilling the criterion are given in brackets.
1  Boolean multi-locus criterion for unadjusted fasting plasma tHcy: [CBS31bpVntr 17-18 or FOLH11561Ct/tt 
or (BHMT595GG and MTHFD2011aa/aG) or MTHFR677CC]
2  Boolean multi-locus criterion for unadjusted post-load plasma tHcy: [CBS31bpVntr 17-18 or FOL-
H11561Ct/tt or MTHFD2011aa/aG or MTHFR677CC]
* P-value anOVa < 0.001
Logic regression
fourteen Dna variants (BHMT595G>a, CBS699C>t, CBS844ins68, CBS31bpVntr, 
COMT324G>a, DHFR146_164del, GCLM-588C>t, FOLH11561C>t, UCP21032-1077dup, 
MTHFD2011G>a, MTHFR677C>t, MTHFR1298a>C, SHMT11420C>t, SLC19A180G>a) and 
183 and 182 complete observations for fasting and post-load plasma tHcy, respectively, 
were included in the logic regression analysis. Single locus results for unadjusted fast-
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ing plasma tHcy with nominal P<0.05 in this subpopulation included BHMT595G>a, 
CBS844ins68, DHFR146_164del, FOLH11561C>t, MTHFR677C>t, and UCP21032-
1077dup. for post-load plasma tHcy CBS699C>t, CBS844ins68, CBS 31bp Vntr, 
MTHFD2011a>G, MTHFR677C>t, SLC19A180G>a, SHMT1420C>t, and UCP21032-
1077dup were found.
 the identified logic tree variables for fasting and post-load plasma tHcy are de-
scribed in figure 4.2. the FOLH11561C>t, MTHFD2011G>a, and MTHFR677C>t were 
consistently included in the Boolean variables. Other included Dna variants were 
BHMT595G>a, and the 31bp Vntr and 844_845ins68 in the CBS gene; the latter two 
variants showed strong lD (r2>0.8). So not all variables that showed consistent single 
locus association were found here (e.g. UCP21032-1077dup) and variants that did not 
show strong marginal association to plasma tHcy were included (e.g. FOLH11561C>t). 
the identified logic regression models for unadjusted and adjusted fasting plasma tHcy 
only differed with respect to inclusion of either the 31bp Vntr or 844_845ins68 in the 
CBS gene, two strongly correlated variants. the identified logic regression models for 
unadjusted and adjusted post-load plasma tHcy were identical (data not shown). 
 the logic regression models included only one tree and divided the study popula-
tion in one group with high and one group with low plasma tHcy (fig. 4.2). median 
differences in plasma tHcy for the two groups were 5.2 and 16.6 µmol/l for unadjusted 
fasting and post-load, respectively. the two groups showed, as expected, statistically 
significant different plasma tHcy concentrations (anOVa P<0.001). the explained vari-
ance in unadjusted fasting, adjusted fasting, unadjusted post-load and adjusted post-
load plasma tHcy was 18%, 17%, 16% and 15%, respectively, which was much more 
than the sum of the marginal contributions (table 4.4). anOVa showed that for unad-
table 4.4  Percentage explained variance (adjusted R2) of plasma tHcy concentration by DNA 
variants based on coding and subsample used in logic regression (n=183 and 182 for fasting 
and post-load tHcy, respectively).
DNA variant Fasting Fasting adjusted Post-load Post-load adjusted 
BHMT595G>A 1.6 0.7 - -
CBS844_845ins68 - 1.1 - -
CBS 31bp VNTR 1.1 - 1.6 1.1
FOLH11561C>T 0.0 0.0 0.0 0.0
MTHFD2011G>A 0.8 0.4 2.6 2.2
MTHFR677C>T 1.3 2.0 2.1 3.2
all DNA variants 4.8 4.5 6.6 6.7
all with pair-wise interactions 16.0 17.0 16.7 16.9
logic regression Boolean variable 17.5 17.4 16.4 15.2
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justed fasting plasma tHcy statistically significant interactions between the 31 bp Vntr 
in CBS and MTHFD2011G>a, 31 bp Vntr in CBS and BHMT595G>a, FOLH11561C>t 
and MTHFD2011G>a, BHMT595G>a and MTHFR677C>t, and MTHFD2011G>a and 
MTHFR677C>t were observed in addition to marginal effects of MTHFR677C>t and the 
31 bp Vntr in CBS. for unadjusted post-load plasma tHcy we found statistically signifi-
cant interactive effects between MTHFD2011G>a and MTHFR677C>t, FOLH11561C>t 
and MTHFD2011G>a, and FOLH11561C>t and the 31 bp Vntr in CBS and no statisti-
cally significant marginal effects.
Discussion
in the numerous papers that have described the associations between Dna variants in 
candidate genes and plasma tHcy in the past, relatively few efforts have been directed 
towards characterization of multi-locus effects(14). factors that may have inhibited these 
types of analyses are the requirement of genotyping of multiple Dna variants, the 
need for large sample sizes, and the absence or unfamiliarity with efficient techniques 
of analysis. However, the application of a haplotype or multi-locus genotype approach 
offers potential advantages over the single-locus approach in the elucidation of the 
genetic aetiology of multi-factorial traits. tools to perform these types of analyses are 
now widely available(1,2). therefore, we re-examined the 36 Dna variants that we 
have measured over the last 13 years using haplotype and logic regression analysis. 
We found no haplotype associations independent of the single locus effects. logic 
regression analysis learned that a frequent multi-locus genotype was associated with a 
median increase in fasting plasma tHcy concentrations of ~5 µmol/l.
 the results for the separate Dna variants measured in this population were 
published and discussed by us previously. the small differences between the asso-
ciation results of the current and previous studies can be attributed to differences in 
number of genotyped individuals and/or approach in statistical analysis. the simul-
taneous presentation of all single locus results showed that these were dominated 
by MTHFR677C>t and variants in CBS, especially for post-load plasma tHcy, but also 
several other Dna variants contributed to tHcy variation, although less convincing. this 
is in line with findings from other studies(14). the MTHFR677C>t SnP was the most 
important marginal contributor to variation in plasma tHcy in our population due to its 
large effect and common allele frequency of 30% but the explained variance was still 
limited to ~2%. the explained variance by MTHFR677C>t varies among studies; e.g., 
estimates from just under 2%(48) and over 12%(49) have been reported. these differ-
ences may be attributed to the interpopulation variety in MTHFR677C>t frequency(50) 
and other sources of genetic or environmental heterogeneity between these popula-
tions.
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Our study confirmed the absence of the MTHFR677t and MTHFR1298C allele on one 
chromosome which indicates tight physical linkage between the loci or, possibly, fetal 
non-viability(51,52). also, the measured variants in CBS and COMT showed lack of recom-
bination and were located in one block with limited haplotype diversity. the presence 
of high lD within CBS has been reported for a subset of our population previously(34) 
and by others(53,54). interestingly, we found that the insertion allele was strongly linked 
with the 17 repeat allele of the CBS 31 bp Vntr (D’ 0.95, r2 0.83). However, Vyletal 
et al.(54), also found haplotypes containing the 844_845ins and the 18 and 21 allele 
in a Czech population. the effect of the two Dna variants on plasma tHcy was difficult 
to disentangle in our population due to the high correlation. Previous studies have 
indicated aberrant splicing and differences in CBS enzyme activity for different number 
of repeat units for CBS 31 bp Vntr(30), and no influence of the CBS844_845ins(68bp) 
on the size of the mrna product(55) which supports a causal role for the first, and the 
indirect measurement of this effect by the latter Dna variant. a high correlation be-
tween COMT324a>G and COMT36t>C SnP was found; conditional analysis and known 
functionality indicated causal importance of 324G>a, as we already reported(20). 
 the haplotype analysis did not lead to identification of haplotype effects on top of 
single locus effects. this points towards the absence of stronger lD between haplo-
types and unmeasured causal variants compared to the single Dna variants, which is 
very likely related to our strategy of selecting functional variants, and the absence of 
allelic interactions between the measured Dna variants(2). 
 a multi-locus genotype based on BHMT595G>a, the 31bp Vntr (or 844_845ins68) 
in the CBS gene, FOLH11561C>t, MTHFD2011G>a, and MTHFR677C>t distinguished 
two groups with large differences in fasting and post-load plasma tHcy. the deleteri-
ous multi-locus genotype was found in 10% of our study subjects. it explained 17% 
of the variation in plasma tHcy in our population, largely via statistical interactions, 
and, to a lesser extent, via marginal effects of MTHFR677C>t and CBS 31 bp Vntr. this 
underlines the importance of the combination of Dna variants in maintaining adequate 
levels of plasma tHcy. it would be very interesting to study whether this subgroup, that 
is genetically predisposed to high plasma tHcy, is also at higher risk for developing 
tHcy-associated disease states.
 We previously reported the interaction between ATIC346C>G and SLC19A180G>a(19) 
and 31 bp Vntr in CBS and MTHFR677C>t(16) based on traditional regression analysis 
in our study population. the latter two variants were also included in the multi-locus 
genotype in the current study. Our logic regression analysis also confirmed the modify-
ing effect of the CBS844_845ins68 on plasma tHcy increase in MTHFR677tt homozy-
gotes as recently reported by Summers et al.(56). Other studies, that have investigated 
combined genotype effects using traditional regression methods, have reported 
statistical interactions between the MTHFR677C>t and SLC19A80a>G(51), MTHFR677C>t 
and MTR2576a>G and MTRR66a>G(57), and MTHFR677C>t and MTHFR1298a>C, 
m u lt i - l O C u S  a n a l Y S i S  f O r  P l a S m a  t H C Y  93
SLC19A80a>G, MTR2576a>G, and MTRr66a>G(58). these genotype combinations were 
not part of the multi-locus genotype identified in the current study. Post-hoc analysis 
in our population using traditional regression analysis showed statistical interaction 
between MTHFR677C>t and MTRR66a>G for unadjusted fasting plasma tHcy only (data 
not shown).
 a strong point in our study is the measurement of a large number of (potentially) 
functional Dna variants in several key genes in homocysteine metabolism. this 
increased our prior chance of finding biologically meaningful genetic determinants of 
plasma tHcy. We have most likely not captured all genetic variation in the chosen can-
didate genes which makes it impossible to make final statements about involvement 
on gene level. future studies would benefit from inclusion of additional Dna variants 
to cover all variation within the genes.
 a potential source of bias in gene-association studies is presence of population 
stratification. Our study population was recruited from a small geographic area in the 
Hague and we only included individuals from known Caucasian ancestry, thereby 
limiting the chance of population stratification bias. in addition to crude analyses, 
we performed analyses for age, sex, and creatinine adjusted plasma tHcy levels. the 
standardized measurement of fasting as well as post-load plasma tHcy minimized the 
variation due to short-term dietary intake and allowed for comparison of the genetic 
associations for two homocysteine phenotypes. 
 Our study population at large consisted of 500 individuals which gave us 80% 
power to detect a statistically significant association for Dna variants that explained 
1.5% of the trait variance at an alpha level of 0.05. unfortunately, fewer subjects were 
analysed due to missing genotype information which limited our power (e.g. 300 indi-
viduals gave 80% power to detect a Dna variant with r2 2.5% at alpha 0.05). missing 
values also hampered logic regression analysis. to increase the number of included 
individuals, we omitted Dna variants that showed no marginal effect on plasma tHcy, 
thereby introducing a bias against these Dna variants. external validation studies will 
need to verify whether the large effect on plasma tHcy concentration of the identified 
multi-locus genotype in our population can be generalized. 
 Our systematic multi-locus association analysis for a large number of candidate 
gene variants allowed us to characterize lD patterns, demonstrate the absence of 
allelic interactions between the measured gene variants and the absence of strong lD 
between the estimated haplotypes and unmeasured causal variants. moreover, our 
analysis approach led to the identification of a multi-locus genotype that divided our 
population in two subgroups that showed over 5 µmol/l difference in median fasting 
plasma tHcy. the presence of interactions and small marginal effects of Dna variants, 
selected for their high prior probability of involvement in plasma tHcy level, confirmed 
the complex character of plasma tHcy and underlines the importance of multi-locus 
analysis in the elucidation of its genetic background.
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an association study of 45 
folate- related genes in spina 
bifida: involvement of cubilin 
(CUBN) and trna aspartic acid 
methyltransferase 1 (TRDMT1) 
abstract
Background:
Spina biﬁda is a class of neural tube defects, which are congenital malfor-
mations of the central nervous system with a prevalence of 0.5 to 12 per 
1000 births globally. In this article we attempt to identify genes related 
to folate and its metabolic pathways that are involved in the etiology of 
spina biﬁda. 
Methods:
We selected 50 folate metabolism-related genes and genotyped polymor-
phisms in those genes. Eighty-seven polymorphisms in 45 genes passed 
quality controls. Associations with spina biﬁda were investigated in 180 
patients and 190 controls. For those polymorphisms that were nominally 
associated with spina biﬁda risk, the relation with serum and red blood 
cell folate, vitamin B12, and homocysteine was evaluated in controls. 
Results:
A polymorphism in CUBN was signiﬁcantly associated with decreased 
spina biﬁda risk, after correction for multiple testing, and was related to 
increased vitamin B12 (p = 0.039) and red blood cell folate (p = 0.001). 
The CUBN gene encodes the intrinsic factor-cobalamin receptor (or cu-
bilin), a peripheral membrane protein that acts as a receptor for intrinsic 
factor-vitamin B12 complexes. Vitamin B12 is an important cofactor in the 
folate metabolism, and low B12 status in mothers has been linked to 
neural tube defects in children. Other interesting ﬁndings include nomi-
nally signiﬁcant associations with polymorphisms in TRDMT1, ALDH1L1, 
SARDH, and SLCA19A1 (RFC1). 
Conclusion:
Our study indicates interesting new candidate genes and functional path-
ways for further study and conﬁrms earlier ﬁndings. None of the genes 
CUBN, TRDMT1, ALDH1L1, or SARDH have been investigated previ-
ously for association with spina biﬁda. 
Introduction
neural tube defects (ntDs) are congenital malformations of the central nervous system 
with a prevalence of 0.5 to 12 per 1000 births globally. Spina bifida and anencephaly 
are the two most common types of ntD. Spina bifida is due to a closure defect of the 
caudal part of the neural tube and is compatible with life. in contrast, cranial closure 
defects of the neural tube result in lethal anencephaly. neural tube defects belong to 
the group of multifactorial disorders caused by genetic predisposition in the presence 
of unfavorable environmental factors.
 low maternal intake of folate was identified as an important environmental risk 
factor for ntDs, leading to preventive measures such as periconceptional folic acid 
supplementation and stimulation of food fortification with folic acid. in this way the 
occurrence and recurrence of ntDs can be reduced by 50 to 85%(1,2,3). metabolites 
of folate play an important role as cofactors of many different enzymes involved in 
processes such as purine and pyrimidine synthesis and Dna- and protein-methylation. 
Given the profound effect of food fortification on neural tube closure in the embryo, it 
is plausible that the efficiency of the endogenous folate metabolism is an important 
determinant of ntD risk. the fact that vitamin B12 (cobalamin) and homocysteine lev-
els, two biochemical parameters involved in folate metabolism, have also been associ-
ated with ntD risk underscores the importance of this metabolism in ntD etiology(4,5,6). 
Genetic variation causing suboptimal functioning of the endogenous folate metabolism 
likely forms the explanation for the fact that even today, in women with normal folate 
levels, supplementary folic acid can still reduce the risk of having a child with an ntD.
 indeed, the 677C>t polymorphism in the methylenetetrahydrofolate reductase 
(mtHfr) gene is associated with an increased risk for ntD(7). a few additional ntD 
risk factors have been identified in other folate-related genes. However, a large part 
of the genetic contribution to ntDs still remains unexplained(7,8). in this article we aim 
to identify genes related to folate and its metabolic pathways that are involved in 
the etiology of spina bifida. in addition, for selected polymorphisms, the relation with 
serum and red blood cell folate, vitamin B12, and homocysteine levels is evaluated in 
the control sample.
Materials and methods
Study Sample
With the approval of central and local ethics committees, patients with nonsyndromic 
spina bifida were recruited from the Dutch population between 1989 and 2001. all 
180 patients with spina bifida aperta included in this study have been described before 
in publications of the participating departments(6,9-11). no information on folic acid 
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supplementation during pregnancy by case mothers was present for the samples col-
lected before 1992, but we can assume that mothers did not use supplementation at 
that time. Supplementation started only in 1992 in the netherlands. for the remaining 
 cases, data on vitamin supplementation by mothers were collected via questionnaires; 
36 mothers had used supplements containing folic acid during pregnancy, 43 moth-
ers had not used any vitamin supplement, and data for five mothers were missing. 
Because only a few mothers had supplementation and dose-information was not avail-
able, we performed our analyses without evaluation of the potential effect modifica-
tion by folic acid supplementation.
 One hundred and ninety subjects of Dutch ethnicity were selected randomly from a 
group consisting of 500 unrelated healthy subjects that was ascertained via a general 
practice in the Hague(12). the characteristics of this population and the measurements 
of serum and red blood cell (rBC) folate, serum vitamin B12, and fasting plasma total 
homocysteine (tHcy) have been described previously(12).
Selection of Candidate Genes and Polymorphisms
Candidate genes and polymorphisms were selected from literature and databases(13,14) 
during 2002. We preferentially chose those polymorphisms that were either functional 
(causing changes in gene function or regulation) or had already shown association 
with any disease or condition. from databases, we preferentially selected single 
nucleotide polymorphisms (SnPs) that had been confirmed, had a known frequency 
in Caucasians, and were potentially functional or within or near exons or the promoter 
region. in genes with known functional polymorphisms, we did not select additional 
variants for analysis.
Genotyping
Genotyping of most SnPs was performed at aSPer Biotech (tartu, estonia) using ar-
rayed primer extension (aPeX) technology (15). Genotyping was performed in our own 
departments if aPeX assay-design for an SnP was not possible and for all non-SnP 
polymorphisms, using restriction fragment length polymorphism analysis(6) or by direct 
determination of allele length. assay conditions for individual polymorphisms geno-
typed in nijmegen, the netherlands, are available from the corresponding author. 
Genotyping of 154 polymorphisms (146 SnPs and 8 repeat polymorphisms) was 
attempted. as controls for genotyping, 5% blind duplicates and blanks were included 
in all sample plates. in addition, in selected samples eight SnPs genotyped by aSPer 
were genotyped by a second technique to confirm assay integrity. for quality control 
reasons, we included only those polymorphisms in the analysis that (1) had a minor 
allele frequency higher than 0.02, (2) were in Hardy-Weinberg equilibrium (p value 
>0.01), and (3) had less than 25% missing genotypes. Of the 154 polymorphisms in 50 
genes selected for analysis, 87 polymorphisms in 45 genes passed the quality controls.
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Statistical Analysis
test for deviation from Hardy-Weinberg equilibrium was performed with chi-square or 
fisher’s exact tests in controls using the GenHW add-on package(16) or a monte Carlo 
exact test(17). Genotypic chi-square tests for association of the diallelic sequence vari-
ants with case-control status were performed assuming a dominant, recessive, and a 
genotypic model. Odds ratios (Ors) and 95% confidence intervals (Ci) were constructed 
using logistic regression. multiallelic markers were recoded into diallelic variants (table 
5.1) and analyzed as described previously. nominal (i.e., uncorrected for multiple 
comparisons) two-tailed p values are presented. Correction for multiple comparisons 
according to the false discovery rate controlling procedure(19) was applied with a 
q-value setting of 0.05 using the multproc add-on package developed by newson(20). 
Given our sample size, this study has a 78% power to find with nominal significance 
(p value <0.05) a genetic variant with an Or of 1.5 and a minor allele requency of 
40%. the relation between the nominally associated polymorphisms and age and sex 
adjusted serum and rBC folate, vitamin B12, and tHcy levels was evaluated using linear 
regression. the distributions of the biochemical parameters were skewed to the right 
and therefore logarithmically transformed before analysis. all analyses were performed 
in Stata version 9.0 (StataCorp lP, College Station, tX). 
 Haplotype analyses were conducted only for those genes that showed suggestive 
nominal association in the single locus chi-square analysis (nominal p value <0.10). 
Pairwise linkage disequilibrium (lD; D and r2) for diallelic sequence variants located in 
one gene was computed using Haploview (Broad institute, Cambridge, ma). Haplo-
type association analysis was performed (for haplotypes with a frequency 2%) using 
Whap(21). two strategies were followed: haplotype analysis for identified blocks and 
sliding window approach for 2, 3, and 4 consecutive sequence variants in a gene. We 
used 1000 permutations to generate empirical p values in Whap.
 explorative analysis of gene-gene interactions in relation to risk of ntD was per-
formed using the logic regression package in r (version 2.3.1)(22) for those sequence 
variants that showed single locus associations with a nominal p value <0.10. ten-fold 
cross-validation was performed to identify the best model.
 
Results
table 5.1 describes the genes and polymorphisms that were selected for analysis. 
Genotype frequencies, Ors, and 95% Cis for the six polymorphisms that displayed a 
nominal chi-square p value <0.05 for association with spina bifida risk are displayed 
in table 5.2. these nominally significant findings included two uncorrelated (r2 = 
0.003) polymorphisms in CUBN, and one in TRDMT1 (=DNMT2), ALDH1L1, SARDH, and 
SLC19A1 (=RFC1). after correction for multiple testing using the false discovery rate ap-
proach, only rs1907362 in CUBN was statistically significantly associated with disease 
status (critical p value 0.0004065). 
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Haplotype analysis was performed for CUBN, ALDH1L1, SARDH, and BHMT. no hap-
lotype blocks and no strong lD between variants in these genes were found (all r2 
< 0.8). Sliding marker window analysis resulted in nominal associations for marker 
windows in CUBN. However, no haplotype effect on top of the single locus effect of 
the rs1907362 variant was present (data not shown).
 the best multilocus model identified in logic regression contained the polymor-
phisms rs1907362 in CUBN and rs2295809 in TRDMT1. However, no indication for 
statistical interaction between the two SnPs was found. logistic regression analysis 
confirmed the nominal significance of both effects and statistical additivity of the two 
variants. the two genes are direct neighbors on chromosome 10, though the two poly-
morphisms rs1907362 (CUBN) and rs2295809 (TRDMT1) are not highly correlated (r2 = 
0.03).
 the analyses for the spina bifida-associated polymorphisms and levels of biochemi-
cal parameters showed nominally statistically significant associations for rs1907362 in 
CuBn and increased rBC folate (p = 0.001) and vitamin B12 levels (p = 0.039) (table 
5.2). also, rs2295809 in TRDMT1 was associated with increased rBC folate (p = 0.002).
Discussion
in this study, we identified several novel candidate genes for spina bifida aperta and 
could confirm some prior association findings. the two polymorphisms in CUBN and 
TRDMT1 that were most strongly associated with spina bifida risk showed association 
with vitamin B12 and/or rBC folate levels. With the exception of SLC19A1, none of the 
genes from our top findings - CUBN, TRDMT1, ALDH1L1 or SARDH - has been investi-
gated for their association with spina bifida before, to our knowledge.
 the CuBn gene encodes the intrinsic factor-cobalamin receptor (cubilin), a periph-
eral membrane protein that acts as a receptor for intrinsic factor-vitamin B12 complexes 
as well as many other compounds, including proteins and lipids(23). During embryonic 
development, the gene mediates ligand endocytosis by absorptive epithelia at the 
maternal-fetal interfaces, trophectoderm and visceral endoderm, but is also expressed 
by developing neuroepithelial cells and the neural tube. although intronic, a possible 
functional character of SnP rs1907362 (G>a), or an SnP in lD, is supported by the find-
ing that the risk-decreasing a allele was nominally associated with increased vitamin 
B12 levels and strongly increased rBC folate levels.
 TRDMT1 codes for a methyltransferase that methylates a specific rna molecule, 
the aspartic acid transfer rna (trnaasp)(24). the a allele of the disease-associated 
rs2295809 was associated with increased rBC folate in the control population, which is 
in line with its risk-reducing effect observed in this study.
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the ALDH1L1 and SARDH genes also represent interesting new candidates for further 
study. a recent report on ALDH1L1 shows midline-specific expression in the developing 
central nervous system of mouse embryos. the authors explicitly mention the potential 
of this gene for involvement in ntDs in humans(25).
 Sarcosine dehydrogenase, encoded by SarDH, is involved in the breakdown of cho-
line via betaine, catalyzing the oxidative demethylation of sarcosine to form glycine, 
and is important as a supplier of one-carbon units to the folate metabolism. interest-
ingly, intake of choline and polymorphisms in choline metabolizing genes were found 
to influence ntD risk in previous studies(26,27).
 SLC19A1 encoding the reduced folate carrier is responsible for the uptake of dietary 
folate (in the form of folate monoglutamates) in the small intestine(8). the polymor-
phism assessed in this study (rs1051266, 80aG) causes a change in amino acid at posi-
tion 27. Several earlier studies have assessed the effect of this variant on ntD risk(28-33). 
most of them indeed showed an increased risk for carriers of the GG genotype(28-31). 
these data are compatible with our findings showing a reduced ntD risk for aa carri-
ers.
 the results of our study should be viewed in the context of some strengths and 
limitations. Strengths include the many folate-related genes investigated, the homoge-
neous spina bifida aperta background of the Dutch study population, and the availabil-
ity of folate, vitamin B12, and tHcy measurements in healthy individuals. limitations are 
the relatively small sample size (180 patients and 190 controls) and the incomplete 
coverage of the genes in terms of lD. furthermore, maternal genotypes were not 
available, so we were not able to distinguish maternal effects from those based on the 
child’s genotype. Our biochemical analyses indicate that a genotype has consequences 
on the phenotypic level in a direction that might help explain its association with ntDs, 
though it is clearly debatable whether such effects are comparable between adults 
and the developing embryo. in future studies, larger, well-characterized samples of 
children and mothers should be investigated for association of genes with spina bifida. 
in addition, information on folate supplementation in the mother should be taken into 
account. Preferably, such studies should be performed in a genome-wide effort, to 
reduce the bias introduced by current knowledge of candidate genes for spina bifida.
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role for mitochondrial 
 uncoupling protein-2 (UCP2) 
in hyperhomocysteinemia and 
venous thrombosis risk?
abstract 
Background: 
Hyperhomocysteinemia has been associated with an increased risk of 
venous thrombosis, which might be mediated through an oxidative stress 
dependent mechanism. The function of uncoupling protein-2 (UCP2) is 
still under debate, but it has been suggested to play a role in reduction 
of mitochondrial reactive oxygen species. In the present study, we inves-
tigated whether the 45 bp deletion/insertion (del/ins) polymorphism 
in the UCP2 gene is associated with elevated homocysteine levels and 
whether it might be associated with an increased risk of recurrent venous 
thrombosis (RVT). 
Methods: 
The 45 bp del/ins polymorphism in the UCP2 gene was genotyped by 
PCR analysis in 161 RVT cases and 386 controls of Caucasian origin in 
which fasting-and post-load homocysteine levels were previously deter-
mined. Statistical analysis was performed to assess whether the UCP2 45 
bp del/ins polymorphism was associated with plasma total homocysteine 
levels and venous thrombosis risk. 
Results: 
Post-load homocysteine levels were positively associated with UCP2 45 
bp ins/ins genotype (p=0.02). None of the UCP2 45 bp ins/del geno-
types were associated with fasting plasma homocysteine levels. The fre-
quency of the UCP2 45 bp ins/ins genotype was 12.4% in RVT cases 
compared to 8.3% in controls, which resulted in an odds ratio of 1.8 (95% 
CI 1.0–3.4).
Conclusions: 
The results of our study show that the common 45 bp del/ins poly-
morphism in the UCP2 gene is associated with hyperhomocysteinemia, 
which might increase the risk of venous thrombosis. However, the mecha-
nism is not fully understood and additional studies should be performed 
to conﬁrm our ﬁndings.
Introduction
Hyperhomocysteinemia has been associated with an increased risk of deep vein 
thrombosis and pulmonary embolism. Both genetic and environmental factors contri-
bute to elevated homocysteine levels. early data from case-control studies showed a 
clear association between hyperhomocysteinemia and venous thrombosis(1), whereas 
data from prospective studies showed a much less, though still, significant increased 
relative risk(2). in addition, in a recent meta-analysis it was demonstrated that the 
5,10-methylenetetrahydrofolate reductase (MTHFR) 677 tt genotype, which is a 
genetic determinant of hyperhomocysteinemia, increased the risk of venous thrombo-
sis(3). the above-mentioned studies all provided evidence that hyperhomocysteinemia 
was associated with an increased risk of venous thrombosis. However, results from the 
first randomized controlled trials showed that homocysteine-lowering by B-vitamin 
supplementation does not prevent recurrent venous thrombosis(4, 5). Currently, the 
question rises whether homocysteine is causally related to venous thrombosis itself or 
is a marker of disturbed intracellular metabolism. Studying genetic variation in candi-
date genes might provide an answer to the mechanism underlying the prothrombotic 
actions of homocysteine or related metabolites, which might involve oxidative stress, 
Dna hypomethylation and/ or proinflammatory effects(6). 
 Preliminary results of our unpublished study, in which we studied the association 
of homocysteine levels with single-nucleotide polymorphisms (SnP) in folate/neural 
tube defect related genes in 190 control individuals by a SnP array, showed a positive 
association of the uncoupling protein-2 (UCP2) gene 45 bp deletion/insertion (del/
ins) polymorphism and postload homocysteine levels. this SnP array included three 
SnPs in the UCP2 gene [i.e., the –866 G>a transversion (rs659366), the 45 bp del/ins 
polymorphism and the 544 C>t transition (rs660339)], of which only the 45 bp del/ins 
polymorphism was associated with post-load homocysteine levels (p=0.02) (unpub-
lished results). these results, together with the postulated role of UCP2 as a regulator 
of mitochondrial reactive oxygen species (rOS) production, were the rationale for the 
present study. 
 mitochondrial uncoupling proteins (uCPs) are located in the mitochondrial inner 
membrane and the function of the best-described uncoupling protein (i.e., uCP1) 
involves translocation of protons from the inner membrane space to the matrix to 
uncouple atP synthesis to produce heat(7). in addition to uCP1, four other putative uCPs 
with unknown physiological roles have been described (uCP2–5)(7, 8). among these four 
putative uCPs, uCP2 has been the focus of much research, because it is thought to be 
involved in the regulation of mitochondrial rOS production rather than being a mito-
chondrial uCP(9). Several variations in the UCP2 gene have been described, of which 
in particular the 45 bp del/ins polymorphism in the 3’-untranslated region of exon 8 
has been shown to be functional, i.e., mrna transcribed from the insertion allele had 
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a shorter half-life in cultured myoblasts than mrna transcribed from the deletion al-
lele(10). 
 in this study, we investigated whether the UCP2 45 bp del/ins polymorphism is 
associated with hyperhomocysteinemia and recurrent venous thrombosis (rVt). We 
genotyped the UCP2 45 bp del/ins poly-morphism in 169 cases with rVt and 390 
controls of Caucasian origin and examined its association with fasting- and post-load 
homocysteine levels and rVt risk. 
Materials and methods 
Patient material 
Patients were selected from an anticoagulant clinic where they were registered as 
having rVt(1,11). Patients with a history of two or more episodes of venous thrombosis 
(n=473) were invited to participate in the study, of which 185 agreed to take part in 
the study. almost all patients received coumarin therapy. Controls were selected from 
the general population in the Hague. a total of 2812 individuals were approached to 
take part in a health survey of risk factors for cardiovascular disease and 532 agreed 
to take part; however, 500 individuals actually took part in the study(11). Of these 500, 
only individuals that were of Caucasian origin (n=462) were included in this study. 
after overnight fasting, blood samples were collected before and after 6 h of an oral 
methionine load(11). Plasma total homocysteine (fasting and post-methionine load) 
levels were measured according to standard methods as described previously(11). in 
the present study, UCP2 45 bp del/ins genotypes were obtained for 161 rVt cases and 
386 controls (these controls included the 190 controls that were initially analyzed by 
the SnP array and that were re-genotyped for this study). Characteristics of the initial 
study group are presented in table 6.1. 
Determination of the UCP2 45 bp insertion 
Genomic Dna was isolated from peripheral blood lymphocytes according to standard 
procedures(12). the 45 bp del/ ins polymorphism in the gene coding for UCP2 is a 45 
bp sequence that is duplicated(13). in general, the sequence with the 45 bp fragment is 
referred to as deletion, whereas the sequence with a duplication of the 45 bp frag-
ment is referred to as insertion(10). PCr was carried out in a total volume of 50 ml on 
the iCycler thermocycler (Biorad, Veenendaal, the netherlands) containing 200 nm 
of forward (CaGtGaGGGaaGtGGGaGGtG)(14) and reverse (GCaGGaCGaaGattCtGGCtG) 
primers, 200 mm of dntPs, 1.5 mm mgCl2 (invitrogen, Breda, the netherlands), 5% 
DmSO, 1x PCr buffer (invitrogen) and 1 u of recombinant Dna polymerase (invitro-
gen). in the case of the deletion, a fragment of 453 bp was obtained, and in the pres-
ence of the insertion, a fragment of 498 bp was obtained. fragments were separated 
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table 6.1  Baseline characteristics of study population.
Variable* Cases 
(n=185)
Controls 
(n=500)
p-value
Age (year) 62 (42-79) 50 (34-69) <0.01
Sex (men) 94 (51%) 208 (42%) 0.03
Post-menopausal women 64 (35%) 138 (28%) <0.01
Time between 1st event and study (years) 17 (range 1 to 58) - -
Time between last event and study (years) 7 (range 1 to 30) - -
Type of venous thrombosis
Only pulmonary embolism (PE)
Only deep vein thrombosis (DVT)
Both DVT and PE 
43
73
69
- -
Smoking (yes/no) 61 (33%) 167 (34%) 0.9
B-vitamin (yes/no) 23 (12%) 76 (15%) 0.9
Fasting homocysteine (μmol/L) 12.2 (8.3-20.8) 10.7 (6.7-15.5) <0.01
Postload homocysteine (μmol/L) 43.6 (29.3-68.0) 37.0 (25.5-57.3) < 0.01
Creatinine (μmol/L) 81 (61-112) 74 (55-99) <0.01
Folate (nmol/L) 13.5 (7.7-23.5) 12.7 (7.0-23.6) 0.2
Vitamin B12 (μmol/L) 241 (118-466) 217 (125-389) 0.04
Vitamin B6 (nmol/L) 25.8 (12.7-55.7) 27.6 (15.7-54.8) 0.03
Riboflavin (nmol/L) 10.2 (4.9-37.1) 9.1 (4.0-25.9) 0.07
MTHFR 677 C>T (MAF) 33.3% 29.1% 0.21
*  Data are given as medians with 10th to 90th percentiles in parenthesis for continuous variables and as 
numbers with percentages in parenthesis for categorical variables; maf = minor allele frequency
by gel electrophoresis on a 2% agarose gel. in addition, four samples per genotype 
were sequenced on the 3130 Xl Dna analyzer according to the protocol of the manu-
facturer (applied Biosystems, nieuwerkerk a/d ijssel, the netherlands) to validate the 
genotyping method. 
Statistical analysis 
to determine whether the UCP2 45 bp del/ins polymorphism was associated with 
elevated homocysteine levels, geometric means and confidence intervals were calcu-
lated, and a one-way analysis of variance (anOVa) was performed. Odds ratios (Ors) 
and 95% confidence intervals (95% Cis) were calculated for UCP2 45 bp genotypes in 
relation to recurrent thrombosis risk. logistic regression analysis with UCP2 genotypes 
as a continuous variable was applied to test for a trend among the three genotypes in 
relation to rVt risk. a p<0.05 was considered statistically significant; all p-values were 
two-tailed. 
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table 6.2  Fasting- and postload total homocysteine levels for different UCP2 genotypes.
UCP2 45bp del/ins
ANOVA pDEL/DEL
Meana (95%CI)N
DEL/INS
Meana (95%CI)N
INS/INS
Meana (95%CI)N
Controls (n=386 )
Fasting tHcy (μmol/L)
Post-load tHcy (μmol/L)
Cases (n= 161)
Fasting tHcy (μmol/L)
Post-load tHcy (μmol/L)
10.3 (9.8-10.8)207
37.1 (35.5-38.8)206
12.4 (11.4-13.5)71
42.4 (39.5-45.6)71
10.9 (10.2-11.7)147
40.2 (38.2-42.3)145,b
13.4 (12.1-14.9)70
46.8 (43.3-50.6)70,c
10.5 (9.4-11.7)32
41.9 (36.7-47.8)32,b
12.3 (10.3-14.7)20
40.6 (34.6-47.7)20
0.38
0.02
0.42
0.09
a Geometric mean 
b P< 0.05 compared to UCP2 45bp del/del genotype 
c P=0.07 compared to UCP2 45bp del/del genotype 
tHcy = plasma total homocysteine
table 6.3  Genotype frequencies of UCP2 45bp del/ins polymorphism in RVT cases and controls.
UCP2
45bp del/ins
Controls
N (%)
Cases
N (%)
OR 
[95%CI]
del/del
del/ins
ins/ins
207 (53.6%)
147 (38.1%)
32 (8.3%)
71 (44.1%)
70 (43.5%)
20 (12.4%)
1.0a
1.4 [0.9-2.1]
1.8 [1.0-3.4]b
a reference category
b Ptrend = 0.03
Results 
We examined whether plasma total homocysteine (fasting and/or post-load) levels 
were different between cases and controls with different UCP2 45 bp del/ins geno-
types. Presently, Dna was available from 169 of the 185 rVt cases and 390 of the 462 
Caucasian controls. Genotype data were obtained from 161 rVt cases and 386 controls 
of which 51% and 41% were male, respectively (p=0.04). mean age of cases and 
controls was 62.3±14.1 years and 51.0±13.4 years, respectively (p=0.01). mean plasma 
fasting homocysteine levels were 12.9±6.5 µmol/l for cases and 10.5±4.7 µmol/l for 
controls (p=0.01). Post-load homocysteine levels were 44.0±15.5 µmol/l for cases and 
38.6±14.5 µmol/l for controls (p=0.01). 
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UCP2 45 bp del/ins allele frequencies did not differ from that expected under Hardy-
Weinberg equilibrium (p=0.09). fasting homocysteine levels were not different 
between rVt cases and controls with different UCP2 genotypes (p=0.42 and p=0.38, 
respectively; table 6.2). Post-load homocysteine levels were significantly elevated 
among controls with the UCP2 45 bp del/ins and ins/ins genotypes compared to those 
with the UCP2 del/del genotype (p=0.02, table 6.2). in rVt cases, a slight association 
was observed between the UCP2 45 bp del/ins genotype with post-load homocysteine 
levels compared to the UCP2 45 bp del/del genotype, although this was not significant 
(p=0.07, table 6.2). 
 in addition, we examined whether the UCP2 45 bp ins/ins genotype occurred more 
often in rVt cases than in controls. UCP2 45 bp del/ins genotyping was performed as 
described in genomic Dna of 169 rVt cases, of which a reliable genotype could be ob-
tained from 161 cases. the UCP2 45 bp ins/ins genotype was present in 12.4% of the 
rVt cases and 8.3% of the controls, which led to an Or of 1.8 (95% Ci 1.0–3.4) (table 
6.3). a positive trend was observed for the UCP2 45 bp insertion allele in relation to 
rVt risk (ptrend=0.03). Correction for age and sex differences between rVt cases and 
controls did not change the outcome of this analysis (data not shown). 
Discussion 
in this study, we tested the hypothesis that the common 45 bp del/ins polymorphism 
in the UCP2 gene is associated with hyperhomocysteinemia and rVt risk. We found a 
positive association of the UCP2 45 bp ins/ins genotype with post-load homocysteine 
levels and showed that this genotype was more frequently present among rVt cases 
than controls. 
 the role of uCP2 is still under debate but one of its suggested roles is protection 
against mitochondrial rOS production(8, 15, 16). in a previous unpublished study, we found 
evidence for a positive association between the 45 bp insertion in the UCP2 gene 
and hyperhomocysteinemia. as hyperhomocysteinemia is suggested to be involved 
in oxidative stress, we investigated the role of the UCP2 45 bp del/ins polymorphism 
in relation to fasting-and post-load total homocysteine levels. in controls, we found 
a positive association between the UCP2 45 bp del/ins and ins/ins genotypes with 
post-load homocysteine levels in comparison with the UCP2 45 bp del/del genotype. 
in cases, we observed a positive association with post-load homocysteine levels in 
relation to the UCP2 45 bp del/ins genotype but not to the UCP2 ins/ins genotype, 
which might be explained by the small number of cases with the UCP2 ins/ins geno-
type (n=10, table 6.2). this is the first study that reports an association between UCP2 
and hyperhomocysteinemia and therefore more studies are warranted to confirm our 
results. 
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as hyperhomocysteinemia is associated with increased rVt risk, we hypothesized that 
if the 45 bp del/ins polymorphism is associated with hyperhomocysteinemia this also 
increases rVt risk. the UCP2 ins/ins genotype was more frequently present among 
rVt cases than in controls, which led to a 1.8-fold almost significant risk compared to 
the UCP2 del/del genotype. However, to confirm our findings, the results of this study 
need to be confirmed in a second, preferably larger case-control study, in which also 
gene-gene (e.g., MTHFR) and gene-environmental (e.g., folate, rOS) interactions can 
be studied. 
 recent studies suggest that hyperhomocysteinemia is associated with mitochondrial 
dysfunction(17). Homocysteine infusion in rats was shown to inhibit complex i activity 
of mitochondrial oxidative phosphorylation, which led to enhanced rOS production(18). 
in addition, in cultured endothelial cells it was shown that homocysteine infusion led 
to the translocation of proteins to the mitochondria, which might be caused by an 
increased intramitochondrial oxidative burst(19, 20). the role of UCP2 in relation to rOS 
production is still under debate, but it is expected to be involved in mitochondrial 
function some way or another(8). Our results with UCP2 in humans are in line with the 
findings from in vitro studies that hyperhomocysteinemia is associated with altered mi-
tochondrial functioning. However, results from homocysteine infusion studies suggest 
that homocysteine is causally related to mitochondrial dysfunction, whereas our results 
suggest the opposite (i.e., that homocysteine is a reflection of mitochondrial dysfunc-
tion). future studies should investigate this more closely. 
 this is the first study that examined a possible association between UCP2, hyperho-
mocysteinemia and rVt risk. the results of our study show that hyperhomocysteinemia 
is associated the 45 bp del/ins polymorphism in the UCP2 gene, which might increase 
rVt risk. 
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a Hybrid Design: Case-Parent 
triads Supplemented by Control-
mother Dyads 
abstract
Hybrid designs arose from an effort to combine the beneﬁts of family-
based and population-based study designs. A recently proposed hybrid 
approach augments case-parent triads with population-based control-
parent triads, genotyping everyone except the control offspring. Includ-
ing parents of controls substantially improves statistical efﬁciency for 
testing and estimating both offspring and maternal genetic relative risk 
parameters relative to using case-parent triads alone. Moreover, it al-
lows testing of required assumptions. Nevertheless, control fathers can 
be hard to recruit, whereas control offspring and their mothers may be 
readily available. Consequently, we propose an alternative hybrid design 
where offspring-mother pairs, instead of parents, serve as population-
based controls. We compare the power of our proposed method with 
several competitors and show that it performs well in various scenarios, 
though it is slightly less powerful than the hybrid design that uses control 
parents. We describe approaches for checking whether population strati-
ﬁcation will bias inferences that use controls and whether the mating-
symmetry assumption holds. Surprisingly, if mating symmetry is violated, 
even though mating-type parameters cannot be directly estimated using 
control-mother dyads alone, and maternal effects cannot be estimated 
using case-parent triads alone, combining both sources of data allows 
estimation of all the parameters. This hybrid design can also be used to 
study environmental inﬂuences on disease risk and gene-by-environment 
interactions. 
Introduction
Genetic factors may increase risk for congenital disorders via direct effects of the 
inherited genotype of the offspring or via the genotype of the mother. maternal effects 
can arise because the genetic variants carried by the mother influence the prenatal 
environment in which the fetus develops, thereby increasing disease risk. under such 
a mechanism, the genotype distribution in the case mothers is different from that in 
the control population, whereas transmission of the genetic variant to the offspring 
conforms to mendelian expectation. Disentangling offspring from maternal genetic ef-
fects can increase insight into the etiology of disorders with early onset in life, such as 
congenital malformations and childhood cancers. 
 the case-parents design, comprising affected offspring and their two parents, 
permits testing and estimation of offspring- and maternally mediated genetic ef-
fects(1,2). Offspring effects are evaluated by the apparent over-transmission (compared 
to the mendelian expectation of 0.5) of deleterious alleles from heterozygous parents 
to affected offspring. maternal genotype effects are assessed through deviations from 
genotype mating symmetry in the case-parents data under the assumption of mat-
ing symmetry in the source population. that is, a deleterious allele that acts via the 
mother will be more prevalent in mothers than in fathers of affected offspring. the key 
mating-symmetry assumption cannot, however, be evaluated using case-parent triads 
alone. 
 another design that can be used to disentangle offspring and maternal genetic 
effects ascertains affected children and their mothers as well as a random sample of 
unaffected children and their mothers. in such a case-mother/control-mother design, 
the offspring-mother pairs are the units for analysis. Both offspring and maternal ef-
fects are assessed through case-control comparisons; no mating-symmetry assumption 
is required. unlike the case-parents design, however, this design is vulnerable to bias 
due to the existence of genetically distinct subpopulations. Weinberg and umbach(3) 
describe the strengths and weaknesses of both the population-based case-mother/
control-mother and the family-based case-parents design. 
 to bring together the advantages of both family-based and population-based ap-
proaches, nagelkerke et al.(4), epstein et al.(5) and Weinberg and umbach(3) have pro-
posed various hybrid designs that combine both kinds of data. One hybrid approach(3) 
enrolls case-parent and control-parent triads and genotypes case-parent triads but only 
the parents of control offspring (case-parent triad/control parents design). this hybrid 
design greatly improves power for the evaluation of offspring-and maternally medi-
ated genetic effects. it allows testing for bias from population stratification; and, if bias 
is detected, confounding is avoided by using only the case-parent triads. in addition, 
the assumption of parental mating symmetry in the population at large can be tested, 
and maternal genetic effects can be validly estimated even if mating symmetry is 
rejected(3). 
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the case-parent triad/control-parents hybrid design calls for both control parents to be 
genotyped. fathers, however, are often hard to recruit while mothers and unaffected 
offspring may already be available. this paper presents an alternative hybrid design 
where control-mother dyads replace parents of controls. exposure information would 
still be collected for both the case offspring and the unrelated control offspring. in the 
hybrid design that genotypes control parents, one can directly estimate the mating-
type frequencies in the source population. in the proposed design that genotypes con-
trol-mother dyads instead, the information on those frequencies is indirect because the 
genotype of the control child acts as a surrogate for the father’s genotype. this feature 
introduces some challenges. We demonstrate that, even in scenarios with missing gen-
otype data, this alternative hybrid design has a greater power than the case-parents or 
the case-mother/control-mother designs but has slightly reduced power compared to 
the hybrid design that uses control parents. We also show that this alternative hybrid 
design retains the ability to test for bias due to population stratification and, thereby, 
to examine whether case-parents and control data can be safely combined. finally, we 
describe procedures for checking the assumption of mating symmetry and for making 
valid inference on maternal effects even when that assumption fails. 
Analysis of case-parent triad/control-mother dyad data
Our alternative hybrid approach starts with a random sample of affected individuals 
and a random sample of unaffected individuals. Cases and their parents are enrolled 
and genotyped but only mothers of controls and the controls themselves are geno-
typed. We are interested in testing for association between disease risk and the 
offspring and maternal genotypes at a di-allelic autosomal locus. We assume that the 
disease is rare and that mendelian transmission probabilities hold for that locus in 
the underlying population, and hence among controls. Validly combining information 
from case and control families requires an assumption that any population structure is 
benign with respect to bias, an assumption that can be probed with the data at hand. 
neither Hardy-Weinberg equilibrium (HWe) nor random mating is required for validity. 
let p denote the frequency of the minor or ‘‘variant’’ allele. Which allele is designated 
as the ‘‘variant’’ has no effect on estimation or testing beyond the mathematical 
inversions. let M, F and C represent the number of variant alleles (0,1,2) carried by 
the mother, father and child, respectively. D is an indicator variable for disease status, 
which is 1 for case families and 0 for control families. 
 following Schaid and Sommer(6), we define nine different mating types based on 
the number of variant copies carried by the mother and the father. these mating types 
along with their possible offspring genotypes lead to 15 possible (M,F,C) categories, 
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table 7.1  Expected counts of case-parent triads and control-mother dyads under mating 
asymmetry or mating symmetry. 
mating asymmetry mating symmetry
MFa Cb affected mating types expected countc mating types expected countc
00 0 yes 00 Bμ00 00 Bμ00
01 0 yes 01 Bμ01/2 01/10 Bμ01/4
01 1 yes 01 Bμ01R1/2 01/10 Bμ01R1/4
10 0 yes 10 Bμ10S1/2 01/10 Bμ01S1/4
10 1 yes 10 Bμ10R1S1/2 01/10 Bμ01R1S1/4
02 1 yes 02 Bμ02R1 02/20 Bμ02R1/2
20 1 yes 20 Bμ20R1S2 02/20 Bμ02R1S2/2
11 0 yes 11 Bμ11S1/4 11 Bμ11S1/4
11 1 yes 11 Bμ11R1S1/2 11 Bμ11R1S1/2
11 2 yes 11 Bμ11R2S1/4 11 Bμ11R2S1/4
12 1 yes 12 Bμ12R1S1/2 12/21 Bμ12R1S1/4
12 2 yes 12 Bμ12R2S1/2 12/21 Bμ12R2S1/4
21 1 yes 21 Bμ21R1S2/2 12/21 Bμ12R1S2/4
21 2 yes 21 Bμ21R2S2/2 12/21 Bμ12R2S2/4
22 2 yes 22 Bμ22R2S2 22 Bμ22R2S2
0-d 0 no 00 or 01 μ00+ μ01/2 00 or 01/10 μ00+ μ01/4
0- 1 no 01 or 02 μ01/2 + μ02 01/10 or 02/20 μ01/4 + μ02/2
1- 0 no 10 or 11 μ10/2 + μ11/4e 01/10 or 11 μ01/4 + μ11/4e
1- 1 no 10 or 11 or 12 μ10/2 + μ11/2 + 
μ12/2e
01/10 or 11 or 12/21 μ01/4 + μ11/2 + 
μ12/4e
1- 2 no 11 or 12 μ11/4 + μ12/2e 11 or 12/21 μ11/4 + μ12/4e
2- 1 no 20 or 21 μ20 + μ21/2 02/20 or 12/21 μ02/2 + μ12/4
2- 2 no 21 or 22 μ21/2 + μ22 12/21 or 22 μ12/4 + μ22
a  Copies of variant allele carried by the mother and the father.
b  Copies of variant allele carried by the child.
c   “B” is a normalizing factor whose inclusion ensures that the total fitted count for case triads matches the 
corresponding total observed count and, similarly, for control dyads. under mating symmetry, stratification 
parameter µmf includes the stratum with m and f reversed.
d   “-”is used to denote a missing paternal genotype.
e   When M=1, the expected counts in cells where C=0 and C=2 sum to the expected count in the cell where 
C=1.
and, consequently, one can imagine two 15-cell multinomial distributions of offspring 
and parental genotypes, one for control triads and one for case triads. in hybrid de-
signs, typically the full (M,F,C) data are recorded for case families, whereas only partial 
data are collected from control families; here, only (M,C) data. initially, we assume that 
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any genotyping called for by the design is complete, but missing-data methods can be 
employed if some genotypes are missing(7). 
 for control families, expected counts in the 15-cell multinomial can be modeled 
using mendelian transmission probabilities and mating-type parameters (µmf), which 
are proportional to the frequencies of mother-father pairs with M = m and F = f in the 
source population. the expected counts for control-mother dyads (the last 7 lines of 
table 7.1) arise from the 15-cell multinomial by summing counts across the geno-
types of possible fathers. the distribution of control-mother dyads has two noteworthy 
features: first, the (M,C) cells (0,2) and (2,0) are not possible, leaving only seven cells 
with non-zero expected counts. Second, and less obviously, the following relationship 
is a consequence of mendelian transmission alone: when M = 1, the expected count 
for C = 1 is the sum of the expected counts for C = 0 and 2. this constraint reduces the 
available degrees of freedom (dfs) contributed by the seven control-dyad cells from six 
to five. 
 for case families, expected counts in the 15-cell multinomial involve not only 
mating-type parameters and mendelian probabilities but also four genetic relative risk 
parameters. We denote these relative risk parameters as follows: R1 (R2) is the relative 
risk for offspring carrying one (respectively, two) copies of the variant compared to off-
spring carrying none; S1 (S2) is the relative risk for offspring whose mother carries one 
(respectively, two) copies of the variant allele compared to offspring whose mother 
carries none. Combining the 15 cells for case-parent triads with the 7 cells for control-
mother dyads yields a 22-cell multinomial for the proposed design (table 7.1). 
 for the case-parents design and for the hybrid design that uses parents of controls, 
the multinomial expected cell counts are all products of parameters and can be fitted 
using log-linear Poisson regression. Because the expected counts for control-mother 
dyads involve sums of parameters, however, the expected counts in table 7.1 for the 
22-cell multinomial are not themselves log-linear. a straight-forward way to proceed 
with fitting either model is to regard the 22-cell multinomial as a version of the full 
30-cell multinomial (15 cells each for case families and control families), that is miss-
ing genotype data for fathers of controls by design. thus, one can use missing-data 
methods like the expectation-maximization (em) algorithm(8) in conjunction with a log-
linear model for the 30-cell multinomial. use of the em algorithm also allows inclusion 
of any case-parent triads or control-mother dyads with missing genotypes that may 
arise through genotyping failure or incomplete ascertainment. for valid analysis, one 
must be able to assume that these genotype data are missing at random conditional 
on disease status and the observed genotypes. When control fathers are missing only 
by design, this assumption is satisfied without doubt because all of them are missing. 
 assuming a multiplicative model for risk and no bias from population structure, a 
log-linear model for the full 30-cell multinomial (corresponding to table 7.1, column 5) 
would be: 
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in[E(count | M = m, F = f, C = c, D = d)] = ln(µmf) + ß1dI(c=1) + ß2dI(c=2) 
 + α1dI(m=1) + α2dI(m=2) + γd + ln(Offmfc)                                                     
(1)
i() is an indicator function which takes a value of 1 if the parenthetical condition is met 
and 0 otherwise. ß1 and ß2 denote the natural logarithms of the offspring genetic 
relative risks, R1 and R2, respectively, and α1 and α2 denote the natural logarithms of 
maternal genetic relative risks, S1 and S2, respectively. γ corresponds to the natural 
logarithm of the normalizing factor B. the offset, denoted by Offmfc, is the constant 
multiplier (1, ½ or ¼) given in table 7.1, column 5. in this model, the nine mating-type 
parameters, µmf, are common to both cases and controls and can be interpreted as 
proportional to the mating-type frequencies in the source population. 
 this model is fundamental to the analysis of data from our proposed design. modi-
fications of the model by omitting or including certain additional terms allow one to 
construct likelihood ratio tests (lrts) of hypotheses about the genetic relative risk pa-
rameters or to test the assumptions about bias from population stratification or about 
mating symmetry. in addition, models addressing maternal-fetal incompatibility can be 
constructed by including two additional relative risk parameters(9). all tests of assump-
tions that we subsequently develop under the four risk parameters in model (1) can 
be developed and applied without difficulty when these two additional risk parameters 
are present. 
 lrts in this missing-data situation must be based on the observed-data likelihood, 
not the pseudo-complete-data likelihood. We have used the program lem(10) in our 
subsequent analyses. lem was designed to fit log-linear models with missing data via 
the em algorithm. Consequently, dealing with missing fathers among controls or with 
other patterns of missing data does not require special programming. the program al-
lows incorporation of the mendelian constraints and returns valid test statistics as well 
as valid estimates for risk parameters and their standard errors. examples of the lem 
scripts that we used are available at http://www.niehs.nih.gov/research/atniehs/
labs/bb/staff/weinberg/index.cfm#downloads. 
Association of offspring or maternal genotypes with risk
an lrt statistic for any particular subset of the four relative risk parameters can be 
calculated by computing twice the change in maximized observed-data log like-lihood 
between a version of model (1) that estimates all parameters and a version that fixes 
the subset to be tested at their null values (most often, zero). for calculating a P value, 
this lrt statistic is referred to a X2 distribution whose dfs equal the number of param-
eters in the subset. model (1) can be modified, if desired, to accommodate specific 
modes of inheritance like recessive, dominant or log-additive. 
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to this point, we focused on model (1) with nine mating-type parameters (table 7.1, 
column 5). We call this model the mating-asymmetry model because it places no 
constraints on the mating-type parameters. mating symmetry is frequently assumed(2,6) 
and is required for inference on maternal genetic effects with a case-parents design. 
mating symmetry means that the probability of parents with M = m and F = f is the 
same as the probability of parents with M = f and F = m in the source population. in 
terms of the µmf parameters, mating symmetry implies three constraints, namely: 
µ01 = µ10, µ02 = µ20, and µ12 = µ21, in effect reducing nine mating types to six (table 
7.1, column 6). the mating-symmetry model can also be described algebraically using 
model (1) with the understanding that the mating-type parameters and offsets are 
changed to those of table 7.1, column 7. any tests that can be carried out on the rela-
tive risk parameters under the original nine-mating-type model (mating asymmetry) 
can also be carried out under the six-mating-type model (mating symmetry). When 
mating symmetry holds in the general population, tests under the mating-symmetry 
model will be more powerful than tests under the mating-asymmetry model because 
the former model involves fewer parameters. using either nine or six mating types, 
model (1) employs the same mating-type parameters for both cases and controls and, 
thereby, relies on an assumed absence of bias from population structure, as does any 
case-control study. 
Checking assumptions: absence of bias from population structure 
for assessing the contribution of variant alleles to risk, the key to the power gains pos-
sible with this hybrid design is that control-mother dyads contribute to the estimation 
of the mating-type parameters. the two sets of mating-type parameters will truly be 
equal only if there is no bias due to population structure. the existence of such a bias 
requires not only that genetic population structure be present but also that the risk in 
noncarriers be correlated with allele frequency across subpopulations. Whenever this 
bias is present, model (1) is not valid for combining data from case and control families. 
 a test for bias from population structure is simply a test of whether model (1) with 
common mating-type parameters for cases and controls fits the data as well as an 
extended model with distinct mating-type parameters for cases and controls. Such a 
test could be conducted under either mating asymmetry or mating symmetry; and, 
in principle, the extended model would involve eight or five additional parameters, 
respectively. the ability to estimate separate mating-type parameters for cases and 
controls is constrained, however, by the use of control-mother dyads and, under 
mating asymmetry, by the complete aliasing of certain mating types with maternal 
effects. Consequently, the extended model has only three additional dfs under mat-
ing asymmetry and only four under mating symmetry. an alternative approach that 
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will sometimes be more powerful under mating symmetry than the four-df lrt is to 
employ a test for a particular linear trend in the disparity between case and control 
mating-type parameters. this one-df lrt compares model (1) to a model that includes 
the single additional term θ(M+F)d where θ, the unknown trend slope, is zero in the 
absence of bias from population structure. a monotone trend would arise, for example, 
if a population consisted of two distinct subpopulations, each in HWe at the single 
nucleotide polymorphism in question, and their respective baseline risks and allele 
frequencies were correlated. if under either of the testing strategies the fit is statisti-
cally significantly improved by the inclusion of the separate mating-type parameter(s), 
case and control data cannot be validly combined, and the estimation of relative risk 
parameters should be based on the case-parent triads only. 
Checking assumptions: mating symmetry
unlike the case-parents design where mating symmetry is required for assessing 
maternal effects but cannot be checked, the proposed hybrid design allows one to 
assess the assumption and to impose it or not accordingly. enforcing mating symmetry 
when it holds will enhance power, but enforcing it when it fails could bias estimates of 
genetic effects, particularly maternal effects. if bias from population structure is absent, 
the three constraints on the nine µmf implied by mating symmetry can be tested in 
full. the appropriate three-df lrt is constructed by comparing model (1) under mating 
asymmetry (nine mating-type parameters) to model (1) under mating symmetry (six 
mating-type parameters). if mating symmetry is rejected, then the mating-asymmetry 
version of model (1) is used to test and estimate relative risk parameters. 
 ideally, one might like to examine mating symmetry in the source population 
without concern for population structure. unfortunately, the control-mother dyads do 
not supply enough information about the nine mating-type parameters under asym-
metry to fully probe the three mating-symmetry constraints. a partial examination of 
these constraints is possible, however. under mating symmetry, the sum of expected 
counts in (M,C) cells (0,1) and (1,2) equals the sum in cells (1,0) and (2,1) (table 7.1, 
column 7). re-expressed in terms of the µmf, this constraint becomes ½µ01 + ½µ12 + 
µ02 = ½µ10 + ½µ21 + µ20. thus, a one df lrt can be constructed by comparing a model 
in which the two sums are constrained to be equal to a model without that constraint. 
this test probes mating symmetry only in part because the two sums can be the same 
even when mating symmetry fails. this test, though limited, would be important in 
settings where the presence of bias from population structure forced one to rely on the 
case-parents component of the hybrid design for inference about risk parameters, but 
a check on the assumption required for examining maternal effects was desired. inter-
estingly, this test is closely related to the 1-tDt(11). When applied to case-mother dyads, 
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the 1-tDt tests for offspring genetic effects assuming both mating symmetry and the 
absence of maternal genetic effects; when applied to control-mother dyads instead, 
the 1-tDt is asymptotically equivalent to our one-df lrt for mating symmetry.
Power comparisons: relative risk parameters
We compared the power of several study designs for detecting offspring and maternal 
genetic associations with disease: the family-based case-parents design, the popula-
tion-based case-mother/control-mother design and two hybrid designs (case-parent 
triads/control parents and case-parent triads/control-mother dyads). for all these 
designs, we assessed power for a four-df lrt of the null hypothesis that R1 = R2 = S1 = 
S2 = 1 under several alternative risk scenarios. for the two hybrid designs, we inves-
tigated the tests under both the mating-symmetry and mating-asymmetry models. 
We used traditional logistic regression for the case-mother/control-mother design; we 
used log-linear Poisson regression for the other designs. 
 Our power calculations are based on the noncentrality parameter for a four-df X2 
lrt. We calculated the noncentrality parameter as the lrt statistic constructed by 
treating expected counts under the specified alternative hypothesis as data(12). Values 
of the noncentrality parameter can be translated to power values using the noncentral 
X2 distribution with four dfs. to calculate expected counts, we considered populations  
with allele frequencies ranging over the interval from zero to one where parental 
mating-type frequencies obeyed HWe and, consequently, exhibited mating symmetry. 
(note HWe is simply a convenience here; it is not needed for the validity of our analy-
ses.) We based all our calculations on 150 case families and 150 control families (the 
case-parents design used only the 150 case families). We plotted the noncentrality 
parameters as a function of allele prevalence and included horizontal reference lines 
corresponding to specific levels of power for a four-df lrt at a level 0.05. When the 
noncentrality parameter exceeds a given reference line, the lrt’s power exceeds the 
specified power. transformation of the noncentrality parameter to a different planned 
sample size with the same case:control ratio (say, for K cases) is accomplished by mul-
tiplying the noncentrality parameter values from our figure by K/150. for any a level, 
the ratio of two noncentrality parameters corresponds to the relative efficiencies of the 
corresponding two designs, i.e., the ratio of the sample sizes needed to achieve the 
same power. 
 We considered four distinct risk scenarios. the first scenario included a gene-dose 
effect of the fetal genotype but no effect of the maternal genotype, specifically, R1, R2, 
S1, S2 were 2, 3, 1, 1, respectively. the second scenario included a gene-dose effect 
of the maternal genotype and no effect of the fetal genotype, specifically, R1, R2, S1, 
S2 were 1, 1, 2, 3, respectively. the third involved recessive effects of both the fetal 
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and maternal genotypes (R1, R2, S1, S2 were 1, 2, 1, 3, respectively). the final scenario 
included a recessive effect of the fetal genotype and a dominant effect of the maternal 
genotype (R1, R2, S1, S2 were 1, 3, 2, 2, respectively). in all four scenarios, either hybrid 
design exhibited better power across the range of allele frequencies than both the 
case-parent triads and the case-mother/ control-mother design (fig. 7.1). in addi-
tion, the hybrid using parents of controls always performed somewhat better than the 
hybrid using control-mother dyads, reflecting that the former design provides more 
mating-type information from control families. analyses of the hybrid designs that en-
forced mating symmetry generally provided more power than those that did not, but 
the difference in power depended on the scenario. in the scenario with maternal but 
without offspring effects (fig. 7.1, panel b), the power of hybrid designs when mating 
symmetry was not enforced was the same or close to that of the case-mother/control-
mother design. the relative efficiency of the case-parents design compared to the 
case-mother/control-mother design depended on the particular scenario. 
 We also examined the same set of four scenarios when each individual genotype in 
every triad or dyad independently had a 20% chance of being missing (fig. 7.1, right 
column). thus, for example, a triad could be complete, or have exactly one or two or 
all three of its three genotypes missing. the missing genotypes could be the mother, 
father or offspring. Our analyses used all families except those where every individual 
had a missing genotype. for these analyses, we used the em algorithm to recover 
information from families with only partial genotype data. for the case-mother/con-
trol-mother design that used logistic regression, invoking the em algorithm entails ex-
ploiting the well-known equivalence between logistic models with discrete covariates 
and log-linear models for multi-way tables(12). although missing data lowered all the 
curves compared to their complete-data counterparts (fig. 7.1), the relative efficiencies 
among curves representing the various designs and models were much the same. the 
one exception was the case-parents design; in the scenarios with offspring effects, its 
efficiency was more reduced by missing data than was that of the other designs. 
Power for checking assumptions 
We examined the power of our tests for bias due to population structure for a configu-
ration where mating-type parameters differed between cases and controls. We created 
this configuration by mixing two subpopulations, each in HWe, under a null relative 
risk scenario(3): the first had allele frequency 0.1 and baseline disease risk (risk among 
those with 0 copies of the variant) 0.001; the second had allele frequency 0.5 and 
baseline disease risk 0.003. this mixture induced a trend in the discrepancy between 
the separate case and the control mating-type parameters. 
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figure 7.1  Chi-squared noncentrality parameters and power as a function of allele prevalence 
for various designs and risk scenarios. Vertical axes: left, noncentrality parameter for a four-df 
likelihood ratio test of the null hypothesis R1=R2=S1=S2=1 based on 150 case families and 
150 control families; right, power of corresponding test when α=0.05. Left column (panels 
a-d): no missing genotypes; right column (panels e-h): 20% missing genotypes. First row 
(panels a, e): R1=2, R2=3, S1=1, S2=1; second row (panels b, f): R1=1, R2=1, S1=2, S2=3; third 
row (panels c, g): R1=1, R2=2, S1=1, S2=3; fourth row (panels d, h): R1=1, R2=3, S1=2, S2=2. 
Designs: hybrid with control-mother dyads under mating symmetry (––––––) or mating asym-
metry (– –); hybrid with control parents under mating symmetry (––––––) or mating asym-
metry (– –); case-parent triads (……); case-mother/control-mother (– .–). Curves that nearly 
or completely coincide: (……, – .–) in panel a; (––––––, – –) in panels a, e; (– –, – –, ……, – .–) 
in panels b, f; (– –, – –) in panels c, g; (––––––, – –) in panels a, d, e, h.
With 150 case families and 150 control families, this population structure posed a 
serious challenge to the proposed hybrid design under model (1) by producing biased 
relative risk estimates and an inflated type i error rate for testing genetic effects (actual 
α level = 0.43 at nominal α = 0.05). testing for the presence of bias due to population 
structure under mating symmetry at α = 0.10, the power was 0.42 and 0.54 for the 
four- and the one-df test, respectively, corresponding to noncentrality parameters of 
3.71 and 3.03. Doubling the sample size doubles the noncentrality parameters, yielding 
power 0.69 and 0.79, respectively. all these values were near those achieved with the 
hybrid design using control parents where the analogous tests yielded power of 0.41, 
0.53, 0.68 and 0.79, respectively(3). 
 We examined our ability to detect mating asymmetry for the proposed hybrid 
design using a sample size of 150 case families and 150 control families from a 
population with no population structure and null relative risks. for both the one-and 
the three-df tests, we verified that noncentrality parameters were zero under mating 
symmetry, as expected. We considered two specific scenarios where mating was not 
symmetric: one where only the three-df test would have power; a second where both 
the one-and the three-df tests would (table 7.2). the patterns of asymmetry that we 
introduced for purposes of illustration were arbitrary and possibly unrealistic; we had 
no population-based data on mating asymmetry to guide us. for the mating-asymme-
try scenario of table 7.2, column 3, the asymmetry-induced bias for detecting relative 
risks using a model incorrectly assuming symmetry was small (actual α level = 0.055 
at nominal α = 0.05). the one-df test had no power, as constructed; but the power 
of the three-df test was 0.90. for the asymmetry scenario of table 7.2, column 4, the 
asymmetry-induced bias for detecting relative risks using a model incorrectly assuming 
symmetry was large (actual α level = 0.57 at nominal α = 0.05). the three-df test for 
asymmetry had power of 0.86, whereas the one-df test had power of 0.41. 
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table 7.2  Arbitrary mating-type configurations used to examine the power to detect mating 
asymmetry.
Parameter value: proportion of families in each mating type
Mating-type 
Parameter
Under mating symmetry:
HWE with p=0.5a
Under arbitrary mating asymmetry 
½µ01+½µ12+µ02 =
½µ10+½µ21+µ20
½µ01+½µ12+µ02 ≠
½µ10+½µ21+µ20
μ00 0.0625 0.0625 0.0625
μ01 0.1250 0.0950 0.0950
μ10 0.1250 0.1550 0.1550
μ02 0.0625 0.0875 0.0375
μ20 0.0625 0.0375 0.0875
μ11 0.2500 0.2500 0.2500
μ12 0.1250 0.1050 0.1050
μ21 0.1250 0.1450 0.1450
μ22 0.0625 0.0625 0.0625
a  Hardy-Weinberg equilibrium with allele frequency p=0.5.
Discussion
the popularity of family-based designs is due, in part, to their robustness to the insidi-
ous bias that genetic population structure can induce in population-based case-control 
comparisons. Population-based case-control designs, however, are superior for studying 
exposure effects on risk. the original motivation for combining family-based and popu-
lation-based components was to use information from both sources to increase power 
for studying offspring genetic effects(4). family-based designs achieve robustness by 
conditioning on parental genotypes but thereby sacrifice information parental geno-
types can offer about genetic risks. any allele that increases risk in the offspring should 
be over-represented in the parents of cases compared to the parents of controls. 
Hybrid designs use their population-based component to provide additional informa-
tion that can improve inference on genetic risks. the possibility that genetic population 
structure might bias a combined analysis could be addressed at best obliquely when 
the population-based component included only control subjects(5). Hybrid designs that 
use control parents or control-mother dyads to enhance power offer a more straightfor-
ward ability to check for bias due to population structure while preserving the option of 
dropping back to the case-parents component when population structure is detected. 
 the primary motivation for considering a hybrid design that uses control-mother 
dyads instead of a hybrid design that uses parents of controls is a practical one: recruit-
ing mothers of controls is easier than recruiting both mothers and fathers. thus, larger 
a n  a l t e r n a t i V e  H Y B r i D  D e S i G n  143
sample sizes should be easier to achieve and possible bias from selective refusals of 
fathers (or of mothers with concerns about paternity) can be reduced. On the other 
hand, control-mother pairs provide less direct information about mating-type param-
eters in the underlying population than do control-parent pairs. this feature is reflected 
in our results on power. the hybrid with control parents provided slightly more power 
for testing offspring and maternal genetic effects than did the hybrid with control-
mother dyads. 
 in practice, the best design might be a hybrid of the two hybrid designs considered 
here. One could plan to recruit the parents of controls but, when the father is unavail-
able, try to recruit the control-mother dyad instead. again, missing-data methods like 
the em algorithm can be used for inference. Presumably the power for such a design 
would correspond to noncentrality parameters that fall between the curves of the 
two hybrid designs (fig. 7.1). this hybrid-of-hybrids design would be tantamount to a 
design where case-parent triads are augmented by control-parent triads but missing 
data are dealt with in the analysis. the only advantage of genotyping control offspring 
when both parents are available, however, is the capacity to test the basic assumption 
of mendelian transmission, an assumption that is not often questioned. for studying 
both offspring and maternal genetic effects on disease risk, hybrid designs that use 
control parents or control-mother dyads offer additional benefits over the case-parents 
design. the case-parents design is capable of studying the maternal genetic effects 
under the assumption of mating symmetry in the source population but offers no way 
to check that assumption. Hybrid designs provide information not only for checking 
that assumption but also for studying maternal genetic effects even when mating 
symmetry is not satisfied. these features were delineated previously for the hybrid 
that uses control parents(3), and we have shown here that they are maintained when 
control-mother pairs are substituted for control parents. two different phenomena can 
masquerade as maternal genetic effects if not properly accounted for: mating asym-
metry in the underlying population; and imprinting, where the effect of a transmitted 
allele depends on the parent of origin. after detecting a maternal effect, the investiga-
tor should ideally exclude the possibility that it was wholly or partly attributable to one 
of these other sources. With a case-parents design, mating symmetry in the underly-
ing population must remain an assumption. the case-mother/control-mother design 
implicitly tolerates mating asymmetry. With either hybrid design, mating symmetry 
can be checked; and, if rejected, maternal effects can be studied under a model that 
accommodates mating asymmetry. imprinting can be accommodated by the case-
parents design using a log-linear model that incorporates parent-of-origin effects(13). 
although we have not considered it here, this same modeling tactic could be adapted 
for the hybrid designs or for the case-mother/control-mother design as well. 
 an appealing feature of hybrid designs that involve either parents of controls or 
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control-mother pairs is the ability to check key assumptions. the corresponding weak-
ness is that these tests, particularly the key test for bias from population structure, 
appear to have limited power. for example, with 150 case and control families, we had 
little power to detect bias from population structure under a scenario which, if it went 
undetected, would induce substantial bias in inference. Power seemed somewhat bet-
ter for detecting mating asymmetry in our examples; but we could certainly produce 
other examples where power was more limited. larger sample sizes would help, of 
course. With a hybrid design, a simple practical precaution is to compare risk estimates 
under models that do and do not make a particular assumption. With concern about 
population structure, comparing relative risk estimates from the hybrid design with 
those from its case-parent triad component alone might provide reassurance. Similarly, 
with concern about mating symmetry, one could compare estimates from the mating-
symmetry and the mating-asymmetry models. 
 the hybrid designs that we have considered will be useful for studies of complex 
phenotypes such as a birth defect where environmental factors will likely also play a 
role. the log-linear model for the 30-cell multinomial for case triads and control triads 
together can in principle be extended to incorporate environmental factors assessed 
categorically. Consequently, environmental risks and gene-by-environment interactions 
can be evaluated under either hybrid design. Postulating appropriate models for check-
ing bias from population structure might be challenging, however, because exposure 
prevalence could change across genetically distinct subpopulations. 
 We have also demonstrated the potential increase in power that the hybrid designs 
can achieve when bias from population stratification is absent. the relative gain in ef-
ficiency (as measured by the ratio of the curves) depends on the underlying scenario. 
We based these power comparisons on equal numbers of case families in each design 
reflecting that the number of case families available is often a limitation when design-
ing a study. the hybrid designs considered here require genotyping five individuals per 
case compared to only three or four, respectively, for the case-parents or the case-
mother/control-mother designs. to compare designs when each of them genotyped 
750 individuals (the number measured in the hybrid designs in fig. 7.1), one would 
modify figure 7.1 by multiplying the noncentrality curves for the case-parents design 
by 5/3 and those for case-mother/control-mother design by 5/4 (curves for hybrid 
designs remain the same). On that per-genotype basis, hybrid designs were not the 
most efficient in every scenario that we considered; however, they were more efficient 
than case-mother/ control-mother designs in general and more efficient than the 
case-parents design in realistic scenarios where genotypes were missing at random. in 
our view, any disadvantage in power per genotype of hybrid designs compared to the 
case-parents design is more than offset by the greater flexibility that hybrid designs of-
fer for checking assumptions and evaluating effects of exposures. the cost of genotyp-
ing should not be the investigator’s sole concern. 
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in summary, we have studied a hybrid design that combines data from case-parent 
triads and control-mother dyads. it provides the same flexibility as, though slightly less 
power than, a hybrid design that was introduced previously, one that uses the parents 
of controls instead of control-mother dyads. When needed but testable assumptions 
are met, either of these hybrid designs has a better power for studying both offspring 
and maternal genetic effects on disease risk than would a family-based case-parents 
design or a population-based case-mother/control-mother design. 
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application of multi-locus 
 analytical methods to identify 
interacting loci in case-control 
studies
Abstract
To identify interacting loci in genetic epidemiological studies the applica-
tion of multi-locus methods of analysis is warranted. Several more ad-
vanced classiﬁcation methods have been developed in the past years, 
including multiple logistic regression, sum statistics, logic regression, and 
the multifactor dimensionality reduction method. The objective of our 
study was to apply these four multi-locus methods to simulated case-
control datasets that included a variety of underlying statistical two-locus 
interaction models, in order to compare the methods and evaluate their 
strengths and weaknesses. The results showed that the ability to identify 
the interacting loci was generally good for the sum statistic method, 
the logic regression and MDR. The performance of the logistic regression 
was more dependent on the underlying model and multiple comparison 
adjustment procedure. However, identiﬁcation of the interacting loci in a 
model with two two-locus interactions of common disease alleles with 
relatively small effects was impaired in all methods. Several practical 
and methodological issues that can be considered in the application of 
these methods, and that may warrant further research, are identiﬁed and 
discussed. 
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Introduction
Complex diseases or traits are a result of the interplay between and among genes and 
environmental factors. One way in which genetic factors can act together in relation to 
a certain trait is epistatically. Generally speaking, epistasis refers to the phenomenon 
that the relation between a gene and a trait outcome is dependent on another gene. 
more specifically speaking, from a statistical point of view, epistasis or gene-gene in-
teraction has been defined as the presence of non-additivity in a mathematical model 
that describes the relation between genetic variants and a trait in a population(1,2). 
 the ability of multi-locus methods of analysis to detect and incorporate statistical 
gene-gene interaction in genetic association studies is likely to favour the chance of 
retrieving causal genes and a better prediction of trait outcome based on genotype 
data(1,3). researchers that want to identify interacting loci in their genetic association 
studies through application of multi-locus techniques can nowadays choose from a 
variety of methods and software packages that are readily available, in addition to tra-
ditional multiple regression analysis. the goal of our study was to apply four available 
multi-locus classification techniques, namely multiple logistic regression, the set as-
sociation method as implemented in the Sumstat software, the multifactor dimension-
ality reduction (mDr), and logic regression, on simulated data to identify strengths and 
weaknesses in the application of these methods. more specifically, we have focussed 
on their ability to identify causal loci that may be statistically interacting according 
to some specific underlying model. this will give researchers more insight into the 
performance of the methods and allow more informed choices about when and how 
to apply them. 
 many multi-locus methods that can be applied to in-vestigate gene-gene inter-
actions have been introduced in the past decade, as reviewed by Hoh & Ott(4) and 
thornton-Wells et al.(5). a number of these methods are particularly suitable for genetic 
case-control association studies, and for some of those freely available software has 
been introduced. the mDr software was introduced in 2003 and was especially devel-
oped to analyse high-order joint effects of loci (and environment) in genetic associa-
tion case-control and sib-pair study designs(6). the general idea behind the non-para-
metric and genetic model-free mDr approach is that it reduces the dimensionality of 
the multi-locus data by pooling those combinations of genotypes that can be defined 
as high-risk and those that can be defined as low-risk, based on the case-control ratio 
for the specific multi-locus genotype. the reduction of the dimensionality of the data 
overcomes the problem of a low number of observations in high-order data combina-
tions. an exhaustive search over all possible high-order genotype combinations for a 
varying number of loci is performed, and the best combination of single nucleotide 
polymorphisms (SnPs) for a certain model size is chosen based on classification error. 
using cross-validation the ability of the new one-dimensional multi-locus variable to 
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predict case-control status, and in addition its cross-validation consistency, is deter-
mined. the locus or combination of loci that has the best predictive value and highest 
cross-validation consistency is considered to be the outcome of interest. an empirical 
p-value for the testing accuracy and cross-validation consistency of the final selected 
model can be determined using a permutation testing procedure. the mDr method 
has successfully identified interacting loci in several real data applications(7-12), and 
its performance has been evaluated on simulated data with a focus on a number of 
epistasis models that show no or small single locus main effects(11,13). 
 logic regression is a generalized regression methodology that was introduced 
in 2001 and was also mainly developed to study high-order interactions in genetic 
studies(14,15). it has been implemented in freely available software as an r and S-Plus 
package. in short, the goal of logic regression is to find Boolean combinations of binary 
predictors, for example SnPs, that are associated with the outcome of interest and that 
are incorporated into a regression model. the combinations of the binary predictors are 
efficiently organized in a tree form. the performance is evaluated by comparing the 
fitted values and response using a scoring function that is dependent on the type of 
regression. So instead of modelling the interaction between several SnPs using a high 
number of model parameters in a regression model, a combination can be captured 
through one tree parameter using Boolean operators; SnPs that are included in the 
same regression tree instead of in separate trees may be act-ing in a non-additive 
way on the scale of interest. the building and selection of the logic trees can be done 
using a stochastic simulated annealing algorithm, and the size and number of trees can 
vary. model selection can be guided by comparing the predictive values of the models, 
based on cross-validation or permutation testing procedures. the latest software ver-
sion also includes a monte Carlo regression option that can identify several best tree 
models that are related to trait outcome and that may fit the data equally well(16). the 
method has been applied to a post PtCa restenosis dataset and has also been success-
fully used in the analysis of simulated genetic data(14,15). 
 the set-association method, as implemented in the Sumstat software, introduced in 
2001 by Hoh et al.(17), is a non-parametric method that uses sum statistics to evalu-
ate the joint effect of loci related to trait outcome. the locus or set of loci associated 
with the trait of interest is identified by creating and testing sum statistics that capture 
the combined information from multiple SnPs. Based on single locus test statistics, 
for instance Chi-square values from 2 by 3 tables, Chi-square values for deviation 
from Hardy Weinberg equilibrium, or Chi-squares for pair-wise interactions, SnPs are 
selected and added to the sum statistic that is calculated for an increasing number 
of loci. the SnPs are chosen based on the value of the test statistic and are added 
sequentially to the sum statistic in order of decreasing value. the significance of each 
sum is evaluated using a permutation procedure. then, the smallest empirical p-value 
for the sum statistic is in its turn evaluated for global significance via permutation tests, 
thereby correcting for the testing of multiple sums. So the goal is to find the subset of 
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loci that is most significantly associated with the trait of interest. this method has been 
evaluated for its power by use of simulated data without a focus on interaction(18,19), 
and has been applied in several case-control genetic association studies(17,20,21). 
 as well as several advantages, such as transparency, familiarity, and the estimation 
of interpretable effect parameters, the traditional multiple logistic regression technique 
has known disadvantages in identifying in-teracting loci in case-control association 
studies. Sparse data can easily become a problem in studies with relatively small 
sample sizes when including (high-order) interaction parameters. furthermore, the 
number of tests can be very high when the number of SnPs included in the study, and 
the order of interactions to evaluate, becomes large. this can all lead to unreliable pa-
rameter estimates, inflated type i errors, and low power to detect the associated loci. 
methods to deal with multiple comparisons like the Bonferroni correction, the false 
Discovery rate (fDr), and randomization procedures, have been introduced as solu-
tions to mitigate elevated type i error rates. another difference from the previous dis-
cussed techniques is that the logistic regression is a parametric, model-based method 
that requires enumeration of the (interaction) model(s) to analyse; the available choice 
of model definitions that can be used in logistic regression to investigate gene-gene 
interactions is large. logistic regression has successfully identified interacting loci in 
the past in studies that included a relatively small number of loci, and it was recently 
shown that it is also feasible to successfully apply the technique to identify interacting 
loci in genome-wide association studies(22). 
 the general interpretation of statistical interaction as deviance from additivity 
makes its presence dependent on the scale that is used (i.e. logit, or penetrance). 
the multiplicative model on a penetrance scale is often considered to represent the 
standard statistical interaction model; this model approximates an additive model 
on the log odds scale, implicit in the standard logistic regression model commonly 
used in the analysis of case-control studies. However, other statistical models besides 
the multiplicative also meet the criterion of non-additivity. in complex diseases the 
statistical interaction present in the collected population data is not known beforehand. 
it will then be important to know if the applied multi-locus methods can detect the 
interacting loci for different underlying interaction models. therefore, we evaluated the 
performance of the above-mentioned multi-locus methods for a selection of two-locus 
statistical interaction models. 
Materials and Methods 
Statistical Interaction Models 
We used the penetrance scale to define two-locus interaction models. the penetrance 
is the probability of being affected given the genotype at, in our case, both loci, and 
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it can range from 0 (no penetrance) to 1 (full penetrance). We simulated 5 two-locus 
interaction models with reduced penetrance based on the classification schemes 
described by li & reich(23) and those models described in earlier papers on epistasis 
(figure 8.1). they include a ‘multiplicative model’ (mod1) and a ‘heterogeneity based 
model’ (mod2). the multiplicative is characterized by multi-locus penetrances that 
result from the product of the single locus contributions. the heterogeneity model is 
often considered a non-interactive model, in which both loci increase disease risk inde-
pendent of the genotype at the other locus but it can also be viewed as a non-additive 
and therefore interactive model, as stated by Cordell(2). 
 furthermore, we simulated a ‘conditional dominant or recessive model’ (mod3), 
where one locus portrays dominant or recessive behaviour dependent on the genotype 
at the other locus. We also included an ‘exclusive Or’ (mod4) and ‘missing lethal geno-
type’ (mod5) based model. the first reflects the situation in which the risk of disease 
is elevated if a subject is heterozygous for one locus but not both. in the second model 
the disease risk is elevated when exactly two disease alleles are present, the risk 
being higher when both are at the same locus. these last two models are special be-
cause they show no main effects of the single loci in case of a disease allele frequency 
of 0.5. 
 We also simulated a model in which two two-locus interactions, both based on 
the ‘missing lethal genotype’ model (mod5), increased disease risk according to a 
heterogeneity model (mod6); the interaction was considered present if either one or 
the other or both sets of criteria for two-locus interactions were satisfied. the allele 
frequencies of both markers in both interactions were set to be equal. note that this 
model also did not display any marginal single locus effects for the 0.5 frequency. 
finally, a null model (modnull) was generated in which the disease status of 200 out 
of the 400 randomly selected subjects was set to case. 
Data Simulations 
the data simulations were performed in Stata Version 8. We simulated the models by 
defining the penetrance and frequency for all two-locus genotype combinations for the 
variety of underlying disease models (figure 8.1). We assumed that the two bi-allelic 
polymorphisms were both in Hardy Weinberg equilibrium and in linkage equilibrium. 
four different allele frequency models were generated, where both loci had an expect-
ed frequency of 0.5 (f0.5), 0.3 (f0.3), 0.1 (f0.1) or 0.05 (f0.05). in addition to the two 
causal SnPs eight non-causal SnPs were generated. three of these had a frequency of 
0.5, three of 0.3 and two had an allele frequency of 0.1. 
 to generate one simulated sample, 100 cases based on a high-risk genotype 
combination and 300 controls were randomly selected out of the complete simulated 
dataset with 150000 observations. to obtain a more realistic representation of a com-
plex disease model, we introduced 50% phenocopies into every model by randomly 
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changing the disease status of 100 controls to case status thus creating datasets 
containing 200 cases and 200 controls. By doing this, we forced the disease prevalence 
of the population from which the final sample was selected to be twice that of the 
original simulations, since the 100 original true genetic cases now represented 50% of 
the total number of cases. as a result, the relative effect of the low frequency causal 
alleles was higher than that of the more frequent causal alleles. the final expected 
penetrances, the marginal penetrances and corresponding population prevalence of the 
disease are depicted in table 8.1. for each combination of disease and allele frequency 
100 replicates were simulated, which resulted in a total of 2800 datasets. 
figure 8.1  Two-locus penetrances for the models used for data simulation.
Statistics 
Multiple Logistic Regression Analysis 
the parametric multiple logistic regression technique requires specification of the 
statistical model and parameters that we want to evaluate for association with disease. 
We chose to fit a full logistic regression model for each pair of loci. the loci were coded 
using two dichotomous dummy variables: one for the heterozygous group and one to 
indicate the group homozygous for the high-risk allele. the fully fitted logistic regres-
sion model therefore contained an intercept, four parameters for the main effects, 
and four parameters for the interaction terms between the two loci. We applied both 
the Bonferroni (fixed overall type i error to 0.05) and the fDr method (Simes proce-
dure, fDr 0.05) to deal with the multiple comparisons. those single loci or interaction 
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parameters that passed the significance criterion were considered our outcomes of 
interest. the logistic regression analysis was performed in Stata Version 8; we used the 
‘multproc’ add-on package written by r. newson for the Bonferroni and fDr procedure.
table 8.1  Population genotypic penetrances for the simulated case-control data after 
 introduction of the phenocopies. 
marginal penetrance3
Model  MAF1 ƒ002 ƒ01 ƒ02 ƒ10 ƒ11 ƒ12 ƒ20 ƒ21 ƒ22 ƒ0. ƒ1. ƒ2. K4
1 0.5 0.06 0.06 0.06 0.06 0.15 0.15 0.06 0.15 0.15 0.06 0.13 0.13 0.11
0.3 0.03 0.03 0.03 0.03 0.12 0.12 0.03 0.12 0.12 0.03 0.08 0.08 0.05
0.1 0.00 0.00 0.00 0.00 0.10 0.10 0.00 0.10 0.10 0.00 0.02 0.02 0.01
0.05 0.00 0.00 0.00 0.00 0.10 0.10 0.00 0.10 0.10 0.00 0.01 0.01 0.00
2 0.5 0.05 0.05 0.14 0.05 0.05 0.14 0.14 0.14 0.14 0.07 0.07 0.14 0.09
0.3 0.02 0.02 0.12 0.02 0.02 0.12 0.12 0.12 0.12 0.03 0.03 0.12 0.03
0.1 0.00 0.00 0.10 0.00 0.00 0.10 0.10 0.10 0.10 0.00 0.00 0.10 0.00
0.05 0.00 0.00 0.10 0.00 0.00 0.10 0.10 0.10 0.10 0.00 0.00 0.10 0.00
3 0.5 0.03 0.03 0.03 0.03 0.03 0.13 0.03 0.13 0.13 0.03 0.06 0.10 0.06
0.3 0.01 0.01 0.01 0.01 0.01 0.11 0.01 0.11 0.11 0.01 0.02 0.06 0.02
0.1 0.00 0.00 0.00 0.00 0.00 0.10 0.00 0.10 0.10 0.00 0.00 0.02 0.00
0.05 0.00 0.00 0.00 0.00 0.00 0.10 0.00 0.10 0.10 0.00 0.00 0.01 0.00
4 0.5 0.05 0.15 0.05 0.15 0.05 0.15 0.05 0.15 0.05 0.10 0.10 0.10 0.10
0.3 0.05 0.15 0.05 0.15 0.05 0.15 0.05 0.15 0.05 0.09 0.11 0.09 0.10
0.1 0.03 0.13 0.03 0.13 0.03 0.13 0.03 0.13 0.03 0.05 0.11 0.05 0.06
0.05 0.02 0.12 0.02 0.12 0.02 0.12 0.02 0.12 0.02 0.03 0.11 0.03 0.03
5 0.5 0.03 0.03 0.12 0.03 0.07 0.03 0.12 0.03 0.03 0.05 0.05 0.05 0.05
0.3 0.02 0.02 0.12 0.02 0.07 0.02 0.12 0.02 0.02 0.03 0.04 0.07 0.04
0.1 0.00 0.00 0.10 0.00 0.05 0.00 0.10 0.00 0.00 0.00 0.01 0.08 0.01
0.05 0.00 0.00 0.10 0.00 0.05 0.00 0.10 0.00 0.00 0.00 0.01 0.09 0.00
65 0.5 0.06 0.06 0.12 0.06 0.09 0.06 0.12 0.06 0.06 0.08 0.08 0.08 0.08
0.3 0.05 0.05 0.12 0.05 0.08 0.05 0.12 0.05 0.05 0.05 0.06 0.08 0.06
0.1 0.01 0.01 0.10 0.01 0.06 0.01 0.10 0.01 0.01 0.01 0.02 0.09 0.01
0.05 0.00 0.00 0.10 0.00 0.05 0.00 0.10 0.00 0.00 0.00 0.01 0.09 0.00
1 maf = minor allele frequency.
2   ƒij represents the penetrance for a two-locus genotype where the number of disease alleles at the first 
locus is i and at the second locus is j.
3 marginal penetrance defined by ƒi.=∑pjƒij where pj is the frequency of genotype j.
4 K = disease prevalence.
5  only marginal penetrances are displayed; here ƒij represents the marginal penetrance of the ij.. multi-
locus genotype.
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Set-association method 
the set-association method as implemented in the Sumstat software available at 
http://linkage.rockefeller.edu/register was applied. the Chi-square statistic for geno-
typic association with case-control status (2 by 3 table) was chosen as the test statis-
tic. furthermore, we selected the interaction option that computes the Chi-squares for 
all pair-wise interactions, leading to a total number of 55 genotypic input variables for 
every replicate. We calculated sum statistics that contained at most 6 variables (single 
loci and/or interactions) and used 20000 permutations to generate empirical p-values 
for the test statistics. for every replicate the subset of single loci and pair-wise interac-
tion terms with the lowest permuted p-value and largest number of terms was the 
multi-locus combination output of interest. 
Logic Regression 
We performed the analysis using the logic regression module that is available as an r 
package (version 1.3.1; http://bear.fhcrc.org/∼ingor/logic/), and selected the logistic 
regression option. We used 100,000 iterations in the simulated annealing algorithm, 
and annealing temperatures were set so the number of acceptions/rejections during 
the iteration process was optimal. the logic regression can only deal with dichotomous 
input variables, and therefore the SnPs were recoded into two dichotomous dummy 
variables as was done for the logistic regression analysis. We used the ‘select the best 
model’ option and limited the model size to a maximum of 4 and 6 leaves for the two-
locus models, and 8 leaves for the 4-locus model. the outcome of interest was the loci 
present in the final best model, as selected under our model selection settings. 
MDR 
We performed the analysis using mDr version 0.6.1, available at http://www.
epistasis.org/open-source-mdr-project.html. We evaluated model sizes of 2 and 3 loci 
and 4 loci for the 4-locus genetic heterogeneity models, and counted the number of 
replicates that contained the causal loci in the final best model that was identified 
using 10-fold cross-validation. the default values for the parameters that needed to be 
set were used; the threshold case/control ratio for the definition high-risk genotypes 
was set to at least 1:1, tie cells were set to affected, and an exhaustive search method 
configuration was selected. 
Results 
figure 8.2 shows the number of replicates that contained the two causal loci, either 
both loci separately or via an interaction, for all the scenarios and methods. for the 
logistic regression and Sumstat results we could indicate the number of replicates in 
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which the loci were identified via an interaction term, and these therefore would have 
been positive replicates if we would had selected on interaction terms only (black 
shading). for the genetic heterogeneity model, with two two-locus interactions acting 
to increase risk of disease, we counted the number of replicates in which the four 
loci were retrieved, either by identifying the simulated interaction terms or the single 
locus effects (figure 8.3). Because of the low penetrance and low frequency of the 
risk increasing genotypes for mod2f0.05, mod3f0.1 and mod3f0.05, the final simulated 
case-control datasets contained too few cases (<100) and were therefore dropped. 
 for the traditional logistic regression technique, without correction for multiple test-
ing, the interacting loci were identified in almost all replicates, even when the causal 
allele frequency dropped to 0.05. the detection rate was diminished for the four-locus 
models with a frequency of 0.3 and 0.5. after application of the fDr procedure and 
Bonferroni method, the number of replicates in which the causal loci were detected 
was somewhat less in most models, but seriously impaired in the models with an 
allele frequency of 0.5 and the four-locus models, the Bonferroni correction being 
more conservative than the fDr method. the loci were found specifically through the 
interaction terms in mod4f0.5, mod5f0.5 and mod6f0.5, where there were no expected 
marginal effects. Only relying on the interaction parameters generally resulted in lower 
detection of causal loci, and failed especially in mod2. it was also worse for the 0.05 
maf models where the interaction terms were dropped due to sparseness of data. fur-
thermore, we saw that the number of replicates with significant interaction parameters 
was lower for the fDr corrected results and even lower for the Bonferroni results, in 
most scenarios. 
 the number of false positives for the null model in the uncorrected analysis was 
highly inflated. there was a high false positive detection rate for the null model with a 
frequency of 0.1 that could not be mitigated by application of the multiple comparison 
procedures. looking at the results and analysis more carefully showed that the sparse 
number of observations in the genotype cells for this allele frequency led to unreli-
able parameter estimates, and a high rate of extreme low p-values that passed the 
significance criteria, whereas the parameters of the causal loci were often dropped and 
not tested in the 0.05 frequency model, due to too few observations in the heterozy-
gote, but especially homozygous, mutant genotype groups. likewise, the interaction 
terms were dropped, explaining their absence in the null model findings. 
 in general, Sumstat performed very well for the 0.3, 0.1 and 0.05 maf scenarios 
and not well for mod1f0.5, mod2f0.5 and high frequency mod6. regarding the last 
model, in figure 8.3 we only counted those replicates as positive if the correct single 
loci and/or both simulated interaction terms were identified. We saw, however, that in 
the lower frequency models the four causal loci were identified via interaction terms 
between one locus from the first two-locus interaction and one locus from the second. 
if we had counted those replicates as positive results too, the number of replicates 
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figure 8.2 Number of replicates that contained the two causal loci via both single locus parameters and/
or through interaction parameters (black shading) for the 5 two-locus models and the null model. The 
first to the fourth column represent the models with minor allele frequencies of 0.5, 0.3, 0.1 and 0.05, 
respectively.
 
figure 8.3  Number of replicates per method that contained the four causal loci in Mod6 (black shading) 
and ModNull (grey shading) for every MAF.
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in figure 8.3 for the 0.1 and 0.05 frequencies would have been 100 and the results 
for the 0.5 and 0.3 frequencies would have increased to 22 and 32, respectively. for 
all frequencies the Sumstat method retrieved the causal loci for mod4 and mod5 via 
the interaction term, especially for the 0.1 allele frequency, and mod3 was mainly 
dependent on finding the separate single locus effects. the results for both single 
causal loci (not shown) were expected to be symmetrical, but for some models they 
differed substantially up to a maximum of 19 replicates for mod1f0.5. We saw that for 
this genetic model all methods gave asymmetrical results for the two causal loci; the 
first locus was retrieved more often than the second. the overall low number of falsely 
detected loci, as observed in the null model, was low relative to the other methods, 
even without selection on the basis of the empirical sum statistic p-values or the final 
global p-value. in the modnull we saw a higher selection of interaction terms over 
single terms.
 We also checked how the results would change when only the replicates with a 
global p-value of less than 0.05 were considered. the number of false positives in 
the null models was reduced to zero. it had marginal consequences for the results of 
mod1f0.5, mod2f0.5, mod4f0.5, where the number of replicates containing the true 
loci dropped at most 7, and had large consequences for mod3f0.05 and mod5f0.5/
f0.3, where the number of replicates that contained the causal loci was lowered to 16, 
49 and 28, respectively. for the four-locus models the numbers in figure 8.3 changed 
for the f0.5 and f0.3 models to 4 and 14, respectively.
 the results were different if the sum statistic with the smallest number of loci for 
the smallest p-values, instead of the largest number, was chosen (data not shown). 
We then saw that the method was much worse for mod1, mod2f0.3 and mod3 in 
terms of elevated type i error, because the p-value often reached its minimum of zero 
after including one of the two causal loci. the method was also not able to identify the 
four loci in mod6f0.1 and mod6f0.05. 
 the logic regression analysis retrieved a high number of replicates containing 
the true causal loci, with the exception of the high frequency multiplicative model 
(mod1f0.5) and mod6, where it had difficulties finding all 4 loci. the amount of noise 
varied; mod1 and mod3 in general contained at least 3 terms related to the two causal 
loci, with the exception of mod1f0.5 and mod2 which contained just two terms refer-
ring to the causal loci and two referring to non-causal loci. the lower frequency mod5 
often contained 4 causal loci terms, and all mod4 contained 2 to 4 causal terms out 
of the four leaves. in all scenarios one tree was constructed, often with the maximum 
number of leaves allowed. the gain from allowing six leaves instead of four was very 
limited, and led to a higher inclusion of non-causal loci (results not shown). the small-
er the model, that is the lower the number of leaves allowed, the lower the number 
of false positive findings. We observed a tendency for a lower number of false positive 
findings for low frequency SnPs, reflected in the decreasing values for modnull from 
f0.5 to f0.05. 
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the high frequency four locus mod6 contained a high number of non-causal loci and 
a varying number of true loci. the performance for the low frequency scenarios was 
remarkably better. the difference between the analysis allowing 6 and 8 leaves was 
most pronounced for the 0.3 and 0.5 mafs, where we saw a higher number of correct 
positive findings but also much higher false positive results for the analysis with 8 
leaves. 
 the same trends in results were observed for the mDr as for the logic regression: it 
retrieved the loci in all situations, except for the high frequency mod6, and the perfor-
mance was slightly impaired in mod1f0.5. Because the model could only contain two 
loci, no non-causal loci were included in those models that correctly identified the loci. 
there was no additional value from models containing three instead of two loci; the 
retrieved number of causal loci remained similarly high but the number of false posi-
tives was substantially higher in the high frequency models. also here we observed a 
bias towards high frequency SnPs for the null model. 
Discussion
We performed a simulation study to identify strengths and weaknesses of four multi-
locus methods employed to identify interacting loci in several case-control scenarios. 
the number of ways in which these methods can be applied is numerous. Due to 
pragmatic and computational reasons we have not used the methods to their full 
capacity regarding model selection and model testing options. therefore we can only 
draw conclusions about the strengths and weaknesses we encountered in the ways we 
applied them to the simulated data. Since we did not fix the type i error for all meth-
ods in an equivalent way it is not possible to make fair direct comparisons of power 
between the methods, and we have focussed on identifying strengths and weaknesses 
for each method separately. 
 in the application of the logistic regression the known problems in standard regres-
sion techniques of inflated findings of false positives, and diminished power caused 
by the presence of sparse data and multiple testing problems, were encountered, 
despite there being only 10 loci in these datasets. We can therefore underscore the 
importance of the use of a model testing procedure, such as permutation tests, even in 
studies with few genetic variants. furthermore, extensions of the traditional regression 
models, that are especially developed to deal with sparse data, like penalized regres-
sion models could be applied. We chose to apply a full model containing parameters 
for the two loci and their interaction terms. We observed that the significance of the 
interaction parameters in a fully saturated two-locus logistic regression model in the 
identification of the causal loci was dependent on the underlying genetic models, the 
allele frequency, and the multiple comparison correction procedure. the use of interac-
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tion parameters especially improved the identification of interacting loci in cases of 
statistical interaction models that showed no expected marginal effects. north et al.(24) 
evaluated how well logistic regression models that included different model param-
eters, including interaction parameters, fitted the data compared to a fully saturated 
model, and how well they corresponded to the true underlying penetrance based 
models for a variety of two-locus disease models. they showed that for some models 
the inclusion of interaction parameters is advantageous but there is no direct corre-
spondence between the interactive effects in the logistic regression models and the 
underlying penetrance based models displaying some kind of epistasis effect(24). the 
latter has been confirmed in our study. 
 an approach that we have not evaluated here but that can be applied to identify 
gene-gene interactions, is the case-only approach. it can be used to efficiently identify 
deviation from a multiplicative model for the relative risks by testing the associa-
tion between loci in the cases. this design can be more powerful than the traditional 
case-control analysis. However, it is restricted to the identification of interactions only; 
the main effects of loci cannot be estimated and tested. furthermore, this approach is 
sensitive to deviation of the underlying assumption of independence of the loci in the 
general population(25); bias will be introduced if linkage disequilibrium between the loci 
of interest exists in the control population. 
 the Sumstat method had difficulty finding the causal loci in the high frequency 
four-locus models, but for the other scenarios the results were good. We have not 
performed the set-association method without construction of the two-locus interac-
tion input variables, and it is therefore not possible to discuss the added value of using 
these in addition to the single locus parameters as a test statistic. We did see that the 
identification of the loci through the interaction parameter or single loci variables was 
dependent on the underlying model and the maf, but the loci were consistently found 
via the interaction term in the ‘exclusive Or’ and ‘missing lethal genotype’ scenarios. 
the inability to deal with interacting loci that show no or weak main effects is an often 
mentioned disadvantage of the set association approach(26). Heidema and colleagues 
state in their review that genetic interactions are only tested for the loci that are incor-
porated into the sum statistic. the fact that loci are incorporated into the sum statistic 
does, in our view, not deal with interactions between these loci since the separate 
test statistics are simply added, but we saw that this can be overcome by introducing 
the interaction test statistics prior to calculating the sum statistics. the current Sumstat 
version is not equipped to handle high-order interactions; only two-locus interaction 
parameters can be constructed. this was not a problem in our simulations, but could be 
a shortcoming in real usage. Selection of the results based on the permutation global 
p-values reduced the type i error perfectly. However, this was at the expense of a large 
loss of power to retrieve the causal loci for some models. 
 the results for the logic regression and mDr were similar. they performed well 
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for all models, with the exception of the high frequency heterogeneity models with 
two different two-locus interactions, and showed a slightly impaired performance for 
the high frequency models with relatively small effect sizes. One disadvantage of our 
procedure is that we did not apply model selection techniques other than limiting the 
number of genetic parameters in the analysis. this meant that we could not evaluate 
the underestimation of the type ii error and overestimation of the type i error in our 
study that was caused by not selecting the optimal model size and not using global 
p-value cut-off points to select the outcome of interest. 
 One of the strengths of the mDr that is often highlighted, is its high power to iden-
tify high-order interactions for loci without a main effect(26). Our results confirm this for 
two-locus interactions. We also saw that this characteristic was not only limited to the 
mDr method, as the logic regression and Sumstat were capable of identifying these 
loci too. We have however not compared their power for a fixed type i error. 
 the number of replicates containing the loci under the null model decreased when 
applying a simple model size limiting strategy, by maximizing the number of leaves 
and loci, respectively. limiting the model size to the smallest possible size considering 
the number of true causal loci was advantageous compared to a larger model. How-
ever, restraining the model size to a number lower than the actual number of causal 
SnPs present in the data obviously impaired the performance of the methods. the 
publicly available mDr software is currently limited to a maximum of 15 loci. When a 
larger number of loci might be involved in the genetic aetiology this limit would be too 
small. 
 there was a tendency in both methods to show a lower number of positive repli-
cates under the null model when the frequency of the SnPs of interest decreased. this 
bias towards high frequency SnPs might warrant follow-up study to investigate more 
carefully the causes and consequences of this preference. 
 to judge if the loci included in the multi-locus combination act additively or not, the 
user of the logic regression and mDr method can evaluate the number of trees and 
the way the loci are included in the trees, and the graphically displayed case-control 
ratios for all multi-locus genotype combinations, respectively. this can become a daunt-
ing task, especially for the mDr method, when the number of loci included increases, 
and also when the number of datasets is large as in our case. We therefore did not 
explore this option in the current study, but we did find that for the logic regression all 
loci were consistently combined in one tree, pointing towards non-additive association 
between the loci and the case-control status in the logistic regression. 
 finding similar results for the mDr method and the logic regression was not surpris-
ing. the similarities in methodology between the mDr and an extension of a recur-
sive partitioning technique related to the logic regression approach were discussed 
by Bastone et al.(27); the mDr method can be viewed as a special form of recursive 
partitioning technique(27). One major distinction between the mDr and logic regres-
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sion is that in the first approach tree growth is restricted to a single split in one tree. 
Based on this fact one might expect the logic regression to perform better under 
genetic heterogeneity because of its ability to create multiple splits and more than 
one tree. also Heidema et al.(26) state that recursive partitioning techniques, of which 
logic regression is one example, should be able to detect genetic heterogeneity. this 
was not confirmed in the results of this study, where the logic regression had difficulty 
identifying the causal loci for some four-locus models. the two-locus heterogeneity 
based model was tackled well by the logic regression as well as by the mDr method. 
ritchie et al.(13) identified the impaired performance under genetic heterogeneity of 
the mDr method. in their simulations the power of the mDr for a model comparable 
to our four-locus model was worse, probably reflecting the selection on the statistical 
significance of the output they used. the authors propose the use of cluster analysis or 
recursive partitioning techniques, to identify clusters of individuals with similar genetic 
backgrounds prior to performing the mDr to mitigate the low power in genetic hetero-
geneity, and state that more research into these methods is needed. 
 We applied the methods on a large number of different statistical interaction mod-
els for a variety of allele frequency possibilities, but our simulations were not exhaus-
tive. the high frequency models with two two-locus interactions turned out to be the 
most challenging. they were not only characterized by interacting risk factors and 
genetic heterogeneity, but also by small expected marginal effects. So even though, in 
the individual situations of a statistical heterogeneity model or an underlying pen-
etrance model with small marginal effects, the causal loci were retrievable, in the 
combined situation power was diminished. furthermore, it is obvious that we have not 
set out to explore the limits regarding model complexity, effect size, allele frequency, 
sample size, and their combinations for these methods. the authors of the methods 
have touched upon these aspects. future research could explore the performance of 
the methods for more complex underlying models with several one-locus effects and 
high-order interactions, gene-environment interactions and covariates. 
 We have simulated data for a small number of SnPs in order to evaluate the perfor-
mance of multi-locus methods regarding the identification of interacting loci. With the 
increasing application of large candidate gene arrays and genome-wide SnP arrays it 
will be of importance to evaluate the strengths and weaknesses of multi-locus meth-
ods for handling large amounts of genetic data where linkage disequilibrium is likely to 
be present. the specific relative strengths and weaknesses in handling a large amount 
of SnP data for a diversity of methods, including logistic regression, the set association 
approach and the mDr, have been recently discussed by Heidema et al.(26). 
 ideally, one would limit the analysis of genetic association data to one or a few 
methods and apply them in a way that would enable capture of all the underlying sig-
nals from associated genes, whether acting singularly or interactively, and give insight 
into the underlying complex aetiology of the disease or trait of interest. Since every 
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method has its own strengths and weaknesses, and within every method a diversity of 
approaches can exist, a multi-analytic approach could help in distinguishing between 
true and false positive findings. it is however important to apply the methods in the 
most optimal way, and to understand the limits of each method in order to correctly 
interpret the results. the results of this study can give researchers insights into how to 
apply the discussed methods best in practice, judge where they perform similarly, and 
help in interpreting the results of the different methods. 
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CHaPter 9
General discussion
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this chapter includes a discussion of the studies described in this thesis. the contribu-
tion of our studies in light of our objectives and recent findings in other studies are 
discussed in section 9.1. next, in section 9.2, we highlight some of the strengths and 
weaknesses related to the study designs and utilized study populations, measurement 
of the main variables, and statistical analyses that have affected our ability to reach 
the objectives of this thesis. Section 9.3 discusses perspectives for future research.
9.1  Contribution of the studies in light of our objectives and recent find-
ings in other studies
Large number of small-scale and small number of large-scale genetic association 
studies for plasma tHcy published in recent years: nothing beats the MTHFR677C>t
Before the start of this project, genetic epidemiological research into plasma tHcy had 
generally focused on a limited number of nonsynonymous variants in candidate genes 
in small scale association studies. the studies resulted in the conclusive identification of 
the MTHFR677C>t as determinant of plasma tHcy as well as folate concentrations and 
inconclusive findings for other potential genetic determinants including the 31 bp Vntr 
in CBS(1) (see also table 1.1). a meDline search for english reports published between 
January 2005 and august 2008 using the terms [(homocysteine) anD (gene)] yielded 
707 studies; hand-searching of the available abstracts indicated that 179 papers 
contained information on Dna variants as well as plasma tHcy concentrations. mostly, 
these concerned small (n<400) to moderate-size (n=400-1000) studies that included 
diseased and/or healthy individuals and in which the association between previ-
ously described nonsynonynous Dna variants for plasma tHcy as well as disease was 
evaluated. a number of these genetic analyses have been performed in large-scale 
(n>1000) epidemiological studies in which plasma tHcy and additional one-carbon 
metabolites have been measured. these include the ‘norwegian Colorectal Cancer 
Prevention (nOrCCaP)’ study(2,3), the ‘Hordaland Homocysteine study’(4), the ‘Cardio-
vascular risk in Young finns Study’(5), the ‘Health in men study’(6), the ‘national Health 
and nutrition examination Survey Dna Bank (nHaneS) iii’(7), and the ‘Women’s Health 
Study’(8). 
 the MTFHR677C>t was by far the mostly studied Dna variant for which predomi-
nantly positive associations with increased plasma tHcy were reported, especially 
among the moderate-size(9-25) and large studies(2,3,5,7,8,26-34). the second most studied 
Dna variant was MTHFR1298a>C with mostly negative (e.g. 7,22) but also positive 
results (e.g. 3,25) regarding association with plasma tHcy. However, in allmost all of 
these studies the correlation between the MTHFR1298a>C and MTHFR677C>t was not 
accounted for which may have resulted in false positive findings for MTHFR1298a>C. 
also MTR2756a>G and MTRR66a>G were measured by multiple research groups, again 
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with contradicting association results, also among the moderate and large-scale stud-
ies(3,7,11,18,32,35). Other Dna variants that are displayed in table 1.1 were evaluated in at 
most eight studies. Devlin et al.(30) did not find an influence of the FOLH11561C>t vari-
ant on plasma tHcy concentrations, in contrast to others(4,36). reports for SLC19A180G>a 
and plasma tHcy were predominantly negative but associations with serum folate 
were reported(3,30,36-40). Seven studies generally refuted a relation for TCN2776C>G 
and plasma tHcy(3,11,40-44) and two reports on the TCN267a>G did not find association 
to plasma tHcy(3,40). two large-scale studies (including 6,793 and 10,601 subjects, 
respectively) that have measured the 68 bp insertion/deletion polymorphism in CBS 
showed contradicting results for association to plasma tHcy(3,7). an association between 
the 31 bp Vntr in CBS to plasma tHcy concentrations, previously reported by our group 
in 2001(45), has been replicated in 1,400 subjects of the framingham population(46). no 
other studies on this variant have been published yet. also, no association studies for 
plasma tHcy were found for the CTH1364G>t variant.
 Publications concerning Dna variants other than those already presented in table 
1.1 were relatively sparse. the COMT324a>G has been studied by multiple groups in 
the last eight years, including our group, and showed contradicting results for plasma 
tHcy concentrations(47-51). three reports on the –786t>C variant in eNOS were found 
among the 179 selected studies; two studies showed a positive association between 
this variant and plasma tHcy(26,32) but this was not confirmed in a third study(52). in 
2005, Souto et al.(53) identified a plasma tHcy-affecting haplotype, including SnP 
rs694539, in NNMT via a linkage analysis approach. However, one follow-up study 
refuted an association for rs694539 in NNMT and plasma tHcy in their population(35) 
and a second association study showed inconclusive results(54). PON1163t>a and 
PON1575a>G, two nonsynonymous SnPs in the paraoxonase 1 gene, were studied by 
fredriksen et al.(3) and did not show association to plasma tHcy. Both PON1 polymor-
phisms were also measured by Shin et al.(55); in contrast, they did find an influence of 
PON1163t>a on plasma tHcy. Golledge and norman(6) were the only ones to report 
on 34G>C and 1347C>t in the peroxisome proliferator-activated receptor gamma gene 
(PPARG) and showed convincing association to plasma tHcy for both variants in their 
population consisting of 3,875 elderly men. the association between a 19 bp deletion 
in intron 1 of DHFR that our group reported in 2007(56) was not replicated by a recent 
study by Stanislawska-Sachadyn and colleagues(57).
 most studies reported on one to at most five different genetic determinants simul-
taneously. One of the exceptions concerned the large-scale association study in 10,601 
subjects by fredriksen et al.(3) which described the association between thirteen Dna 
variants relevant to one-carbon metabolism and plasma tHcy. Statistically signifi-
cant associations with plasma tHcy were found for MTHFR667C>t, MTHFR1298a>C, 
MTR2756a>G, and the CBS844_845ins68 variant and not for MTRR66a>G, 
MTHFD1958G>a, BHMT716G>a, CBS699C>t, TCN267a>G, TCN2776C>G, SLC19A180G>a, 
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PON1163t>a and PON1575a>G. furthermore, the genetic associations for eleven ad-
ditional one-carbon metabolites were described(3). Several of the 179 identified studies 
also measured additional one-carbon metabolism intermediates, mostly folate and 
cobalamin levels, generally to evaluate gene-environment interaction on plasma tHcy. 
Only very few studies reported on multi-locus effects for the small number of Dna 
variants that were simultaneously measured. indications for presence of interactions 
between Dna variants were reported by some. for instance, Devlin et al.(30) described 
the marginal and interaction effects for four polymorphisms and reported a plasma 
tHcy increasing interactive effect for MTHFR677tt and SLC19A180GG genotypes. an 
interaction for TCN2776C>G and MTRR66a>G genotypes on plasma tHcy was reported 
by aléssio et al.(42) while Yang et al.(7) described an interaction between MTHFR677C>t 
and MTRR66a>G on plasma tHcy. 
 Overall, research efforts by numerous groups in recent years mainly focused on 
evaluating previously identified nonsynonymous variants in genes related to re-
methylation of homocysteine to methionine and folate cycle. association to disease 
phenotypes and plasma tHcy were mostly studied using less than 400 subjects. 
relatively few studies have concentrated on variation in one-carbon metabolism genes 
related to transsulfuration and transmethylation. Only three studies, including our 
study described in chapter 2, specifically aimed at identification of new or established 
genetic determinants of plasma tHcy using a non-hypothesis-driven genome-wide 
linkage approach(53,58,59). Contradicting (linkage and) association results among studies, 
which may be due to population heterogeneity or chance, were found for many Dna 
variants, also for those that are known to affect the product encoded by the gene. So 
after years of study, the MTHFR677C>t variant still stands out as most important and 
only established marginal genetic determinant of plasma tHcy concentrations. Other 
potential determinants, like CBS 31 bp Vntr, have been identified but await convincing 
replication in other populations.
Our genome-wide linkage study suggested positional candidate regions and showed 
no overlap with the two other genome-wide linkage studies for plasma tHcy
three genome-wide linkage studies for plasma tHcy, including our study described in 
chapter 2 of this thesis, have been published in 2005 and 2006(53,59). the heritability 
estimate of 44% for plasma tHcy in our study indicated potential for the identification 
of genetic determinants for plasma tHcy in our study population. However, we were 
not able to identify Qtls with convincing statistical evidence. also, we could not repli-
cate the linkage signals for three regions that were found by Souto and colleagues(53) 
based on 21 extended pedigrees. in this Spanish linkage study a new candidate gene 
for plasma tHcy, nicotinamide N-methyltransferase (NNMT), was revealed(53). How-
ever, subsequent association studies for NNMT variation in other populations could not 
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confirm a strong role for these variants in plasma tHcy concentrations(35,54). the third 
linkage study that was published shortly after ours by Kullo et al.(59) identified four 
linkage regions with statistically significant and tentative evidence in 390 non-Hispanic 
white sibships; the regions did not contain any known genes involved in homocysteine 
metabolism. again, no overlap in linked regions for this study, that of Souto and col-
leagues(53) and ours was found. Differences between the three linkage studies may be 
ascribed to genetic and/or environmental heterogeneity among the populations or to 
the relatively low power of the studies. We tried to replicate our findings in the Homo-
cysteine in families (HOfam) study, a Dutch family study of patients with vascular dis-
ease and hyperhomocysteinemia comprising 306 individuals in 51 pedigrees(60). three 
markers located in the linked region of chromosome 16 and one marker located in the 
linked regions on chromosome 12 and 13 were genotyped. a non-significant multi-
point lOD score of 1.15 was found on chromosome 16 for age, sex and MTHFR677C>t 
adjusted plasma tHcy; no other signs of linkage were found (data not published). We 
conclude that we contributed to additional positional candidate regions that may har-
bour Qtls for plasma tHcy regions.
Our extensive candidate-gene association studies supported MTHFR677C>T and vari-
ants in CBS as main but modest marginal determinants of plasma tHcy and indicated 
new candidates
to our knowledge, chapters 3 and 4 in this thesis described the most extensive can-
didate-gene association studies for fasting as well as post-load plasma tHcy in terms 
of number of measured Dna variants in a single study population, so far. the results of 
our association study of 79 Dna variants in 40 one-carbon metabolism-related genes 
in chapter 3 underlined the major importance of the Dna variants MTHFR677C>t, 
CBS g.14037(31bp)16-21, and CBS844_845ins(68bp) in our population as published 
by us previously(45,61-63). the latter two variants showed strong lD. Other Dna vari-
ants that had not been studied in relation to one-carbon metabolites by others were 
identified, although not with statistically significant evidence (e.g. rs4819205 in FTCD, 
a gene encoding formiminotransferase cyclodeaminase and involved in the folate 
cycle). the set-based analysis of sub-pathways emphasized the major role for genetic 
variation in transsulfuration genes in plasma tHcy levels, especially post-load. We also 
found association to genetic variants of methyltransferase genes (e.g. SnPs in NNMT, 
DNMT3A, AHCY) in line with reports from Souto et al.(53) on NNMT and Gellekink et 
al.(49) on catechyl-o-methyltransferase (COMT). the strong association between three 
SnPs in atiC and plasma tHcy was disputed based on further study by our group(38). 
all in all, the application of a large-scale custom SnP-array approach identified new 
potential candidate genes that may harbour variants with somewhat smaller influ-
ence on plasma tHcy compared to MTHFR677C>t in the general population. Our study 
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provided new leads for the future search for genetic determinants of plasma tHcy and 
one-carbon metabolism in general.
Trait-specific and shared genetic determinants of one-carbon intermediates illustrated
the measurements of folate, methionine as well as homocysteine concentrations 
in chapter 3 illustrated some similarity in underlying genetic risk factors but mostly 
dissimilarity in main single locus effects for these three one-carbon metabolism 
intermediates that have all been associated to disease. the MTHFR677C>t was a main 
determinant of serum folate as well as a strong determinant of plasma tHcy. this find-
ing has also been reported by others (e.g. 3,64). all three metabolites showed associa-
tion to variation in CUBN although to different SnPs. for other Dna variants and genes 
dissimilarity in associations with the three metabolites was observed (e.g. plasma tHcy 
was strongly influenced by Dna variants in CBS in contrast to methionine and folate 
concentrations, only methionine was strongly negatively associated to Dna variants 
in BHMT). the large-scale study by fredriksen et al.(3) described above also found dif-
ferences and overlap among genetic determinants of several one-carbon metabolites. 
the importance of awareness of multiple effects of genetic variants in the interpreta-
tion of mendelian randomization studies has already been emphasized; the association 
between the genetic variant that predisposes to a certain environmental phenotype 
and disease that is studied via mendelian randomization may be confounded by pleio-
tropic effects(65). Hence, knowledge on the metabolic profile of Dna variants facilitates 
application and interpretation of mendelian randomization studies and elucidation of 
pathogenic mechanisms.
Multi-locus analysis: a combination of five genetic variants explained 17% of variation 
in plasma tHcy concentration
in chapter 4 we performed a multi-locus analysis including haplotype association and 
logic regression analysis for 14 candidate Dna variants. Previous analyses of multi-
locus genotype effects have focussed on first-order statistical interactions for a limited 
number of Dna variants using traditional regression or anOVa techniques(11,30,38,42,66) 
or evaluated interaction for MTHFR677C>t with the total number of mutant alleles 
in other Dna variants(67). Our choice for logic regression analysis allowed a thorough 
search over 14 Dna variants for multi-locus effects that may include higher-order 
interactions. this allowed the identification of a relatively common 5-locus genotype 
that was highly associated with increased fasting plasma tHcy: 10% of subjects that 
carried the genotype {CBS 31bp Vntr 18-18 and FOLH11561CC and (MTHFD2011GG 
or BHMT595Ga) and MTHFR677Ct/tt} had on average 5 µmol/l higher plasma tHcy 
concentrations compared to the 90% that did not. this multi-locus genotype included 
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pair-wise statistical interactions that had been identified by us (MTHFR677C>t and 
CBS 31 bp Vntr) previously(68). By the way, this multi-locus genotype showed a much 
weaker but still significant association to serum folate concentrations and explained 6% 
of its variation. Our study emphasized that it is the combination of multiple detrimental 
genetic variants that has the potential to explain observed variation in plasma tHcy, 
and hence the polygenic and interactive qualities of this complex trait. 
 it also indicates that the use of multi-locus genotypes in mendelian randomiza-
tion studies can achieve higher power compared to studies that rely on the much 
smaller single locus effect of MTHFR677C>t. for example, homozygous mutant state 
for this genotype results in on average 2 µmol/l higher plasma tHcy compared to CC 
and Ct genotypes and can be found in the population with a frequency of ~12%. the 
multi-locus genotype, with similar frequency in the population, resulted in 5 µmol/l 
higher plasma tHcy. assuming that a 1 µmol/l difference in plasma tHcy is related to 
8% risk reduction for venous thrombosis (Vt), one would expect to find 20% and 40% 
increased Vt risk for the MTHFR677tt and high homocysteine multi-locus genotype, 
respectively. evaluation of these effects in a case-control setting with 80% power and 
an α of 5% would require 4107 cases and controls for MTHFR677C>t and 1142 cases 
and controls for the multi-locus genotype. this potential relaxation of sample size 
requirements when using multi-locus genotypes that produce substantial differences 
in intermediate phenotypes has been touched upon in one of the recent papers by 
ebrahim and Davey Smith(69); the evaluation of associations between combinations of 
unlinked polymorphisms and disease has been termed ‘factorial mendelian randomiza-
tion’. 
Identification of new candidate genes for NTD that are not dependent on plasma tHcy
the many studies in recent years into the role of genetic variation in ntD aetiology 
have focused on genes related to homocysteine and folate metabolism, including  
MTHFR, MTHFD, MTR, MTRR and SLC19A1. MTHFR677C>t and MTRR66a>G are consid-
ered genetic risk factors for ntD but a large part of the genetic contribution to ntDs 
still remains to be identified(70). Chapter 5 described the most extensive candidate-
gene association study for ntD to date. the application of a custom SnP-microarray 
approach in a case-control setting supported involvement of SLC19A180G>a and 
identified new potential candidate Dna variants in the aetiology of ntD, including SnPs 
in CUBN and TRDMT1. these associations have not been investigated by others to our 
knowledge. 
 Previous studies by us and other research groups have indicated the potential role 
for impaired one-carbon-related methylation in ntD aetiology(71). Our candidate gene 
study described in chapter 3 pointed towards a role for DNMT1, encoding a Dna 
methyltransferase, in folate concentrations but variation in this gene was not found 
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among the strong determinants of spina bifida risk. However, a SnP in TRDMT1 (previ-
ously known as DNMT2) was associated with decreased risk for spina bifida as well 
as increased folate concentrations. trDmt1 does not methylate Dna but aspartic acid 
transfer rna (trna(asp)). in addition, our study suggested involvement of uptake of 
vitamin B12 and folate in ntD aetiology; SnP variation in CUBN and SLC19A1 was asso-
ciated to spina bifida risk; however, only the first showed association to rBC folate and 
cobalamin concentrations. 
 neither of the two Dna variants that showed strong (negative) association to spina 
bifida risk showed nominal association to plasma tHcy, but we did see decreased 
plasma tHcy in line with expectations. also, spina bifida risk was not strongly affected 
by MTHFR677C>t and CBS844_845ins(68bp) genotypes. Hence, our findings do not 
support a key role for plasma tHcy in ntD causality. instead, the simultaneous analysis 
of one-carbon metabolite concentrations and spina bifida-affected individuals under-
lined the potential importance of methylation processes and cobalamin concentrations 
in ntD aetiology, as proposed by others(71-73).
UCP2 involved in venous thrombosis aetiology and plasma tHcy: what is the mecha-
nism?
We were the first and only group to investigate the UCP2 45 bp del/ins for its associa-
tion to plasma tHcy and involvement in recurrent venous thrombosis (rVt) risk. this 
study, described in chapter 6, was triggered by the association between plasma tHcy 
and rVt(74), the fact that oxidative stress has been proposed to underlie the prothrom-
botic actions of homocysteine(75), the potential role of uCP2 in oxidative stress regula-
tion(76) and our initial findings of an association between this variant and plasma tHcy 
in a small study sample (data not published). also, some studies indicated involvement 
of uCP2 in development of atherosclerosis(77) and cardiovascular risk(78). the results 
of our study in chapter 6 indicated that UCP2 45bp del/ins may moderately increase 
post-load plasma tHcy as well as rVt risk. the small effect of the genetic variant on 
plasma tHcy (<6% change in plasma tHcy concentration versus wild-type) and the rela-
tively large effect on rVt risk (Or 1.4) suggests that the genetic variants exerts at least 
a part of its effect via other ways than plasma tHcy concentrations. in addition, it sug-
gests that the high levels of plasma tHcy in rVt cases should be largely due to other 
causes. this is supported by the fact that logistic regression analysis for rVt including 
both the UCP2 45bp del/ins and plasma tHcy concentrations as independent variables 
showed an Or comparable to the crude Ors for UCP2 45bp del/ins genotypes and a 
very strong association for plasma tHcy and rVt. Genetic association analysis strati-
fied for plasma tHcy quartiles, hampered by low power, does not show indications for 
effect modification (data not shown). Hence, the underlying mechanism linking uCP2 
and homocysteine to rVt is still unclear and elucidation relies on future studies. 
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New hybrid design offers powerful, valid, and flexible alternative for studies into 
 maternal and offspring genetic effects
the comparison of the new hybrid design with four existing designs that all allow the 
evaluation of offspring and maternal effects as described in chapter 7 has increased 
insight into their relative performance in terms of power and underlying assumptions. 
the study is an addition to existing methodological papers in this research area(79-82) 
and a continuation of the work by Weinberg and colleagues(83,84). in line with these 
papers, we illustrated that power for the popular case-parent triad and control-moth-
er/case-mother dyad designs were more or less similar depending on the underlying 
genetic model, though different underlying assumptions have to be met, and we, 
again, showed the surplus value of hybrid designs in terms of power, validity, and 
flexibility. in addition, we offered an alternative hybrid design for a situation in which 
fathers of controls may be hard to recruit or control-mother dyads are readily available. 
We have also explicitly laid out the general case-triad/control-triad design of which all 
the illustrated designs are subsets of. Our research described in chapter 7 also set off 
a study into the optimization of the statistical analysis of case-mother/control-mother 
dyad data that has been recently published(85). Both publications have extended the 
toolbox for genetic epidemiological research into offspring and maternal genotype 
effects that may be especially valuable in the field of complex congenital and early-
onset disorders, like ntDs. We await application of the new design and techniques of 
analysis in the future.
Evaluation of four multi-locus techniques of analysis using simulated data may guide 
application to real data
logistic regression, mDr, logic regression and set-association are popular methods of 
analysis that are applied nowadays (e.g. 86-89) and are likely to be applied in future 
studies to identify multi-locus effects. the mDr, logic regression, and the SumStat 
set-association methods have been described and evaluated by their developers using 
simulated and real data prior to or shortly after the introduction of the methods to the 
scientific public(90-95). However, the number of different underlying statistical interac-
tion models for which the methods were evaluated was restricted and the methods 
were not simultaneously applied to the same data. the application of logistic regres-
sion, mDr, logic regression and set-association analysis to simulated data based on 
six different two-locus causal genetic models was described in chapter 8. the results 
confirmed that the methods were performing well in general, showed that logistic 
regression performed worse and that small differences were observed for the other 
methods depending on underlying models. they also demonstrated that all methods 
were capable of identifying interacting causal Dna variants in the absence of single-
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locus marginal effects, but also showed that the ability to do so was impaired in the 
presence of interaction and genetic heterogeneity (i.e. model in which the presence of 
one out of two two-locus genotypes without single marginal effects increased disease 
risk). the latter was touched upon by ritchie et al.(91) previously and an adaptation of 
the mDr method to deal with genetic heterogeneity has been proposed recently(96). in 
addition, we have been the first to demonstrate the surplus value of incorporation of 
interaction terms in the set-association method. Several studies reporting the simul-
taneous application of traditional logistic regression, set-association, logic regression, 
or mDr analysis to real multi-locus data have been published after our study(87,88,97,98). 
these all showed that the different methods produced overlapping results but also that 
some discrepancies exist. the development and improvement of the mDr and logic 
regression methods has been ongoing(96, 99-104) and new multi-locus methods are being 
introduced (e.g. 105). Developmental changes to the core procedures of the evaluated 
methods of analysis will render our results outdated at some point in time. for now, 
the results of our study may be used to guide and facilitate the analysis and interpreta-
tion of multi-locus data as for our studies described in chapters 4 and 5 of this thesis.
9.2 Strengths and weaknesses of our studies
9.2.1 Study designs and utilized study populations
Modest sample sizes inhibited identification of genetic determinants of plasma tHcy 
and NTD
the linkage analysis performed in chapter 2 allowed hypothesis-free scanning of the 
genome for plasma tHcy Qtls without the need to predefine candidate genes. the 
linkage design is not sensitive for population stratification and it can deal with allelic 
heterogeneity. However, it is not a powerful approach in complex traits in which each 
locus is expected to contribute only a small percentage to trait variance(106). indeed, 
our power calculations showed that our study, that included 264 individuals in 13 
extended pedigrees, had 75% power to identify a Qtl that explains 25% of trait vari-
ance with a lOD score ≥ 1. We were thus underpowered to find loci that explain, say, 
≤ 4% of plasma tHcy variation. the completion of the Human Genome Project(107), 
the inter national Haplotype mapping (Hapmap) project(108,109), and the advances in 
genotyping technologies have enabled a powerful equivalent of genome-wide linkage 
scans for complex diseases: genome-wide association (GWa) or linkage disequilibrium 
(lD) scans. Commercial SnP-arrays that are capable of tagging most of the common 
variation in the human genome have been introduced(109) and examples of successful 
applications have emerged over the last few years(110-112). 
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all studies described in chapters 3 through 6 relied on evaluation of candidate Dna 
variants in a population-based association approach to identify genetic risk factors. 
Population-based association studies are popular in complex diseases for their rela-
tively high power compared to linkage and family-based association designs. However, 
the search for Dna variants with small marginal contributions to a continuous trait or 
disease susceptibility in the study population still requires a large number of individuals 
to reach sufficient precision in estimating and testing genetic effects(113). the case-con-
trol studies described in chapters 5 and 6 were based on 386 controls and 161 cases, 
and 190 controls and 180 cases, respectively. Our study in chapter 5 was only slightly 
underpowered (based on alpha 0.05 and observed maf and odds ratios). the case-
control study for spina bifida risk was underpowered to detect Dna variants with small 
contributions to disease risk; adjustment for multiple comparisons further diminished 
the power of this study. also, the sample sizes in chapters 3 and 4 were too small for 
estimation of small genetic effects with high precision (e.g. 200 individuals, Dna vari-
ant coefficient of determination r2 = 2%; α 0.05; power 52%). 
 in chapter 5 we aimed to identify genetic determinants that are involved in the 
aetiology of spina bifida. the measurement of Dna variants in spina bifida cases and 
controls did allow us to do so. However, this design does not permit differentiation 
between offspring and maternally-mediated genetic effects and has reduced power to 
identify maternal genetic risk factors for spina bifida (see chapter 7).
Well-phenotyped and homogeneous study samples enhanced identification of genetic 
risk factors
Population-based genetic association studies may suffer from bias due to the existence 
of population stratification. in order to minimize the chance for population stratification 
bias, we have excluded the non-Caucasian individuals (based on questionnaire data) 
that were present in the population-based samples of individuals that served as study 
or control population in chapters 3 through 6. the spina bifida cases and recurrent 
venous thrombosis patients described in chapters 5 and 6 were all of Dutch descent 
(based on surname information of patients and (grand)parents) and the latter were 
obtained from the same geographical area as the control samples. Several studies 
based on real and simulated data have shown that false positive and biased associa-
tions due to population stratification are likely to be limited in studies of moderate 
size, except for some unrealistic scenarios(114,115,116). Hence, the presence of residual 
confounding due to population stratification is expected to be limited for our studies. 
the bias resulting from population stratification can increase substantially, however, 
when sample size increases(117). 
 even though confounding due to other factors than population stratification in 
genetic association studies is unlikely, it may still occur by chance, especially in case of 
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small study populations and genetic variants with low maf; the assumed similar distri-
bution of outcome-associated factors over the genotype groups under study may not 
hold in these cases. in the genetic association studies for plasma tHcy concentrations, 
we have performed crude analyses as well as analyses in which plasma tHcy was 
adjusted for age, sex, and, in chapter 4, creatinine, important determinants of plasma 
tHcy. the adjustment for these determinants of plasma tHcy may also have increased 
power due to the removal of variation in outcome attributable to these factors.  
 Causal heterogeneity is a characteristic of complex diseases. Selection of patients 
that are homogenous with regard to their clinical phenotype may decrease causal 
heterogeneity in the study population and, hence, increase the power of the study. 
Several studies have suggested differences in genetic susceptibility factors for the dif-
ferent types of ntDs(118-120). the spina bifida patients that have been studied in chapter 
5 were selected from an ntD patient collection that has been ascertained at differ-
ent time-points via a Dutch society for patients with central nervous system defects 
and via the paediatric neurology department of the radboud university nijmegen 
medical Centre. for our study, we included only those patients with sporadic spina 
bifida aperta, an open closure defect located at the caudal part of the neural tube. 
the venous thrombosis cases described in chapter 6 concerned only those patients 
that experienced at least 2 episodes of venous thrombosis. Venous thrombosis mainly 
manifests itself in two related conditions: deep vein thrombosis (DVt) and pulmonary 
embolism (Pe). around 90% of Pe are the result of thrombi in the deep veins of the 
lower extremeties. although factor V leiden mutation is a strong risk factor for DVt and 
not Pe, in general the two conditions are viewed as a single disorder with shared risk 
factors(121). 
9.2.2 Measurements of main variables
Availability of standardized measurements of fasting and post-methionine load 
plasma tHcy concentrations enhanced identification of genetic risk factors
all blood samples in the control population and rVt cases were collected after an over-
night fast to minimize the inter-individual variation due to short-term dietary intake. 
in addition, plasma tHcy measurements 6 hours after a standardized oral methionine-
load were determined. all studies relied on a single measurement of plasma tHcy. the 
standardized performance of multiple measurements may reduce the analytical varia-
tion and thus the intra-person variation (which is the sum of the intra-person biologi-
cal and analytical variation (also called coefficient of variation (CV))) and, hence, the 
power of the study. the intra-person variability for plasma tHcy is ~8% (6.5% using the 
method used in our studies(122)) and a single measurement in cross-sectional studies in 
healthy populations, although it may underestimate the effect under study, is generally 
regarded as sufficient(123).
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Post-load and fasting plasma tHcy concentrations show strong correlations (see chapter 
3) and share underlying risk factors. the stress induced by a high oral load of methio-
nine has been used in the past to identify genetic defects in the vitamin B6-dependent 
transsulfuration pathway(123). Since then, post-load plasma tHcy has been associated 
with cardiovascular disease risk(124), also independent of fasting plasma tHcy(125). Our 
group found a considerably higher heritability for post-load concentrations compared 
to fasting plasma tHcy(60). Hence, the measurement of post-load plasma tHcy as well 
as fasting plasma tHcy may have increased our chance of identifying genetic determi-
nants involved in plasma tHcy-related disease traits.
Studies did not fully utilize increase in knowledge about DNA variation and advances 
in genotyping technologies in recent years 
the association study described in chapter 4 is based on low-throughput genotyping 
of Dna variants, performed between 1995 and 2007. Generally, only one Dna variant 
in a gene was measured. in addition to SnPs, fine-scale structural variants including 
insertions, deletions, and Vntr variants were measured and analyzed. it has become 
clear that the human genome entails many small, intermediate, and large-scale struc-
tural variations, including copy-number variations (CnVs)(126) that may show an impor-
tant influence on disease traits(127,128). We haven’t included the latter types of variants 
in our studies; insight in their prevalence in the human genome, adequate genotyping 
techniques, and methods of analysis, are still under development(127,129). 
 the selection of genes and Dna variants in the study described in chapters 4 and 6 
was based on gene sequencing of coding regions (in patient populations) and reported 
findings from others. Dna variants with proven or potential functionality (i.e. affecting 
the amount or activity of the encoded protein) were prioritized. the 50 genes selected 
for the studies described in chapters 3 and 5 were involved in different folate-related 
processes. the Dna variants were selected from literature and databases during 
2002. again, variants that changed the function or regulation of a gene product and 
those that had already shown association with a disease trait were prioritized. if not 
available, potentially functional, confirmed SnPs or SnPs within or near exons and in 
the promoter region that may be in lD with unknown causal variants were selected. 
this approach increased our prior chance of identification of biologically meaning-
ful Dna variants for plasma tHcy and ntD in population studies, reduced the amount 
of genotyping efforts and number of tests that needed to be performed, and fully 
exploited the extensive knowledge on homocysteine and one-carbon metabolism and 
our current understanding of ntD aetiology(130). it did however not lead to coverage 
of all variation present in the selected genes and pathways in the general population. 
Given that there is incomplete understanding of the molecular pathways underlying 
disease traits and that the full function of the studied genes and their dependence on 
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Dna variation is not known, this may have resulted in incomplete assessment of the 
association between the genes and the traits of interest. 
 the selection of SnPs with the aim of gene or regional coverage of SnP variation 
has been improved dramatically by revelation of the sequence of the human genome 
and the execution of the Hapmap Project(108,109). it is now possible to efficiently select 
a subset of SnPs that capture (or tag) the common SnP variation that is present in a 
certain genomic region or even the whole genome in the Hapmap populations prior to 
any genotyping effort. in addition, the improvements in genotyping technologies have 
reduced the costs of large-scale genotyping, increasing the feasibility of extensive 
candidate-gene or GWa studies in large study populations. indirect measurement of 
rare variants (maf<0.01) via a tagging approach remains difficult however, due to poor 
capability of common SnPs to tag rare variants. 
 the genotyping of the Dna variants analyzed in the studies presented in chapters 
4 and 6 was performed at different time-points over a period of 12 years and based 
on low-throughput genotyping techniques. unfortunately, genotyping efforts have not 
been completed for all ascertained individuals due to low Dna quality and absence 
of Dna. applied quality-control measures to detect and minimize genotyping errors 
varied per genotyping effort and included duplicate genotype assignment, duplicate 
measurements, blank control wells, and tests for HWe. all analyzed Dna variants in 
chapters 4 and 6 complied to HWe, with exception of the multi-allelic 31 bp Vntr in 
CBS which showed only a slight deviation (P-value HWe 0.022). large deviations from 
HWe have been used as an indication for genotyping errors, although some discour-
age the use of HWe to track genotyping errors(131,132). Hence, tentative interpretation 
of allelic association results for the 31 bp Vntr in CBS may be warranted but does not 
necessitate omission of the results. 
 Genotyping for the studies in chapters 3 and 5 was mainly performed using a 
customized SnP-micro-array approach developed and executed by asper Biotech, 
estonia, from 2003 until 2005. additional non-SnP variants were genotyped sepa-
rately. Of the 154 Dna variants that were selected, only 79 and 87 variants in chapter 
3 and 6, respectively, passed the quality controls. these included a maf>0.05 or 0.02, 
<25% missing genotype data, and HWe P-value>0.01, in order to ensure exclusion of 
genotyping errors and those Dna variants for which we were largely underpowered 
in our studies. We chose for the lenient percentage of 25% missing genotype data to 
be able to include variants for which genotyping had only been performed in a subset 
of the data and to exclude Dna variants with low success rates indicating low assay 
quality. the high failure rate was largely due to SnPs that were non-polymorphic in our 
population but also to failure of HWe. errors in design and execution of the SnP micro-
array approach have contributed to this inability of genotyping some of the selected 
SnPs. the extensive experience with SnP-arrays that has been acquired by commercial 
companies and research groups in the last 5 years has dramatically improved quality 
and genotyping success rates for current SnP-array platforms. 
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9.2.3 Statistical analysis
Use of advanced analyses optimized evaluation of DNA variant associations but op-
portunities for improvement exist
the advantages of haplotype analysis have been discussed extensively by others 
(e.g.(139)). We used Whap(133) to perform haplotype estimation and analysis. With help 
of Whap a weighted regression analysis was performed that takes the potential uncer-
tainty in the deduced haplotypes for an individual into account and, hence, prevents 
the invalid results that may arise in the application of methods that use the most likely 
haplotype pair per subject(134,135).
 the multi-locus logic regression analysis allowed the identification of a common 
multi-locus genotype that was highly associated to plasma tHcy concentrations. Simu-
lation studies described in chapter 8 and studies by Kooperberg et al.(92) and ruczinski 
et al.(93) showed the ability of this technique to identify interacting susceptibility loci. 
the application of a simulated annealing algorithm as implemented in logic regres-
sion to identify the best model for available genetic variants and outcome trait may 
result in overfitting of the model on the data with limited fit to external data. Hence, 
we used cross-validation techniques to choose the best model size. However, several 
models of different sizes performed similar in the cross-validation analysis. increased 
sample sizes will improve model selection and follow-up studies in independent 
replication samples will learn whether the selected model and multi-locus genotype is 
applicable to other populations. if the goal is to evaluate the overall importance of the 
analysed SnPs for trait outcome instead of identifying a single best model, a monte 
Carlo variant of logic regression analysis can be applied(103).
 the logic regression analysis described in chapter 4 was hampered by the presence 
of a large number of samples with incomplete genotypes for the analyzed Dna vari-
ants. also, we had a high drop-out rate for SnPs selected for the SnP-microarray ap-
proach. in addition to loss of power, the presence of missing values and complete-case 
analysis may result in biased effect estimates, depending on the underlying pattern of 
missing values. the precision and validity of the effect estimate can be improved by 
application of (multiple) imputation techniques(136). Several methods to impute miss-
ing genotypes have been described and evaluated(137). Successful application of these 
methods in the studies described in this thesis will however be impaired by the low 
SnP density and lD. 
 Chapter 3 reports the genetic association between the Dna variants and three 
one-carbon intermediates separately. this allowed a global evaluation of the similari-
ties and dissimilarites in associated Dna variants across traits. also, chapters 5 and 6 
measured genetic association for multiple disease phenotypes. the individual analysis 
of the separate traits did however increase the multiple testing burden and did not 
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exploit the existing correlations between the phenotypes. more advanced methods 
for the simultaneous genetic association analysis for multiple correlated traits have 
recently been proposed(140,141). Such methods may lead to more powerful approaches 
in gene identification and increase insight in genetic underpinnings of disease traits.
9.3 Future perspectives
Inconclusive results RCTs for plasma tHcy-reducing therapy: still analyse genetic deter-
minants plasma tHcy
in the last decades, convincing evidence for causal involvement of homocysteine 
concentrations in several chronic diseases has been described: homocystinuric patients 
exhibit vascular disease, an abundance of retrospective and prospective observational 
studies confirm a positive linear relation between plasma tHcy concentrations and risk 
for several disease phenotypes, meta-analyses of mendelian randomization studies for 
vascular disease and ntD, of which most have focussed on MTHFR677C>t, have shown 
overall positive results, periconceptional folic acid supplementation reduces the risk of 
ntD pregnancies, B-vitamin therapy has been shown to reduce cardiovascular disease 
risk in homocystinuric patients, and plausible mechanisms for pathogenic effects of 
plasma tHcy have been reported. all these findings support a causal and modifiable 
relation between homocysteine concentrations and disease. 
 evidence from randomized intervention trials with plasma tHcy-lowering therapy 
was eagerly awaited to conclusively underscore this ‘homocysteine hypothesis’ for 
vascular disease. However, unconvincing effects of B-vitamin therapy on vascular dis-
ease risk and mortality(142,143), with an exception for ischemic stroke(144), were reported. 
also, a decreased risk for (recurrent) venous thrombosis after homocysteine-lowering 
therapy could not be convincingly confirmed(145,146). and although one meta-analysis 
of randomized clinical trials underlined the positive effects of B-vitamin therapy on 
flow-mediated dilatation (fmD), a marker of endothelial function(147), a recent meta-
analysis by Potter et al.(148) provided negative results for fmD and carotid intima-media 
thickness after long-term homocysteine-lowering treatment with B-vitamins in subjects 
with history of stroke. Overall, the trial results for vascular disease were disappointing 
and led to increased speculation about non-causality for plasma tHcy in vascular dis-
ease causation(149). Several studies have however underlined that some characteristics 
of the randomized clinical trials may have impaired the ability to convincingly show 
the positive effect of B-vitamin therapy. these include insufficient sample sizes to reli-
ably detect the effects of B-vitamin therapy, especially in populations where folic acid 
fortification has been introduced, additional deleterious effects of B-vitamin therapy, 
a too short duration of B-vitamin therapy to reverse the negative effect of exposure 
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to high homocysteine levels in the past, and the fact that only specific groups may be 
susceptible for positive influence of B-vitamin therapy(142,150,151). evidence from ongoing 
studies may contribute to the elucidation of the apparent inconsistencies among the 
trials and between the observational and experimental studies. 
 as already described in chapter 1, knowledge on the genetic aetiology of plasma 
tHcy concentrations that is generated by epidemiological studies can contribute 
to the elucidation of the mechanistic role of plasma tHcy and aetiology of disease 
phenotypes. However, studies by several research groups into genetic determinants 
of plasma tHcy in the past years have unfortunately led to relatively little progress in 
knowledge on genetic factors for plasma tHcy (see section 9.1); the MTHFR677C>t is 
still the most replicated and important determinant of plasma tHcy concentration but 
with a modest marginal effect that is heterogeneous among different populations. as 
a result, mendelian randomization studies have been hampered by the unavailability 
of Dna variants with strong, robust, and specific effects on plasma tHcy concentration. 
One of our major findings described in this thesis was the identification of a common 
multi-locus genotype that predisposed to extremely diverse concentrations of plasma 
tHcy concentration. these findings may facilitate more powerful mendelian randomiza-
tion studies. future studies will need to show whether the large effect of the com-
mon multi-locus genotype identified in our population in chapter 4 can be replicated 
in other populations. they can also focus on identification of plasma tHcy associated 
multi-locus genotypes based on a larger and/or diverse number of Dna variants. then, 
studies into association between the multi-locus genotypes and disease traits may be 
performed more efficiently. 
figure 9.1  Simplified presentation that depicts the potential intermediate role of one-carbon 
metabolism (OCM) biochemical parameters between fundamental genetic and environmental 
risk factors and the ultimate disease phenotype.
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But also study additional one-carbon metabolism biochemical parameters ánd disease 
phenotypes
the ambiguity about causality and modifiability of plasma tHcy in common disease 
aetiology and the established importance of one-carbon metabolism in several es-
sential physiologic processes and diseases argue for measurement of a wider variety 
of one-carbon metabolites (e.g. folate, methionine, S-adenosylhomocysteine, asym-
metric dimethylarginine, B-vitamin concentrations). Preferably, markers that more 
specifically reflect essential one-carbon metabolism related processes are included 
as well. for instance, markers of Dna methylation potential (e.g. determination of 
S-adenosylhomocysteine/S-adenosylmethionine ratio (see also152), global and/or 
gene-specific Dna methylation), nucleotide synthesis (e.g. determination of uracil 
incorporation in Dna building blocks), oxidative stress (e.g. glutathionine, malondialde-
hyde), and endothelial dysfunction (e.g. flow-mediated dilatation) can be measured. 
the genetic analysis of this wider variety of one-carbon metabolism biochemical 
parameters in conjunction with plasma tHcy and disease facilitates the identification 
of new intermediates and increases insight in one-carbon metabolism-related disease 
mechanisms (see figure 9.1). it requires the simultaneous measurement of multiple 
one-carbon metabolism biochemical parameters in large numbers of samples. the 
latter is facilitated by the recent development of advanced analytical platforms that are 
focused on one-carbon metabolism(153) and improvement in metabolite measurement 
in general. 
 this principle of measurement of multiple metabolites and disease was demonstrat-
ed by our simultaneous study of folate-related polymorphisms for spina bifida as well 
as folate, plasma tHcy, and cobalamin concentrations. the two strongest genetic pre-
dictors of spina bifida risk, an intronic SnP in CUBN, involved in uptake of cobalamin, 
and an intronic SnP in TRDMT1, an rna methyltransferase, also showed association to 
folate and/or cobalamin concentrations which underlined the potential importance of 
these genes and directly provided clues about a possible disease mechanism. these 
two genes have not been evaluated for involvement in spina bifida aetiology by oth-
ers, to our knowledge. replication of associations of these genes to spina bifida risk 
and folate and cobalamin in other independent populations will be a next step in char-
acterization of the role of these genes in spina bifida aetiology. in addition, we showed 
that the link between variation in UCP2, an oxidative stress-related gene, and recurrent 
venous thrombosis can be identified in human population studies. How plasma tHcy is 
positioned in this disease mechanism remains to be elucidated. additional studies with 
measurements of markers of oxidative stress will provide valuable information.
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Future genetic epidemiological studies into plasma tHcy and related one-carbon me-
tabolism biochemical parameters and diseases will need to exploit developments in 
the field of genetic epidemiology
as stated previously, numerous efforts of multiple research groups to elucidate the 
genetic underpinnings of plasma tHcy via genetic epidemiologic studies have been 
relatively unsuccessful in the past years. the disappointing results are related to the 
application of designs and analyses that do not face up to the complexity of the trait 
under study, even though its complexity is expected to be less than that of the hetero-
geneous disease trait itself. Challenges for future genetic epidemiologic studies include 
the up-scaling of sample sizes, the performance of extensive genotypic characteriza-
tion, the utilization of large-scale sequence data, the incorporation of epigenetic and 
gene expression data, and application of advanced study designs and analyses. Over-
coming these challenges allows for a more efficient evaluation of the role of genome 
variation and may spur the elucidation of one-carbon metabolism involvement in 
disease in coming years. a brief explanation of each challenge is given below.
up-scaling of sample sizes
High precision estimation of the small effects of a large number of Dna variants and 
their joint interactions on a number of quantitative disease traits and, especially, quali-
tative disease outcomes requires large samples sizes (>>1000)(154). also, availability of 
independent replication samples is needed to evaluate whether the identified effects 
can be confirmed in other populations. One must bear in mind however, that genuine 
heterogeneity between study populations (e.g. variability in lD pattern, variability in 
exposure to environmental factors) may cause non-replicability(155). the necessary 
increase in sample size is facilitated by the initiation and existence of biobanks and 
international collaborations (consortia) like the Wellcome trust Case Control Consor-
tium (WtCCC)(156) and POlYGene(112). as already touched upon in section 9.1, several 
researchers have used available samples from large-scale studies and consortia to 
powerfully study the associations between one-carbon metabolites, disease, and Dna 
variants (‘norwegian Colorectal Cancer Prevention (nOrCCaP)’ study(2,3); ‘Hordaland 
Homocysteine study’(4); ‘Cardiovascular risk in Young finns Study’(5); ‘Health in men 
study’(6); ‘national Health and nutrition examination Survey Dna Bank (nHaneS) 
iii’(7);‘Women’s Health Study’(8); meGa study(157)). also, recent genome-wide associa-
tion initiatives contain valuable data on genotype and one-carbon metabolism-related 
phenotype data (see below). new studies should exploit these existing and future 
large-size sample collections and collaborations in the search for and characterization 
of genetic determinants of one-carbon metabolism phenotypes and related diseases. 
also, standardization and harmonization of blood sample collection, metabolite mea-
surements, and collection of environmental information in population-based cohorts is 
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required to allow for evaluation of gene-environment interaction and deal with popula-
tion heterogeneity(158).
extensive genotypic characterization
as stated previously, the availability of high-density data on genetic variation in a num-
ber of populations allows the efficient selection of tagSnPs (in addition to functional 
Dna variants) for common variation in candidate genes or genomic regions of interest. 
it has also led to the development of genome-wide SnP-arrays that allow a relatively 
powerful scan of the human genome for trait susceptibility loci. results of a genome-
wide association study (GWaS) for plasma tHcy concentrations are expected in due 
time (personal communication van meurs159). GWaS efforts may show whether the ge-
nome contains previously unknown Dna variants that show robust single or multi-lo-
cus association to plasma tHcy; these may be of more influence than the candidate loci 
that have been studied so far. two separate studies have recently reported on single 
locus GWa results for methionine(160) and cobalamin concentrations(161). no signifi-
cant associations for methionine were reported but strong associations between SnP 
variants in fucosyltransferase 2 (FUT2) and plasma cobalamin in 1,658 subjects and 
an independent replication sample (n = 1,059) were found; FUT2, that has not been 
previously considered as a candidate gene for cobalamin concentrations, is proposed 
to affect cobalamin absorption and associated genotypes showed ~8% difference in 
plasma vitamin B12 levels for the different genotype groups. the SnP also showed GW 
association, although much weaker, to plasma tHcy concentration(161). 
 in addition, genome-wide copy-number variation (CnV) measurements using spe-
cific probes positioned on SnP-arrays and measurement of CnVs in large populations 
is an area of attention and development. CnVs have been shown to influence several 
phenotypic traits independent from SnPs(127) and may well contribute to variation in 
one-carbon metabolism phenotypes. 
 Commercial SnP-arrays containing 12(162) and 57(163) functional and key poly-
morphisms in candidate genes involved in one-carbon metabolism are available. 
advantages of these arrays compared to the genome-wide SnP-arrays include direct 
measurement of high priority candidate Dna variants, also of low frequency, and lower 
costs. However, SnP density of these arrays is low and it is very likely that not all 
functional gene variation that contributes to the trait of interest is covered; evaluation 
of candidate gene Dna variants that are not on these SnP-arrays via direct measure-
ment or tagging approaches is warranted. a more thorough selection of potentially 
interesting folate-related SnPs was performed by us and is described in chapter 5 
of this thesis. an example of a comprehensive SnP selection procedure for a custom 
cardiovascular gene-centric array was described recently; the selection was based on, 
among others, results from candidate-gene and genome-wide association studies for 
CVD traits and intermediate phenotypes, pathway tools, and expression profiling stud-
ies, and resulted in a content-focused array containing almost 50,000 SnPs(164).
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utilization of large-scale genome sequence data
in the past few years, sequencing technologies have rapidly improved. the current 
next-generation sequencing technologies are capable to sequence Dna at high speed 
and reasonable cost and can facilitate the elucidation of the role of Dna variation in 
complex disease traits. these technniques have already been successfully applied on 
small scale to completely resequence individual genomes, resequence targeted ge-
nomic regions, and for the discovery of inherited and acquired structural variation(165). 
application of these new techniques to large-scale population studies especially offers 
new ways to investigate low-frequency and structural variants in positional or candi-
date regions. the data produced by the 1000 Genomes Project, in which the genomes 
of at least a thousand people from around the world will be sequenced, can be used 
to obtain high-resolution insight into genome variation that is present in ethnically 
diverse populations and may affect disease traits(166). 
incorporation of epigenetic and gene expression data
in addition to Dna variation, epigenetic variation, such as methylation or histone modi-
fication, may contribute to the heritability of one-carbon metabolism related traits. 
Hence, investigation of epigenetic effects is warranted when aiming for complete 
understanding of the molecular mechanisms underlying plasma tHcy and related traits 
and diseases. 
 next to genome annotation information, knowledge about the functional conse-
quences of Dna variations on gene expression and activity has been used in the past 
to select candidate polymorphisms and affirm the potential role of Dna variants in 
pathogenic mechanisms that link genes to phenotypic traits. However, information 
for a number of one-carbon metabolism candidate Dna variants is still lacking(167). in 
addition, future positional candidates may be evaluated for their influence on gene 
expression as well. also, identification of regulatory Dna variation on a regional or 
genome-wide scale may contribute to elucidation of disease pathology(168-170). the 
development of infrastructure and statistical tools will be of importance to allow for 
efficient combination and utilization of these different layers of information (i.e. Dna 
variants, epigenetic variation, transcripts, metabolites, and disease). 
application of advanced genetic epidemiological designs and analyses
in congenital disorders like ntD in which the influence of maternal as well as offspring 
genotype effects are likely to play a role, the application of study designs that allow 
powerful differentiation between these effects is warranted to improve the character-
ization as well as the identification of genetic risk factors. 
 Valid en powerful evaluation of multi-locus effects can be facilitated by use of 
advanced techniques of analysis. the importance of the development, evaluation, and 
implementation of multi-locus techniques that can deal with large number of Dna 
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variants and environmental factors is recognized and ongoing(171). the development of 
user-friendly software packages will facilitate real applications of these new tech-
niques.
 in addition, future genetic studies, in which multiple correlated one-carbon me-
tabolism phenotypes are measured, may profit from analytical strategies that exploit 
the existing cross-trait covariance and reduce the multiple testing burden. for instance, 
multivariate tests of association(141) and principal components analyses(140) may be 
 applied.
 also, incorporation of prior biological knowledge (e.g. enzyme kinetics, biological 
interaction of molecules) about one-carbon metabolism and related pathways in statis-
tical genetic analysis as recently proposed by several researchers(172-174) may improve 
power and decrease false positive results.
Genetic epidemiological studies contribute to the understanding of complex disease 
aetiology. identification and characterization of susceptibility genes facilitates de-
velopment of diagnostic, prognostic, preventive and therapeutic tools. Plasma tHcy 
concentration has been viewed as important intermediate in clinical aetiology. it has 
especially raised much interest due to the fact that this one-carbon metabolism inter-
mediate is modifiable by diet and B-vitamin supplementation. the potential decrease 
of vascular disease burden by homocysteine-lowering therapy is currently under 
debate, however. identification of robust, strong genetic predictors of plasma tHcy will 
contribute to knowledge on whether plasma tHcy is indeed a causal intermediate or a 
bystander in disease aetiology and may shine light on the disappointing results of the 
homocysteine-lowering trials for vascular disease. Genetic epidemiological studies for 
a wider variety of one-carbon metabolism biochemical parameters are warranted and 
may identify new intermediates for disease and result in new insights into therapeutic 
and preventive measures. evaluation of gene-environment interactions may reveal 
which groups respond to certain nutritional interventions and which not. to enable 
all this in coming years, the exploitation of new measurement techniques and the 
generation and utilization of vast amounts of genetic and phenotypic data is required, 
as well as the application of study designs and methods of analysis that can deal with 
the increasing complexity of the data at hand.
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Homocysteine is a sulphur-containing intermediate in one-carbon metabolism. Plasma 
total homocysteine (tHcy) concentration is associated with several multifactorial dis-
orders including vascular disease, venous thrombosis (Vt), neural tube defects (ntDs), 
alzheimer’s disease, schizophrenia, and cancer. the mechanisms underlying the as-
sociation between plasma tHcy concentration and disease are unclear. elucidation of 
the genetic aetiology of plasma tHcy-related diseases can aid in the understanding of 
disease aetiology and the development of diagnostic tools and therapeutic measures 
but is difficult due to the aetiologic complexity of multifactorial diseases. Genetic analy-
sis of plasma tHcy concentration is easier and promotes the elucidation of the underly-
ing pathology of homocysteine-related diseases. However, despite extensive research, 
which was mainly focussed on single locus effects of a limited number of candidate 
genes, the genetic aetiology of plasma tHcy is unresolved. application of advanced ge-
netic epidemiological study designs and analyses may promote the elucidation of the 
genetic background of plasma tHcy concentration and related diseases. the main ob-
jective of this thesis was to identify Dna variants that influence plasma tHcy concentra-
tions and ntDs and Vt by use of genetic epidemiological studies (part 1). the second 
objective of this thesis was to develop and evaluate genetic epidemiological tools that 
facilitate the identification and characterization of genetic risk factors (part 2).
Chapter 1 contains a general introduction on this thesis and includes a description 
of homocysteine metabolism, the relation between plasma tHcy concentration and 
disease, the role for plasma tHcy as intermediate phenotype in genetic studies for 
complex multifactorial diseases, current knowledge on the genetic aetiology of plasma 
tHcy and plasma tHcy-related genetic determinants of ntD and Vt, and genetic epi-
demiological designs and analyses that may enhance the elucidation of genetic risk 
factors. also, the objectives and outline of this thesis are given. 
Part 1: Genetic determinants of homocysteine and related diseases
in chapter 2 we aimed to map quantitative trait loci for plasma tHcy by performing a 
linkage analysis in 13 extended families comprising 264 individuals with measurement 
of plasma tHcy and 377 genetic polymorphic markers spread over the autosomal ge-
nome. the estimated heritability of age and sex adjusted plasma tHcy in this popula-
tion was 44%. We identified one area on chromosome 16q12 with suggestive linkage 
evidence (lOD score 1.76). two areas with weak linkage evidence were located on 
chromosome 12q14 (lOD score 1.57) and 13q31 (lOD score 1.52). a database search 
indicated that the region on 12q14 harboured speculative potential candidate genes: 
serine hydroxymethyltransferase 2 (SHMT2) and methyltransferase like 1 (METTL1).
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in chapter 3 we tried to identify genetic determinants of the one-carbon intermediate 
metabolites folate, homocysteine, and methionine using an extensive candidate-gene 
association strategy. We successfully genotyped 79 Dna variants in coding and non-
coding regions in 40 one-carbon metabolism-related genes using a SnP-microarray 
approach in 190 unrelated Caucasian individuals. We classified the 40 genes in 5 meta-
bolic processes: folate cycle, remethylation, transmethylation, transsulfuration, other. 
We applied single-locus association analysis and a multi-locus set-based analysis for 
the 5 gene subsets. SnP rs1801133 (MTHFR677C>t) was main determinant of serum 
folate (nominal P=0.002); other strong determinants included rs8101626 in DNMT1 
(nominal P=0.003) and rs1801394 (MTRR66a>G) (nominal P=0.011). MTHFR677C>t 
was also nominally associated to fasting and post-load plasma tHcy (nominal P=0.026 
and 0.006, respectively). SnP rs2276598 (DNMT3a1523G>a) showed nominal associa-
tion to fasting tHcy (nominal P=0.035). CBS844_845ins(68bp) was significant determi-
nant of post-load tHcy (nominal P=0.0005; family-wise P=0.044) and explained 6.3% 
of its variance. a non-synonymous variant (rs672346) in BHMT (nominal P=0.014) and 
3’ utr rs1078004 in ICMT (nominal P=0.030) were related to methionine. Substantial 
overlap in strong Dna variants for fasting and post-load plasma tHcy was present. Only 
MTHFR677C>t showed strong association to more than one of the three metabolites. 
in conclusion, our extensive candidate-gene study resulted in establishment of known 
and identification of new candidate Dna variants for folate, homocysteine, and methio-
nine concentrations.
 Chapter 4 describes the analysis of 36 gene variants (of which most are known 
or suspected to affect function of the encoded protein) in 19 candidate genes related 
to homocysteine metabolism using haplotype and logic regression analysis in 461 
unrelated Caucasian individuals. Our goal was to identify and characterize multi-locus 
genetic determinants of plasma tHcy concentration. for completeness, single locus as-
sociation results were presented too. these were in line with our previous publications 
and showed a main role with modest marginal effects for CBS844_845ins(68bp), CBS 
31bp Vntr, COMT324G>a, MTHFR677C>t and potential minor roles for other Dna vari-
ants in plasma tHcy. no haplotype effects in addition to the single locus effects were 
found. fourteen Dna variants and 182 individuals were included in logic regression 
analysis. this analysis identified the following logical genotype combination: {CBS 31bp 
Vntr 18-18 and FOLH11561CC and (MTHFD2011GG or BHMT595Ga) and MTHFR677Ct/
tt}; it was present in 10% of the study population and associated with 5 µmol/l 
higher median fasting plasma tHcy. it explained ~17% of plasma tHcy variance in our 
population; the 5 Dna variants separately explained ~5% of variance. 
 in chapter 5 we aimed at identifying genetic determinants related to folate and its 
metabolic pathways that are involved in the aetiology of spina bifida, the most com-
mon type of ntDs, using an extensive candidate-gene association study. We analysed 
87 Dna variants in 45 genes in 180 patients and 190 controls based on application of 
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the SnP-array described in chapter 3. for those variants that showed nominal associa-
tion to spina bifida, the relation with age and sex adjusted folate, cobalamin, and tHcy 
concentration was evaluated in the control sample. the strongest association with 
spina bifida that remained statistically significant after correction for multiple testing 
was found for rs1907362 in CUBN, encoding the intrinsic factor-cobalamin receptor (or 
cubilin). this intronic SnP was associated with decreased spina bifida risk and increased 
red blood cell (rBC) folate (P=0.001) and cobalamin levels (P=0.039). the second 
strongest association was found for the intronic rs2295809 in TRDMT1, encoding one of 
the many methyltransferases, which showed association to increased rBC folate too. 
Other top findings included variants in ALDH1L1, SARDH, and SLC19A1. no haplotype 
effects on top of main effects of single Dna variants were found. the identified multi-
locus logic regression model included rs1907362 in CUBN and rs2295809 in TRDMT1 as 
separate variables and we did not find statistically significant interactions between the 
two variants.
 in chapter 6 we evaluated whether a 45 bp deletion/insertion variant in candidate 
gene UCP2, a potential regulator of mitochondrial reactive oxygen species production 
and oxidative stress, was associated with elevated plasma tHcy and increased risk for 
recurrent venous thrombosis (rVt) in 161 rVt cases and 386 controls. We did not find 
an association between fasting plasma tHcy and the variant. We did however find a 
positive association between the UCP2 45 bp insertion/deletion and post-load plasma 
tHcy in controls (P-value anOVa 0.02) and indications for association in rVt cases 
(P-value anOVa 0.09). the frequency of the UCP2 45 bp ins/ins genotype was 12.4% 
in rVt cases compared to 8.3% in controls (ins/ins vs. del/del: Or 1.8 (95% Ci 1.0 to 
3.4)).
Part 2: Genetic epidemiological designs and analyses
Chapter 7 presented a new hybrid design augmenting case-parent triads and control-
mother dyads as population-based controls. Comparison to competing designs (i.e. 
case-parent triad, case-parent triad/control parents hybrid, and case-mother/control-
mother dyad designs) showed that it is a powerful approach for testing both offspring 
and maternal genetic relative risk parameters under various scenarios, though it is 
slightly less powerful than the hybrid design that uses control parents. in addition, it 
allows testing of absence of population stratification bias, an underlying assumption 
in combining case and control data, and presence of mating symmetry. even if the 
assumptions of absence of population stratification bias and presence of mating sym-
metry are not fulfilled, the hybrid design allowed for valid estimation of offspring and 
maternal genetic relative risk parameters.
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in chapter 8 we evaluated the application of traditional logistic regression analysis, the 
multifactor dimensionality reduction (mDr) method, logic regression analysis, and the 
set-association method for the identification of statistically interacting Dna variants. 
We simulated data for 200 cases and 200 controls for a null model of no genetic ef-
fects, five 2-locus statistical interaction models, and one model containing two 2-locus 
interactions, all defined using the penetrance scale, under four different minor allele 
frequencies. We found that the performance of logistic regression analysis was depen-
dent on the underlying model and the application of multiple comparisons adjustment 
procedures. the ability to identify the causal loci was generally good for the other 
methods. all methods had difficulty identifying the two 2-locus interaction models with 
small or no marginal effects. Several practical and methodological characteristics of the 
methods that we encountered were reviewed.
in conclusion, extensive association studies for over 40 one-carbon metabolism-related 
genes identified novel candidates that warrant follow-up research and known Dna 
variants that had a small contribution in plasma tHcy variation each. application of 
non-parametric multi-locus analysis allowed the identification of a strongly associ-
ated five-locus interacting genotype that explained 17% of plasma tHcy variation in 
our population. the candidate-gene studies also underlined the relative importance of 
MTHFR677C>t and CBS variants. the simultaneous analysis of plasma tHcy as well as 
folate and methionine concentrations indicated dissimilarities in genetic determinants 
for the three metabolites. the latter is important in view of elucidation of complex 
disease mechanisms, especially since the evidence that plasma tHcy itself may not 
be a causal element in disease pathology is accumulating. the simultaneous evalua-
tion of genetic associations for plasma tHcy ánd for rVt or ntD led to identification of 
potential genetic risk factors for these diseases and also indicated whether or not the 
disease-mechanism may be plasma tHcy-related. the evaluation of four multi-locus 
analysis techniques for identification of interacting loci may be used to guide and 
facilitate the analysis and interpretation of multi-locus data as for our studies described 
in chapters 4 and 5 of this thesis. the new powerful and flexible hybrid design for 
identification of both maternal and offspring genotypic effects can be applied in future 
studies into congenital disorders like ntDs.
a discussion of the studies of this thesis and future research perspectives can be found 
in chapter 9.
 
Samenvatting
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Homocysteïne is een zwavelhoudende intermediair in de folaatcyclus en het me-
thionine metabolisme, ook wel bekend als de one-carbon metabolisme route. een 
verhoogde concentratie van plasma totaal homocysteïne (tHcy) is geassocieerd met 
diverse multifactoriële aandoeningen, waaronder hart- en vaatziekten, veneuze 
trombose (Vt), neurale buis defecten (nBD), de ziekte van alzheimer, schizofrenie, en 
kanker. De onderliggende mechanismen zijn echter onduidelijk. 
 Opheldering van de genetische etiologie van de bovengenoemde aandoeningen 
geeft meer inzicht in de pathofysiologische processen en kan leiden tot de ontwik-
keling van preventieve en therapeutische interventies maar is moeilijk vanwege de 
etiologische complexiteit van multifactoriële aandoeningen. Genetische analyse van 
plasma tHcy concentratie is makkelijker en bevordert de opheldering van de onder-
liggende pathologie van ziekten gerelateerd aan homocysteïne. Ondanks het feit dat 
er veel onderzoek naar genetische determinanten van plasma tHcy concentratie is 
verricht, met name naar effecten van een enkele variant in een beperkt aantal kandi-
daatgenen, is de genetische etiologie van plasma tHcy concentratie niet opgehelderd. 
toepassing van geavanceerde genetisch epidemiologische studie designs and analyses 
kan deze opheldering van de genetische achtergrond van homocysteïne en gerela-
teerde aandoeningen bevorderen. 
 Het doel van het onderzoek beschreven in dit proefschrift was het identificeren 
van genetische varianten die plasma tHcy concentraties, en ook het risico op nBD en 
Vt, beïnvloeden aan de hand van genetisch epidemiologische studies (deel 1). Het 
tweede doel van dit proefschrift was het ontwikkelen en evalueren van genetisch 
epidemiologische designs en analyses die de identificatie en karakterisering van gene-
tische determinanten bevorderen (deel 2).
Hoofdstuk 1 omvat een algemene introductie en beschrijft het homocysteïne me-
tabolisme, de relatie tussen plasma tHcy concentraties en ziekte, de rol voor plasma 
tHcy concentraties als intermediair fenotype in genetische studies naar multifactoriële 
aandoeningen, de huidige kennis omtrent genetische determinanten van plasma tHcy 
concentraties en aan homocysteïne gerelateerde determinanten van nBD en Vt, en 
een beschrijving van genetisch epidemiologische studie designs en analyses die de 
opheldering van genetische determinanten bevorderen. tevens worden de doelen en 
inhoud van dit proefschrift beschreven. 
Deel 1: Genetische determinanten van homocysteïne en gerelateerde 
aandoeningen
in hoofdstuk 2 beoogden we de lokalisatie van ‘quantitative trait loci’ voor plasma 
tHcy concentratie middels een koppelingsanalyse in 13 families bestaande uit 264 
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individuen waarin plasma tHcy concentraties en 377 polymorfe markers, verspreid 
over het autosomale genoom, zijn gemeten. De geschatte heritability van plasma tHcy 
concentratie, gecorrigeerd voor leeftijd en geslacht, was 44% in deze populatie. We 
vonden één gebied op chromosoom 16q12 met suggestief bewijs voor koppeling (lOD 
score 1.76). twee gebieden met zwak bewijs voor koppeling waren gelokaliseerd op 
chromosoom 12q14 (lOD score 1.57) en 13q31 (lOD score 1.52). Databank onderzoek 
indiceerde potentiële kandidaatgenen in de 12q14 regio: serine hydroxymethyltrans-
ferase 2 (SHMT2) en methyltransferase like 1 (METTL1).
 in hoofdstuk 3 probeerden we genetische determinanten van folaat, homocys-
teïne, en methionine, intermediaire metabolieten van het one-carbon metabolisme, te 
identificeren aan de hand van een uitgebreide kandidaatgen associatie studie. We heb-
ben 79 Dna varianten in coderende en niet-coderende regionen in 40 one-carbon me-
tabolisme gerelateerde genen succesvol gemeten met behulp van een SnP microarray 
aanpak in 190 ongerelateerde Kaukasische individuen. We classificeerden de 40 genen 
in 5 metabole processen: folaatcyclus, remethylering, transmethylering, transsulfure-
ring, overig. We hebben een single-locus associatie analyse en een multi-locus set-
based analyse voor de 5 genklassen toegepast. SnP rs1801133 (MTHFR677C>t) was 
sterkste determinant van serum folaat (nominale P=0.002); overige sterke determi-
nanten waren rs8101626 in DNMT1 (nominale P=0.003) en rs1801394 (MTRR66a>G) 
(nominale P=0.011). MTHFR677C>t was ook nominaal geassocieerd met nuchter en 
post methionine-load plasma tHcy (nominale P respectievelijk 0.026 en 0.006). SnP 
rs2276598 (DNMT3A1523G>a) liet nominale associatie met nuchter plasma tHcy zien 
(nominale P=0.035). CBS844_845ins(68bp) was een significante determinant van 
post-load plasma tHcy (nominale P=0.0005; family-wise P=0.044) en verklaarde 6.3% 
van de variantie. een non-synonieme variant (rs672346) in BHMT (nominale P=0.014) 
en 3’ utr rs1078004 in ICMT (nominale P=0.030) waren gerelateerd aan methionine. 
Substantiële overlap in sterke Dna varianten voor nuchter en post-load plasma tHcy 
was aanwezig. alleen MTHFR677C>t liet sterke associatie zien met meer dan één van 
de drie metabolieten. Kortom, onze uitgebreide kandidaatgen studie resulteerde in 
constatering van reeds bekende en de identificatie van nieuwe kandidaat Dna vari-
anten voor folaat, homocysteïne, en methionine concentraties.
 Hoofdstuk 4 beschrijft de analyse van 36 gen varianten (waarvan voor de meeste 
bekend is of wordt vermoed dat ze de functie van het gecodeerde eiwit beïnvloeden) 
in 19 kandidaatgenen gerelateerd aan het homocysteïne metabolisme met behulp van 
haplotype en logic regressie analyse in 461 ongerelateerde Kaukasische individuen. 
Ons doel was het identificeren en karakteriseren van multi-locus genetische deter-
minanten van plasma tHcy concentratie. Voor de volledigheid werden ook resultaten 
van single-locus associaties gepresenteerd. Deze kwamen overeen met onze eerder 
gepubliceerde resultaten en lieten een hoofdrol zien, met bescheiden marginale ef-
fecten, voor CBS844_845ins(68bp), CBS 31bp Vntr, COMT324G>a, MTHFR677C>t en 
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potentiële kleine rollen voor andere Dna varianten voor plasma tHcy. er werden geen 
haplotype effecten gevonden onafhankelijk van de single- locus effecten. Veertien 
Dna varianten en 182 individuen waren geïncludeerd in de logic regressie analyse. 
Deze analyse identificeerde de volgende Booleaanse of logische genotype combina-
tie: {CBS 31bp Vntr 18-18 en FOLH11561CC en (MTHFD2011GG of BHMT595Ga) en 
mtHfr677Ct/tt}; deze combinatie was aanwezig in 10% van de studiepopulatie en 
geassocieerd met een 5 µmol/l hogere mediane nuchtere plasma tHcy concentratie. 
De multi-locus combinatie verklaarde ~17% van de variantie in plasma tHcy in onze 
populatie; de 5 Dna varianten afzonderlijk verklaarde ~5% variantie. 
 in hoofdstuk 5 richtten we ons op het identificeren van genetische determinanten 
van folaat en de metabole pathways die zijn betrokken in de etiologie van spina bifida, 
het meest voorkomende type nBD, middels een uitgebreide kandidaatgen associa-
tie studie. We analyseerden 87 Dna varianten in 45 genen in 180 patiënten en 190 
controles met gebruikmaking van de SnP microarray die is beschreven in hoofdstuk 3. 
Voor die varianten die nominale associatie lieten zien met spina bifida, werd de asso-
ciatie met voor leeftijd- en geslacht- gecorrigeerde concentraties van folaat, cobala-
mine, en tHcy geëvalueerd in de controles. De sterkste associatie met spina bifida, die 
statistisch significant bleef na correctie voor de meervoudige toetsing, werd gevonden 
voor rs1907362 in CUBN, coderend voor de intrinsic factor-cobalamin receptor (of cubi-
line). Deze SnP, gelegen in een intron, was geassocieerd met een verlaagd risico voor 
spina bifida en verhoogde concentraties folaat in rode bloed cellen (rBC) (P=0.001) en 
cobalamine (P=0.039). De één na sterkste associatie werd gevonden voor rs2295809 
gelegen in een intron in TRDMT1, coderend voor één van de vele methyltransferases, 
welke ook een associatie met verhoogd rBC folaat liet zien. andere top bevindin-
gen betroffen varianten in ALDH1L1, SARDH, en SLC19A1. er werden geen haplotype 
effecten gevonden die onafhankelijk waren van marginale effecten van single-locus 
varianten. Het geïdentificeerde multi-locus logic regressie model bevatte rs1907362 in 
CUBN en rs2295809 in TRDMT1 als aparte variabelen en we vonden geen statistisch 
significante interactie tussen deze twee varianten.
 in hoofdstuk 6 evalueerden we of de 45 bp deletie/insertie variant in het kandi-
daatgen UCP2, een potentiële regulator van productie van mitochondriële reactieve 
zuurstof radicalen en oxidatieve stress, was geassocieerd met een verhoogd plasma 
tHcy en verhoogd risico voor een recidief veneuze trombose (rVt) in 161 rVt patiënt-
en en 386 controlepersonen. We vonden geen associatie tussen nuchter plasma tHcy 
en de variant. We vonden echter wel een positieve associatie voor de UCP2 45 bp 
insertie/deletie and post-load plasma tHcy in controles (P anOVa 0.02) en aanwijzin-
gen voor een associatie in rVt patiënten (P anOVa 0.09). the frequentie van het UCP2 
45 bp ins/ins genotype was 12.4% in rVt patiënten vergeleken met 8.3% in controles 
(ins/ins vs. del/del: Or 1.8 (95% Ci 1.0 tot 3.4)).
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Deel 2: Genetisch epidemiologische designs en analyses
in hoofdstuk 7 presenteerden we een nieuw hybride design dat patiënt-ouder trios 
uitbreidt met controle-moeder duos als populatie controles. een vergelijking met 
concurrerende designs (d.w.z. patiënt-ouder trio design, patiënt-ouder trio/controle 
ouders hybride design, en patiënt-moeder/controle-moeder duo design) liet zien dat 
het een krachtige aanpak is voor het testen van de genetische relatieve risico param-
eters voor zowel kind als moeder in verschillende scenario’s, alhoewel het iets minder 
power heeft dan het hybride design dat ouders van controles gebruikt. tevens is met 
het nieuwe hybride design mogelijk om de afwezigheid van populatie stratificatie bias 
te testen, een onderliggende assumptie in het combineren van patiënt en controle 
data, en de aanwezigheid van ‘mating symmetrie’. Zelfs als niet wordt voldaan aan de 
assumptie van afwezigheid van populatie stratificatie bias en aanwezigheid van mating 
symmetrie, laat het hybride design een valide schatting van kind- en maternale gene-
tische relatieve risico parameters toe.
 in hoofdstuk 8 evalueerden we de toepassing van traditionele logistische regressie 
analyse, de ‘multifactor dimensionality reduction’ (mDr) methode, logic regressie 
analyse, en de set-associatie methode voor de identificatie van Dna varianten 
die statistische interactie vertonen. We simuleerden data voor 200 patiënten en 
200 controles voor een nul-model (geen genetische effecten), vijf 2-locus statist-
ische interactie modellen, en één model dat twee 2-locus interacties bevatte, allen 
gedefinieerd op basis van penetrantie, voor vier verschillende minor allel frequenties 
(maf). We vonden dat de prestatie van logistische regressie analyse afhankelijk was 
van het onderliggende model en de toepassing van procedures voor de correctie voor 
meervoudige toetsing. Het vermogen om de causale loci te identificeren was over het 
algemeen goed voor de andere methoden. alle methoden hadden moeite met het 
identificeren van de twee 2-locus interactie modellen met kleine of geen marginale 
effecten. Diverse praktische en methodologische karakteristieken die werden ervaren 
in de toepassingen van de verschillende methoden, werden besproken.
Samenvattend kunnen we zeggen dat de uitgebreide associatie studies voor meer 
dan 40 one-carbon metabolisme gerelateerde genen heeft geleid tot identificatie van 
nieuwe kandidaten voor vervolgonderzoek en het vinden van reeds bekende Dna 
varianten die elk een klein deel van de variatie in plasma tHcy verklaarden. toepass-
ing van non-parametrische multi-locus analyse maakte de identificatie van een sterk 
geassocieerd vijf-locus genotype mogelijk dat 17% van de plasma tHcy variatie in 
onze populatie verklaarde. De kandidaatgen studies benadrukten ook het relatief grote 
belang van MTHFR677C>t en CBS varianten. De simultane analyse van plasma tHcy en 
folaat en methionine concentraties liet verschillen in genetische determinanten zien 
voor deze drie metabolieten. Dit laatste is belangrijk in het kader van de opheldering 
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van pathofysiologische mechanismen voor multifactoriële ziekten, met name gezien 
het toenemende bewijs dat plasma tHcy niet zelf een causale factor is. De simultane 
evaluatie van genetische associaties voor plasma tHcy en voor rVt of ntD leidde tot 
de identificatie van potentiële genetische risicofactoren voor deze aandoeningen en 
gaven ook aanwijzingen over het al dan niet gerelateerd zijn aan plasma tHcy van 
het onderliggende ziektemechanisme. De evaluatie van vier multi-locus analysetech-
nieken ter identificatie van interacterende loci kan gebruikt worden ter begeleiding en 
ondersteuning van de analyse en interpretatie van multi-locus data zoals ook gedaan 
is in de studies beschreven in hoofdstukken 4 and 5 van dit proefschrift. Het nieuwe 
krachtige en flexibele hybride design voor de identificatie van genotype effecten van 
zowel moeder als kind kan in de toekomst worden toegepast in studies naar aangebo-
ren afwijkingen zoals nBD.
een discussie van de studies beschreven in dit proefschrift en mogelijkheden voor 
vervolgonderzoek worden gegeven in hoofdstuk 9.
 

D a n K W O O r D  219
Dankwoord
Dit proefschrift is tot stand gekomen middels een interactie tussen veel mensen met 
diverse achtergronden. een geslaagde synergie wat mij betreft! ik wil de betrokkenen 
graag hier bedanken.
Dr. den Heijer, beste martin, dit proefschrift is mogelijk gemaakt door jouw Veni subsi-
die. ik wil je graag bedanken voor je begeleiding en de ruimte en mogelijkheden die 
je me in de afgelopen jaren hebt gegeven om mezelf nieuwe kennis en onderzoeks-
vaardigheden eigen te maken en me in te zetten op meerdere afdelingen binnen het 
umC St radboud. ik heb bewondering voor en geleerd van je enthousiaste en creatieve 
kijk op het (homocysteïne)onderzoek en je vermogen om naast al het klinische werk 
nog bergen succesvol werk op het gebied van onderzoek te verzetten.  
 Dr. Blom, beste Henk, de regelmaat waarmee wij elkaar zagen, heeft enorm ge-
varieerd over de afgelopen jaren. Je hebt me de nodige kennis omtrent homocysteïne 
bijgebracht en veel van de metingen die beschreven staan in dit proefschrift zijn ver-
richt door mensen van jouw lab. ik heb me altijd vrij gevoeld om bij je aan te kloppen 
en weer eens een vraag bij je neer te leggen, of het nu ging om een homocysteïne-
gerelateerde zaak of een andere kwestie. Bedankt voor je open deur.
 Prof. Kiemeney, beste Bart, vanaf het begin van mijn aanstelling heb je op de 
achtergrond meegedacht en met name ook vooruitgedacht over de tijd na mijn pro-
motie. ik wil je bedanken voor je bijdrage aan dit proefschrift en je steun die me ook 
heeft gebracht op de plek waar ik nu zit. Het laatste jaar zijn we intensiever samen 
gaan werken maar het echte werk moet nog beginnen. ik kijk er naar uit.
 Prof. Hermus, beste ad, ik ben in 2004 begonnen als junior onderzoeker op jouw afdel-
ing. Bedankt dat ik in de afgelopen jaren heb kunnen rekenen op je interesse en snelle 
correcties van manuscripten, ook na mijn verhuizing naar de afdeling epidemiologie.
During my PhD training, i spent three months at the Statistical Genetics Group, SGDP, 
iOP, King’s College, london, uK. under supervision of dr. Knight and prof. Sham i 
worked on the study described in chapter 8 of this PhD thesis. Dr. Knight, dear Jo, 
i’ve truly enjoyed our meetings, talks and laughter. thank you very much! Dear prof. 
Sham, thank you for your inspiring supervision during the two weeks i spent at your 
department at the university of Hong Kong. i would also like to thank frühling rijsdijk, 
Desmond Campbell, Ben neale, mei-Hua Hall, and mark Knight for scientific as well as 
social support. i look back at my three months at the Statistical Genetics Group with 
great pleasure and hope to be able to visit you again in the future.
 in 2007 i spent one month at the Biostatistics Branch, nieHS, niH, research triangle 
Park, north Carolina, uSa. Dear dr. Weinberg, dear Clare, dear dr. umbach, dear David, 
dear dr. Shi, dear min, your stimulating and efficient supervision has led to the manu-
script presented in chapter 7 of my PhD thesis. thank you very much for your warm 
220 
welcome and all the time you’ve spent on discussing the designs, lem, and ‘degrees 
of freedom’. i look back on a very pleasant, fruitful collaboration and instructive time. 
Homocysteine research Group, jullie werk, gedrevenheid en kennis hebben bijgedra-
gen aan het resultaat dat hier ligt. Specifieke dank gaat uit naar Sandra Heil, Henkjan 
Gellekink, en ivon van der linden. ik wil hier ook Gerly van der Vleuten en Jacqueline 
de Graaf noemen. ik ben blij dat we onze gedeelde onderzoeksinteresses hebben kun-
nen omzetten in een aantal gezamenlijke publicaties. 
Beste (oud)collega’s van de afdeling endocriene ziekten en afdeling epidemiologie, 
Biostatistiek en Hta, met mijn onderzoek naar de genetische epidemiologie van homo-
cysteïne was ik een vreemde eend in de bijt op beide afdelingen. ik heb echter met 
plezier gewerkt bij endo en voel me op mijn plek bij eBH. Dank voor jullie collegialiteit 
en de interesse die jullie hebben getoond in mijn promotieonderzoek!
Beste collega’s en andere betrokkenen van het lab multifactorieel, afdeling antropo-
genetica, het bijwonen van de werkbesprekingen en het mee mogen werken aan 
een groot aantal projecten hebben meer bijgedragen aan dit proefschrift en aan mijn 
ontwikkeling als genetisch epidemioloog dan jullie misschien wel denken! Dank! Dr. 
franke, beste Barbara, bedankt voor je vertrouwen in mij tijdens mijn eerste stappen 
als genetisch epidemioloog. ik ben blij dat ik je beter heb mogen leren kennen tijdens 
onze gezamenlijke tijd in londen. Dr. Coenen, beste marieke, onze samenwerking is 
in het laatste jaar hechter geworden. ik kijk uit naar een verdere uitdieping van onze 
gemeenschappelijke en aanvullende onderzoeksinteresses.
 
lotte Knapen en ivon van der linden, lieve paranimfen! Onze eerste ontmoeting viel 
praktisch samen met de dag dat ik aan dit promotie-avontuur begon. Jullie zijn in de 
afgelopen jaren erg belangrijk voor me geworden. ik vind het dan ook enorm fijn en 
bijzonder dat jullie op de dag van mijn promotie naast me willen staan.
Beste vrienden, jullie mogen me eindelijk dr. Sita gaan noemen! Bedankt voor al die 
keren dat jullie mijn diepte- en hoogtepunten en alles daar tussen in met me hebben 
gedeeld; mijn speciale dank gaat hierbij uit naar Koen. De met jullie ondernomen ac-
tiviteiten (of dit nu gepaard ging met feestjes en kroegbezoek, thee en koekjes, reizen, 
sportieve of culturele aangelegenheden, of anders) en onze gesprekken hebben me 
enorm gemotiveerd in de afgelopen promotiejaren. ik kijk uit naar onze toekomstige 
‘samenwerking’! 
Papa, mama, en ook Danny en Chantal, dank voor jullie onvoorwaardelijke steun. We 
hebben het vaak gehad over de vorderingen met betrekking tot het proefschrift en ik 
ben trots en blij dat ik jullie eindelijk kan zeggen: het is af!
a B O u t  t H e  a u t H O r  221
About the author
Sita Hendrika Henriette maria Vermeulen was born on the 15th of June 1978 in ap-
peltern, the netherlands. from 1990 till 1996 she attended secondary school at the 
titus Brandsma lyceum in Oss. in 1998 she started with the study nutrition and Health 
at Wageningen university. During her university training she performed an internship 
at the Department of Hygiene and Public Health at the university of Cagliari, italy, and 
at the Department of General Practice, academic medical Center, amsterdam. after 
obtaining her master degree with honours in november 2002, she started working at 
the latter department on a research project on the generalizability of phase iii clinical 
trials. from february 2004 until february 2009 she worked on her PhD project at the 
Department of endocrinology of the radboud university nijmegen medical Centre 
(runmC) of which the results are described in this thesis. During this time, Sita was 
also appointed at the Departments of Human Genetics (dr. B. franke) and epidemiol-
ogy, Biostatistics and Hta (prof. l. Kiemeney) at the runmC as genetic epidemiologist 
and teacher. in the second year of her PhD project Sita received a ‘frye Stipend’ for 
talented female researchers from the radboud university nijmegen. She visited the 
Statistical Genetics Group at the SGDP, King’s College in london, uK (dr. J. Knight, prof. 
P. Sham) and the Biostatistics Branch at the nieHS, niH in research triangle Park, north 
Carolina, uSa (dr. C. Weinberg). Sita has continued her work at the Department of 
epidemiology, Biostatistics, and Hta and at the Department of Human Genetics and has 
focussed on the genetic epidemiology of cancer and pharmacogenetics.
List of Publications
 
radstake tr, Sweep fC, Welsing P, franke B, Vermeulen SH, Geurts-moespot a, 
Calandra t, Donn r, van riel Pl. Correlation of rheumatoid arthritis severity with the 
genetic functional variants and circulating levels of macrophage migration inhibitory 
factor. arthritis rheum. 2005;52:3020-3029. 
van Beynum im, Kapusta l, den Heijer m, Vermeulen SH, Kouwenberg m, Daniels O, 
Blom HJ. maternal mtHfr 677C>t is a risk factor for congenital heart defects: effect 
modification by periconceptional folate supplementation. eur Heart J. 2006;27:981-987. 
Vermeulen SH, van der Vleuten G, de Graaf J, Hermus ar, Blom HJ, Stalenhoef af, den 
Heijer m. a genome-wide linkage scan for homocysteine levels suggests three regions 
of interest. J thromb Haemost. 2006;4:1303-1307.
van der linden iJ, den Heijer m, afman la, Gellekink H, Vermeulen SH, Kluijtmans la, 
Blom HJ. the methionine synthase reductase 66a>G polymorphism is a maternal risk 
factor for spina bifida. J mol med. 2006;84:1047-1054.
Vermeulen SH, den Heijer m, Sham P, Knight J. application of multi-locus analyti-
cal methods to identify interacting loci in case-control studies. ann Hum Genet. 
2007;71:689-700.
Gellekink H, muntjewerff JW, Vermeulen SH, Hermus ar, Blom HJ, den Heijer m. 
Catechol-O-methyltransferase genotype is associated with plasma total homocys-
teine levels and may increase recurrent venous thrombosis risk. thromb Heam. 
2007;98:1226-1231.
Kiemeney l, aben K, Vermeulen S. nieuwe technologie onderzoek erfelijke risicofac-
toren. tijdschrift Kanker. December 2007.
anney rJ, Hawi Z, Sheehan K, mulligan a, Pinto C, Brookes KJ, Xu X, Zhou K, franke 
B, Buitelaar J, Vermeulen SH, Banaschewski t, Sonuga-Barke e, ebstein r, manor i, 
miranda a, mulas f, Oades rD, roeyers H, rommelse n, rothenberger a, Sergeant J, 
Steinhausen HC, taylor e, thompson m, asherson P, faraone SV, Gill m. Parent of origin 
effects in attention/deficit hyperactivity disorder (aDHD): analysis of data from the 
international multicenter aDHD genetics (imaGe) program. am J med Genet B neuro-
psychiatr Genet. 2008;147B:1495-1500.
222 
l i S t  O f  P u B l i C a t i O n S  223
fliers e, rommelse n, Vermeulen SH, altink m, Buschgens CJ, faraone SV, Sergeant Ja, 
franke B, Buitelaar JK. motor Coordination Problems in Children and adolescents with 
aDHD: effects of age and Gender. J neural transm. 2008;115:211-220. 
Kooij JS, Boonstra am, Vermeulen SH, Heister aG, Burger H, Buitelaar JK, franke B. 
response to methylphenidate in adults with aDHD is associated with a polymorphism 
in SlC6a3 (Dat1). am J med Gen B neuropsychiatr Genet. 2008;147:201-208. 
Verhaegh GW, Verkleij l, Vermeulen SH, den Heijer m, Witjes Ja, Kiemeney la. Poly-
morphisms in the H19 Gene and the risk of Bladder Cancer. eur urol. 2008;54:1118-
1126.
Sulem P, Gudbjartsson Df, Stacey Sn, Helgason a, rafnar t, Jakobsdottir m, Steinberg 
S, Gudjonsson Sa, Palsson a, thorleifsson G, Pálsson S, Sigurgeirsson B, thorisdottir 
K, ragnarsson r, Benediktsdottir Kr, aben KK, Vermeulen SH, Goldstein am, tucker 
ma, Kiemeney la, Olafsson JH, Gulcher J, Kong a, thorsteinsdottir u, Stefansson K. 
two newly identified genetic determinants of pigmentation in europeans. nat Genet. 
2008;40:835-837. 
Heil SG, Vermeulen SH, Van der rijt-Pisa BJm, den Heijer m, Blom HJ. role for mito-
chondrial uncoupling protein-2 (uCP2) in hyperhomocysteinemia and venous thrombo-
sis risk? Clin Chem lab med. 2008;46:655-659. 
Kiemeney la, thorlacius S, Sulem P, Geller f, aben KK, Stacey Sn, Gudmundsson J, 
Jakobsdottir m, Bergthorsson Jt, Sigurdsson a, Blondal t, Witjes Ja, Vermeulen SH, 
Hulsbergen-van de Kaa Ca, Swinkels DW, Ploeg m, Cornel eB, Vergunst H, thorgeirsson 
te, Gudbjartsson D, Gudjonsson Sa, thorleifsson G, Kristinsson Kt, mouy m, Snorradottir 
S, Placidi D, Campagna m, arici C, Koppova K, Gurzau e, rudnai P, Kellen e, Polidoro S, 
Guarrera S, Sacerdote C, Sanchez m, Saez B, Valdivia G, ryk C, de Verdier P, lindblom 
a, Golka K, Bishop Dt, Knowles ma, nikulasson S, Petursdottir V, Jonsson e, Geirsson 
G, Kristjansson B, mayordomo Ji, Steineck G, Porru S, Buntinx f, Zeegers mP, fletcher t, 
Kumar r, matullo G, Vineis P, Kiltie ae, Gulcher Jr, thorsteinsdottir u, Kong a, rafnar t, 
Stefansson K. Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. 
nat Genet. 2008;40:1307-1312.
Shi m, umbach Dm, Vermeulen SH, Weinberg Cr. making the most of case-mother/
control-mother studies. am J epidemiol. 2008;168:541-547.
224 
Vermeulen SH, Shi m, Weinberg Cr, umbach Dm. a hybrid design: case-parent triads 
supplemented by control-mother dyads. Genet epidemiol. 2009;33:136-144.
franke B, Vermeulen SH, Coenen mJ, Steegers-theunissen rPm, Schijvenaars mmVaP, 
Scheffer H, den Heijer m, Blom HJ. analysis of 45 folate related genes in spina bifida: 
involvement of Cubilin (CuBn) and trna aspartic acid methyltransferase 1 (trDmt1). 
Birth Defects res a Clin mol teratol. 2009;85:216-226. 
fliers e, Vermeulen S, rijsdijk f, altink m, Buschgens C, rommelse n, faraone S, 
Sergeant J, Buitelaar J, franke B. aDHD and Poor motor Performance from a family 
Genetic Perspective. J am acad Child adolesc Psychiatry. 2009;48:25-34.
Kiemeney la, Grotenhuis aJ, Vermeulen SH, Wu X. Genome-wide association studies 
in bladder cancer: first results and potential relevance. Curr Opin urol. in Press.

Sita
 h
. V
er
m
eu
len
  G
e
n
e
tic e
p
id
e
m
io
lo
g
y o
f h
o
m
o
cyste
in
e
 a
n
d
 re
late
d
 d
isea
se
s
Sita h. Vermeulen
Genetic epidemiology of 
homocysteine and related 
diseases
